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Abstract 
The contribution of metabolic factors to the severity of osteoarthritis (OA) is not 
completely understood. In this study, apolipoprotein E-deficient (ApoE−/−) mice and 
diet-induced hypercholesterolemia animal models were evaluated to define the 
potential effects of hypercholesterolemia on the severity of OA. Under baseline 
conditions, hypercholesterolemic ApoE-/- mice and dietary rat model leads to OA like 
changes that are mainly characterized by a loss of proteoglycans content, collagen, and 
aggrecan degradation, synovial inflammation, osteophyte formation, changes to 
subchondral bone architecture, formation of subchondral bone lesions and eventual 
progression to cartilage degeneration and joint instability.  
Following surgical destabilization/removal of the medial meniscus, the 
progressive degeneration towards OA was dramatically increased in the cholesterol 
fed ApoE-/- mice and dietary rat model compared with that in their wild-type 
littermates. We further show that clinically relevant doses of cholesterol cause 
mitochondrial dysfunction, reactive oxygen species (ROS) overproduction and 
increased expression of degenerative and hypertrophy markers that break down 
cartilage matrix in chondrocytes.  
Furthermore, OA changes induced by hypercholesterolemia were attenuated 
with the treatment of statins (atorvastatin) and mitochondria targeted anti-oxidants 
(mito-TEMPO and MitoQ). The chondro-protective effect of atorvastatin and mito-
TEMPO/MitoQ are largely associated with the suppression of oxidative damage and 
the restoration of extracellular matrix homeostasis of articular chondrocyte, suggesting 
their potential therapeutic efficacy.  
Taken together, our data show that hypercholesterolemia, which can induce 
chondrocyte mitochondrial dysfunction, resulting increased ROS production and cell 
apoptosis, is one of the risk factors for OA progression.  This study may provide the 
basis for development of novel treatments for this OA risk group.  
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Chapter 1: Introduction 
1.1 INTRODUCTION 
High fat intakes and inactive lifestyles are becoming most important concerns in 
today’s modern world. They have led to a ‘growing prevalence of obesity, 
hypercholesterolemia, high blood pressure, dyslipidemia, and a condition known as 
insulin-resistance syndrome or metabolic syndrome’. Metabolic syndrome is well 
known as ancestors to ‘atherosclerosis, cardiovascular disease, and diabetes’. Some 
studies have reported that most of these conditions may also be associated with an 
increased risk of osteoarthritis (OA) (Bierma-Zeinstra & Koes, 2007; S. Dahaghin, 
Bierma-Zeinstra, Koes, Hazes, & Pols, 2007; Martins et al., 2006). To complicate 
matters further, these risk factors can reportedly interact with each other, worsening 
the disease rate and state. However, the majority of OA is caused by metabolic risk 
factors,which can be controlled, treated, or modified, including high blood pressure, 
obesity, lack of physical activity, cholesterol, and diabetes. Therefore, understanding 
the mechanisms by which these systemic factors change the course of OA should be 
an intense area of research to direct patient targeted therapies.  
1.1.1. Cholesterol: A new contributor for initiating OA 
The body’s total cholesterol is derived via dietary intake and the ‘cellular 
cholesterol biosynthetic pathway’. Most cell types, including the chondrocytes, have 
the capacity for cholesterol biosynthesis. Cholesterol is a vital constituent of cellular 
membranes, which controls signalling molecules with other intermediates of the 
cholesterol biosynthetic pathway. It has been reported that cholesterol is essential for 
‘chondrocyte differentiation and bone formation’ (Gentili, Tutolo, Pianezzi, 
Cancedda, & Descalzi Cancedda, 2005). ‘In chondrocytes there is tightly regulated 
expression of proteins playing a role in cholesterol metabolism’(Gentili et al., 2005; 
Zerega et al., 2004). For example, the expression of ‘Apolipoprotein A-I (ApoA-1) 
and ATP-binding cassette transporter (ABCA1) is high in differentiating 
chondrocytes, and drops to the basal level once cells reach hypertrophy’. In contrast, 
‘hypertrophic chondrocytes express highest level of serum amyloid A (SAA) mRNA’ 
(Gentili et al., 2005; Zerega et al., 2004). These results propose that the synthesis and 
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intake of cholesterol should be controlled to avoid from hyperlipidemia phenotype and 
abnormal accumulation of cholesterol in cartilage tissues.  
People who are overweight or obese tend to have high cholesterol levels as 
insulin resistance makes fat metabolism changes. Whether cholesterol levels influence 
the occurrence of OA is a matter of debate. Epidemiological studies have determined 
different conclusions regarding the association beween OA and cholesterol. Some 
found a positive association between elevated serum cholesterol levels and OA (Al-
Arfaj, 2003; M. A. Davis, Ettinger, & Neuhaus, 1988; D. J. Hart, D. V. Doyle, & T. 
D. Spector, 1995; K. Martin et al., 1997; Sturmer et al., 1998), whereas others found 
no direct correlation (Bagge, Bjelle, Eden, & Svanborg, 1991). Insterestingly, serum 
cholesterol and triglycerides were linked with the incidence of bone marrow lesions, 
which are common in OA patients (M. L. Davies-Tuck et al., 2009).  
Abnormal cholesterol accumulation occurs when cholesterol influx into the 
tissue wall (from apoB-containing lipoproteins) exceeds cholesterol efflux. In a more 
recent study it was demonstrated that cholesterol transport genes such as ApoA-1 and 
ABCA1 mRNA levels were significantly lower in OA cartilage compared to normal. 
In addition, the two subtypes of the Liver X receptor  (LXR), namely LXRα and 
LXRβ, mRNA levels were also found to be significantly lower in OA cartilage (A. 
Tsezou, D. Iliopoulos, K. N. Malizos, & T. Simopoulou, 2010). The differential 
expression pattern of these cholesterol efflux genes between normal and OA cartilage 
may signify a causal relationship of cholesterol related mechanisms to development 
and/or progression of OA. Recently, Gierman and co-workers published a study 
demonstrating a significant correlation between the development of OA and 
cholesterol exposure in an animal model, providing the first direct evidence of 
cholesterol involvement in OA (L. M. Gierman et al., 2013). In their study, they 
demonstrated that increased dietary cholesterol can cause OA development in a mouse 
model. They further showed that such an OA development can be inhibited by 
Atorvastatin, a member of the drug class known as statins (L. M. Gierman et al., 2013). 
The next obvious question is how can cholesterol damage the cartilage? The 
mechanisms behind these observations are not fully understood, but there are number 
of ways that cholesterol can cause cartilage damage and these hypotheses are 
summarised below. 
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1.1.1.1. Potential common mechanism in developing hypercholesterolemia-
induced OA and atherosclerosis 
Current information suggests that cholesterol-induced OA development can be 
related to blood vessel dysfunction. This mechanism is similar to the condition leads 
to atherosclerosis in response to hypercholesterolemia (Conaghan, Vanharanta, & 
Dieppe, 2005; Katz, Agrawal, & Velasquez, 2010; Saleh et al., 2007).  As cholesterol 
is a ‘major constituent of the cell membrane, any alterations could affect fluidity and 
function of the membrane’ so that they result in poor cell behaviour and cholesterol 
accumulation (N. Wang, Silver, Costet, & Tall, 2000). It is possible that 
hypercholesterolemia can result in the deposition and oxidation of lipids in tissues, 
causing damage to the cartilage similar to that seen in diseases like atherosclerosis 
(Sevin, Yasa, Akcay, Kirkali, & Kerry, 2013). A main contributing factor of the 
atherosclerotic lesion incidence possibly mirrors the imbalance between cholesterol 
influx and efflux regulation within the tissue (Schwenke & St Clair, 1993). ‘The 
acquisition and evacuation of cholesterol is known to be mediated by a number of cell 
surface receptors, including the scavenger receptor class B type I (SR-BI), CD36 and 
ABCA1’ (Ikonen, 2006). The earliest stage in reverse cholesterol transport is 
associated to ABCA1, ‘a transmembrane protein mediating lipid efflux from cells to 
apolipoproteins (Apo)’. It has been suggested that ‘ABCA1 plays a central role in 
cholesterol homeostasis and alterations in this gene were associated with 
atherosclerosis’ (Rothblat, de la Llera-Moya, Favari, Yancey, & Kellner-Weibel, 
2002; Soumian, Albrecht, Davies, & Gibbs, 2005).  
‘SR-BI, a member of the CD36 superfamily, which is mostly expressed in the 
steroidogenic tissues and liver, where it facilitates selective cholesteryl ester uptake 
from HDL’ (Krieger, 1999; Marcil, Delvin, Sane, Tremblay, & Levy, 2006). SR-BI is 
also expressed in macrophages, including tissue macrophages, monocyte-derived 
macrophages, and macrophages in atherosclerotic lesions (Pagler et al., 2006; 
Rinninger et al., 2003). SR-BI deficiency is related to de-regulation of cholesterol 
homeostasis in the arterial wall that results in an increased susceptibility to 
atherosclerosis (Van Eck et al., 2003). ‘CD36 has been well-known as binding and 
internalizing ‘oxidized low density lipoproteins (oxLDL)’ as well as a large number  
of ligands, such as ‘anionic phospholipids, long-chain fatty acids and other modified 
LDL’ (Adorni et al., 2012). CD36 identifies ‘lipid moieties of oxLDL’ and functions 
as a principal scavenger receptor in the oxLDL uptake (T. Q. Truong, Aubin, 
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Falstrault, Brodeur, & Brissette, 2010). Moreover, increasing evidence proposes that 
‘peroxisome proliferator activated receptors (PPARs)’ (Barbier et al., 2002; Xia et al., 
2012) utilize antiatherogenic effects via increasing cholesterol efflux through initiation 
of the ‘liver X receptor (LXR)–ABCA1 pathway’ (Bultel et al., 2008; Di et al., 2012; 
Hozoji-Inada, Munehira, Nagao, Kioka, & Ueda, 2011; Ouvrier et al., 2009). 
Therefore, it is possible that the same genes and molecular determinants could affect 
cartilage cholesterol homeostasis. This hypothesis is further supported by the study 
showing the expression of some of those genes in the cartilage tissue (A. Tsezou et al., 
2010). In another view, Findlay et al. proposed that blood vessel alterations can leads 
to changed blood flow to the bone that underlies the cartilage in joints. Consequently, 
the bone and the cartilage are deprived of blood, oxygen, and nutrients that contributes 
to the whole tissue’s degeneration (Findlay, 2007). As cholesterol is known to be a 
predominant factor that influences altered blood vessel function, it is possible that the 
above chain of events can lead to OA. However, cartilage and bone homeostasis are 
complex dynamic systems that involve biology, biomechanics and tissue structure. 
Morovere, other potentioal mechanisms, which influence this complex system, will 
disuss under the following sections. 
1.1.1.2. Role of inflammation in cholesterol-induced OA 
‘Obesity and associated metabolic syndromes are related to systemic tissue 
damage and chronic low-grade inflammation’ (Gregor & Hotamisligil, 2011). 
Continuous lipoproteins accumulation, primarily LDL, in the extracellular matrix of 
cartilage can trigger the inflammatory process. C-reactive protein (CRP) is a very 
sensitive marker of inflammation. The presence of inflammation in OA individuals 
were proposed by a finding demonstrated increased levels of CRP and IL-6 in OA 
groups. In this respect, the fact that CRP is associated with obesity is noteworthy. A 
positive association between circulating CRP has been shown in patients with obesity, 
metabolic syndrome, and OA. Interleukin-6 (IL-6) is a proinflammatory cytokine, 
which is produced by many cells, including chondrocytes. Studies have also shown 
increased levels of IL-6 mRNA in the OA specimens and IL-6 has been demonstrated 
to be the key stimulus for the CRP production. Furthermore, IL-6 appears to be related 
with ‘visceral obesity and insulin resistance’. Recent studies clearly highlight the close 
link between inflammation and cholesterol homeostasis through mechanisms in which 
ABCA1 appears to be a major actor. For example, increased intracellular free 
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cholesterol concentration in ABCA1 KO macrophages is accompanied by enhanced 
inflammatory response in macrophages (Faggiotto & Ross, 1984; Faggiotto, Ross, & 
Harker, 1984; H. Li, Cybulsky, Gimbrone, & Libby, 1993). 
Another molecule assumed to play a key role in lipid-induced inflammation is 
the ‘transcription factor nuclear factor-κB (NF-κB)’. Its essential role is regulating 
inflammation and immune responses by activation of different genes, including those 
that encode cytokines, growth factors, and adhesion molecules. ‘NF-κB is redox 
sensitive and activated by radicals’. A large number of different radicals may be 
generated by oxidation of lipoproteins, signifying that lipid-induced inflammation in 
the vascular wall can be mediated by the pro-inflammatory NF-κB activation by 
radicals drived from oxidized lipids. Indeed, induction of hypercholesterolemia in 
pigs, rabbits, mice, and many other animals leads to activation of vascular 
inflammation (Faggiotto & Ross, 1984; Faggiotto et al., 1984; H. Li et al., 1993). 
 
1.1.1.3. Cholesterol activates oxidative stress 
Mitochondrial dysfunction is known to be induced by hypercholesterolemia, 
hyperglycemia, hypertriglyceridemia, and even the process of aging (Lee & Wei, 
2012; Puddu, Puddu, Galletti, Cravero, & Muscari, 2005).  Numerous studies have 
shown an association between increased cholesterol oxidation products (oxysterols) 
and mitochondrion-derived oxidative stress, which typically leads to increased 
production of mitochondrial reactive oxygen species (mtROS) (Lordan, Mackrill, & 
O'Brien, 2009). Excessive and continuous accumulation of oxidised cholesterol 
particles tends to bind to ‘sulphate-containing proteoglycans, where they aggregate 
and become oxidatively modified’. The responsible factors for these alterations are yet 
to be clarified, but in addition to ROS, different membrane and extracellular tissue-
associated enzymes were reported to be involved. There are a number of defence 
mechanisms such as antioxidant vitamins and enzymes, which inhibit oxidative 
damage of lipoproteins accumulation, but in circumstances of a constant lipid overload 
they may finally not function, causing the activation of stress signalling pathways 
(Oliveira et al., 2005). ROS is typically produced under optimal conditions by 
mitochondria, and is neutralized by the mitochondrial cellular defence systems. When 
ROS is overproduced, it can induce deterioration of mitochondrial oxidative stress 
defences, cause irreversible harm at the cellular and molecular levels in vulnerable 
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cells, and contribute to pathologic conditions. ROS can also damage DNA, cellular 
lipids, and  proteins, inducing lipid peroxidation, a condition that can more progress 
mtDNA impairment (Fosslien, 2001). These observations suggest a mechanistic 
explanation that accumulating free cholesterol causes increased superoxide anion 
levels, enhances oxidative stress, and activates a transient inflammatory response 
causing permanent damage to the tissue. It has been shown that increased ROS 
production, particularly, radicals and superoxide, has been related to cartilage 
dysfunction in human (Ostalowska et al., 2006) and animal models of disease (Johnson 
et al., 2004), and there is growing evidence of an association between oxidative stress 
and cartilage degradation in humans (Afonso, Champy, Mitrovic, Collin, & Lomri, 
2007; Regan et al., 2005). Considering the role of cholesterol in triggering an oxidative 
stress environment, using a mitochondrial targeted anti-oxidant would be a novel 
therapy to suppress ROS overproduction leading to prevention of OA. However, 
whether the high cholesterol levels trigger the mitochondria dysfunction in cartilage 
requires further investigation. 
1.1.1.4. Role of cholesterol lowering drugs in preventing OA 
 The growing list of interconnections between cholesterol and OA indicates that 
statins that inhibit de-novo cholesterol synthesis may have a disease modifying effect. 
In one study, Clockaerts et al., demonstrated that the use of statins is associated with a 
decrease in the overall progression of OA of the knee, but not of the hip in a population 
based study (Clockaerts et al., 2012). In addition to its effects on lipid metabolism, 
several anti-inflammatory effects have been ascribed to statins. It has been 
demonstrated that intra-articular injections of statin during OA progression decrease 
the infiltration of inflammatory cells and the expression of matrix-degrading enzymes, 
therefore restraining cartilage degradation (Akasaki, Matsuda, & Iwamoto, 2009). The 
same research group showed that intra-articular administration of HMG-CoA 
reductase inhibitor (e.g., statin) moderates cartilage degradation during OA 
development (Akasaki, Matsuda, Nakayama, et al., 2009). Statins can be capable to 
decrease the OA damage by several immunomodulatory effects on the joint.  However, 
a few questions remain, and the most important regards to what extent cholesterol 
should be reduced to nullify any e off-target ffects and to maintain the levels required 
for cartilage homeostasis.  
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1.2 HYPOTHESIS 
Hypercholesterolemia increases the risk of symptomatic features of OA through 
changes in mitochondrial related ROS pathways; therefore, lower cholesterol and 
targeted reduction of ROS may attenuate OA progression in this specific OA 
phenotype. 
1.3 THE SPECIFIC AIMS OF THE THESIS 
 To investigate the cholesterol distribution in cartilage of OA patients. 
- I hypothesised that higher cholesterol distribution may be a characteristic of 
O A cartilage compared to normal. 
- I also hypothesised that cholesterol regulatory genes may play a role in OA 
development. 
 To study how abnormal cholesterol challenge alters the chondrocytes phenotype 
and mitochondrial function. 
- I proposed that cholesterol accumulation could change cartilage hemeostasis. 
- Mitochondrial dysfunction was suggested as one of possible mechanisms by 
which abnormal cholesterol alters chondrocytes phenotype. 
 To study whether high cholesterol levels could lead to OA development in dietary 
rat and ApoE-/- mouse models. 
- I suggested that high cholesterol intake could contribute to OA initiation 
and/or progression in dietary rat and ApoE-/- mouse models. 
 To investigate whether administration of and anti-oxidant Mito-tempo/MitoQ 
would be a novel alternative therapy to slow down cholesterol-associated OA 
progression.  
- I hypothesised that using anti-oxidant drugs would be a new theraputical drug 
to lessen OA progression caused by high cholesterol levels 
1.4 THESIS STRUCTURE 
This thesis consists of six chapters. Chapter 1 introduces the topics and Chapter 
2 provides an extended literature review on the topics investigated. The main objective 
of this study is to build a new concept on a link between abnormal cholesterol levels 
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and OA pathogenesis at a cellular level. For this purpose, a series of molecular and 
cell biological methods were used to distinguish the changes in knee joints under a 
high cholesterol challenge. We conducted two animal model studies to determine how 
hypercholesterolemia affects the OA phenotype. In these studies, we used both dietary 
rats and ApoE knockout mice to prove the concept, and to test the therapeutical effect 
of atorvastatin and mito-TEMPO/MitoQ  with respect to OA development. In Chapter 
3, the methods and materials relating to each experiment are explained. 
Chapters 4 specifically presents the results obtained from each experiment. 
Results from in-vitro and in-vivo experiments are shown in accordance to each aim of 
this study. Chapter 5 provides a summary and draws conclusions of the studies in the 
former chapters to establish what new insights could been added to the understanding 
of the risk factors and biology of OA.  
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Chapter 2: Literature Review 
2.1 OSTEOARTHRITIS  
Osteoarthritis (OA), a degeradative joint disease, is described by degradation of 
articular cartilage, alterations in subchondral bone, synovial inflammation, and 
osteophyte formation. OA is the most common arthritis and may cause severe 
symptoms such as pain, dysfunction of the joint, and disability (D. T. Felson, Chaisson, 
C. E., Hill, C. L., Totterman, S. M., Gale, M. E., Skinner, K. M., ... & Gale, D. R, 
2001).  In people over age of 50, the increase in occurrence of severe OA is exponential 
(Lawrence, Bremner, & Bier, 1966). OA, can, though, affect young adults (Lowman, 
1955). The condition affects approximately three million Australians, or 
approximately 15% of the population. People with OA are 2 to 3 times more likely to 
report poor health, very high levels of psychological distress and severe and very 
severe pain compared to those without the condition. The economic impact of OA on 
society is also significant.  Based on Australian Institute of Health and Welfare 
(AIHW) disease expenditure data, $1.6 billion was attributed to osteoarthritis in 2008-
09 (the most recent year for which data are available). According to the Australian 
National Hospital Morbidity Database, there were 103,763 hospitalisations in 2012–
13 with a principal diagnosis of OA. Joint replacements surgeries, especially for hips 
and knees, are currently being performed to correct the defect. Moreover, there is no 
definitive drug for OA patients. The fact that a damaged joint is the common feature 
of OA patients with different sub-groups based on the risk profile has made developing 
a drug to  slow or stopthe pathogenesis of OA the focus of researchers for decades 
("Arthritis research foundation,").  
2.1.1 Osteoarthritis pathogenesis 
OA is a ‘whole joint’ disorder and its pathologic alterations happen in all tissues, 
including ‘articular cartilage degradation, osteophyte formation, subchondral bone 
thickening, synovial inflammation, and degeneration of menisci and ligaments’ 
(Andriacchi et al., 2004).  
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2.1.1.1. Cartilage in pathogenesis of OA  
Macroscopically, healthy articular cartilage is a white to yellowish tissue 
covering the joint surface. The synovial fluid creates it smooth looking and delivers its 
low frictional properties. Macroscopically, OA cartilage is typically yellowish or 
brownish, usually soft, with presence of chipping and tiny cracks. The surface displays 
‘roughening in the early stages and obvious fibrillation and matrix loss in the later 
stages, up to the subchondral bone plate is visible’. These alterations can be observed 
and classified radiographically and can be studied in more detail on the histologic 
level. Cartilaginous outgrowths can frequently be found at the margins of joints 
(chondro-osteophytes). In severe cases, there is a total cartilage loss between the bones 
of the joints, creating high friction between the bones, leading to pain and limitation 
of joint mobility.  
 
 
 
 
 
 
 
   
 
 
 
Figure 2.1: Normal versus OA articular structures. (a) Normal tissue without any 
cartilage fissures, synovial inflammation, and subchondral bone thickening. (b) OA 
tissue with central degenerate lesion and 'fibrillated' cartilage, as well as remodelling 
of bone and degeneration of meniscus (Heike A. Wieland, 2005). 
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Microscopically, the structure of articular cartilage is clearly classified as having 
four zones, the superficial zone, middle zone, deep zone, and calcified zone, which 
have different cell structures and matrix organizations (Lyons, Stoddart, McClure, & 
McClure, 2005; A. R. Poole et al., 2001). The majority of the superficial layer consists 
of collagen fibres and a few flattened chondrocytes arranged in a meshwork pattern. 
The middle layer contains chondrocytes that are larger, and the collagen fibres in this 
layer are randomly oriented. In the deep stratum, chondrocytes are arranged in vertical 
columns separated by collagenous fibrils. The last layer is called calcified cartilage as 
it contains partially mineralized matrix and hypertrophic chondrocytes and this zone 
shares many similarities with chondrocytes present in the hypertrophic zone of growth 
plate cartilage (H. J. Mankin, Buckwalter, J.A, 2000; Sun & Kandel, 1999). The 
calcified zone is separated from the deep zone of cartilage by the tidemark. The 
structure of the tidemark consists of 8-10 layers of collagen fibrils arranged as a thick 
bundle (Figure 2.2) (Doulabi, 2014; Lyons et al., 2005; A. R. Poole et al., 2001). 
Normal cartilage consists of evenly stained collagen and proteoglycan rich 
extracellular matrix with distributed cartilage cells. Chondrocytes present less than 5% 
of the total volume of cartilage but are obviously important for the preservation of the 
tissue structure (Aigner & Schmitz, 2011).  
 
 
 
 
 
 
 
 
 
 
Figure 2.2: Modified microscopic healthy cartilage illustrating the zonal 
architecture and distribution of chondrocytes (Li & Aspden, 1997). 
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The microscopic changes that occur in OA cartilage are hallmark features of the 
disease. The surface indications are roughening in the early with obvious fissures and 
cracking, as well as matrix loss in the later stages until the subchondral bone plate 
becomes observable. In addition to the total destruction of the matrix, the degradation 
of matrix molecules also significantly contributes to preceding  processesand final loss 
of the particular matrix regions (loss of Safranin O staining replicating the 
proteoglycans loss in affected cartilage). Destabilization of molecular structures also 
occurs in addition to the degradation of molecular components. For example, 
disruption of the collagen network leads to microscopically and eventually, 
macroscopically evident matrix damage (D. B. Burr & Radin, 2003; Hattori, Ikeuchi, 
Morita, & Takakura, 2005; B. Li & Aspden, 1997).  
Generally, the grading of OA cartilage degradation is relatively difficult as all 
patients have, to at least some extent, distinct symptoms, morphologic changes, and 
histories. Apart from articular cartilage, several other tissues contribute to this process; 
however, the cartilage degradation has traditionally been contributes most to the 
scoring of OA severity (Figure 2.3). Overall, the joint destruction process can be 
assessed  during the OA pathogenesis and the grading system most frequently used is 
‘the histochemical-histologic grading system’ by Mankin and coworkers in 1971 
(Table 2.1).  
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Figure 2.3: Modified histological scoring of cartilage during OA pathogenesis (Jiang 
& Tuan, 2015). 
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Table 2.1: Grading of OA  cartilage according to the Mankin score (H. J. 
Mankin, Dorfman, Lippiello, & ZARINS, 1971). 
Feature Score Histologic feature 
Cartilage structure 0  Normal 
1 Superficial fibrillation 
2 Pannus and superficial fibrillation 
3 Fissures to the middle zone 
4 Fissures to the deep zone 
5 Fissures to the calcified zone 
Chondrocytes 0 Normal 
1 Diffuse hypercellularity 
2 Cell clusters 
3 Hypocellularity 
Safranin-O staining 0 Normal 
1 Slight reduction 
2 Moderate reduction 
3 Severe reduction 
4 No staining 
5 Total disorganization 
Tidemark 0 Intact 
1 Tidemark penetrated by vessels 
 
Articular cartilage is a flexible load bearing tissue that covers the surface of long 
bones at joint site (Freeman, 1973). Articular cartilage is an ‘aneural, avascular, and 
alymphatic structure consisting of only one cell type called chondrocytes’ 
(Buckwalter, 1997), which have different morphologies extending from more flattened 
at the surface to rounder and larger in the deeper zones (M. B. Goldring, 2012). 
Chondrocytes are specific spheroidal cells in charge of synthesizing and maintaining 
the matrix infrastructure (F. Chen, Frenkel, & Di Cesare, 1999). Articular cartilage 
contains principal building components such as water, collagen, and proteoglycans. 
Proteoglycans are responsible to maintain the electrolyte and fluid balance in the 
articular cartilage. 
At the molecular level, chondrocytes in normal adult cartilage are stable and 
differentiated cells, which maintain tissue homeostasis by synthesizing very low levels 
of extracellular matrix components to preserve the structural integrity of the cartilage 
matrix. Normal chondrocytes produce different collagen types: mainly type II, type 
XI, and type IX, generating a ‘fibrillar collagen network’ that lures the large 
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aggregating proteoglycan, aggrecan, along with several other molecules such as small 
proteoglycans. On the other hand, two other collagen types, type X and type VI are not 
produced by all chondrocytes. Collagen type X is only produced by the hypertrophic 
chondrocytes in ‘growth-plate cartilage or in articular cartilage near the tidemark and 
through the calcified cartilage’ (M. B. Goldring, 2012).  
At a molecular level in OA, the “activated” chondrocytes, described by ‘cell 
proliferation, cluster formation, and increased production of both matrix proteins and 
matrix degrading enzymes’ (Sandell & Aigner, 2001). Furthermore, OA chondrocytes 
are also capable of synthesizing typical terminal differentiated markers that point 
towards the fact that OA articular chondrocytes are undergoing differentiation towards 
hypertrophic phenotype (Iannone & Lapadula, 2008; O. Pullig, Weseloh, 
Ronneberger, Kakonen, & Swoboda, 2000). In agreement to this phenotype, it has 
been reported that OA chondrocytes express typical hypertrophic differentiation 
related markers, such as type X collagen (COLX) and runt-related transcription factor 
2 (RUNX2) (Iwamoto et al., 2003; O. Pullig, Weseloh, Gauer, & Swoboda, 2000; O. 
Pullig, G. Weseloh, D. Ronneberger, et al., 2000). Given that chondrocyte hypertrophy 
is a feature of OA cartilage, it is likely that these phenotypic changes can increase the 
expression of degenerative enzymes in cartilage (Cheung, 2005). 
Chondrocytes mainly produce these degradative enzymes in response to stimuli 
such as oxidative stress, injury, mechanical stress, cell-matrix interactions, and 
alterations in growth factor responses and matrices (Mary B Goldring & Marcu, 2009). 
Among proteinases that damage cartilage collagens and proteoglycans in joint 
disorder, aggrecanases and matrix metalloproteinases (MMPs) have been highlighted 
as they damage native collagens and proteoglycans (Cawston & Wilson, 2006; Rengel, 
Ospelt, & Gay, 2007). These consist of the collagenases MMP-13 and aggrecanases 
ADAMTS (ADAM with thrombospondin-1 domains)-5 as the primary degrading 
enzymes in cartilage (Arner, 2002; Glasson et al., 2005; G. Murphy & Nagase, 2008). 
Therefore, a shift in the phenotypic changes of articular cartilage to a chondrocyte 
hypertrophic phenotype can be destructive to the structure, health, and integrity of the 
cartilage, resulting in its degradation. 
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2.1.1.2. Subchondral bone in the pathogenesis of OA  
Periarticular bone can be divided into two anatomic areas that consist of the 
subchondral bone plate and the subchondral trabecular bone. The subchondral bone 
plate contains of cortical bone, which is fairly nonporous and poorly vascularized. 
Subchondral bone is defined from the overlying articular cartilage by the zone of 
calcified cartilage (Mary B. Goldring & Goldring, 2010). The cell-mediated processes 
of remodelling and modelling are responsible for the maintenance of properties and 
architecture of the subchondral bone. Subchondral bone consists of different cell types, 
including osteoclasts, osteoblasts, and osteocytes. Osteoclasts mediate the remodelling 
cycle through bone resorption. Following the resorptive course, a bone formation 
phase is initiated by mediating osteoblasts, and the formation and resorption phases 
are regulated to preserve the bone mass in physiological conditions, while the 
architecture and shape of the bone might be altered (David B Burr, 2004; R. Martin, 
2007). Apart from the impact of bone shape and architecture, the mechanical properties 
of bone are furthermore effected by the composition and organization of the organic 
phase of bone and the content and chemistry of the mineral phase (J. Day et al., 2001; 
Meunier & Boivin, 1997).  
Modifications in the periarticular and subchondral bone that take place in OA 
may also play a role in cartilage pathology (Ruocco et al., 2005). However, it is unclear 
whether alterations in this tissue occur prior to alterations in the cartilage or whether 
subchondral bone modifications are secondary progressions after changes in the 
biomechanical properties of the overlying cartilage. The strong link between both is 
demonstrated by the fact that the cartilage marker and the bone marker were increased 
along with each other in patients with OA (H. L. Quasnichka, J. M. Anderson-
MacKenzie, & A. J. Bailey, 2006; Helen L Quasnichka, Janet M Anderson-
MacKenzie, & Allen J Bailey, 2006; Yamada, Healey, Amiel, Lotz, & Coutts, 2002).  
Radin and coworkers suggested that the integrity of the articular cartilage is dependent 
on the mechanical properties of the underlying bone (Radin & Rose, 1986). However, 
strong evidence for a key role of bone remodelling in the etiology has not been 
established. Several studies along with a previous study in our group have documented 
an increase of subchondral bone turnover and formation of bone spurs accompanied 
by specific architectural changes in the subchondral trabecular bone of OA joints 
(David B Burr, 1998; Goker, Sumner, Hurwitz, & Block, 2000; Karsdal et al., 2013; 
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Pastoureau, Leduc, Chomel, & De Ceuninck, 2003; Pelletier et al., 2004). 
Densification of subchondral bone in OA is a late event that includes only the calcified 
cartilage and subchondral plate; the subchondral cancellous bone underneath the 
subchondral plate may have lower bone density.. However, it has been reported that 
both early-stage bone loss and elevated remodelling, and the late-stage subchondral 
densification and reduced remodelling are significant features of the pathogenic 
procedure results in OA (David B. Burr & Gallant, 2012; Hunter & Spector, 2003; 
Lane, 2002). “The interrelated changes to biochemical and mechanical properties of 
the subchondral bone were consequently a challenge for delineating the molecular 
mechanisms underlying OA initiation”(Hayami et al., 2006). Recently, subchondral 
and trabecular bone mechanical loading in regards to muscle and ligament strenght has 
been proposed as a new pathway contributes to OA pathogenesis. Egloff et al.  
showed that muscle weakness resulted in significantly higher OA scores in the 
patellofemoral joint leading to significant cartilage damage in all four compartments 
of the rabbit knee (Egloff et al., 2014). In another study, peripheral quantitative 
computed tomography measurments reported great changes in bone mineral density 
after anterior cruciate ligament (ACL) reconstruction in trabecular bone wich may be 
associated with greater OA severity (Mundermann et al., 2015).   
It has been radiographically demonstrated that the osteophyte formation and 
subchondral sclerosis may occur in OA joints of patients before alterations in thickness 
of articular cartilage measured as ‘joint space narrowing’ (Figure 2.4). These 
radiographic features are temporally separated, mainly as the bone’s rich blood supply 
allows it to quickly react to changes in the joint, while a physical cartilage loss that 
happens at a late stage of the disease is required in advance to joint space narrowing 
(J. Buckland-Wright, Lynch, & Dave, 2000; J. C. Buckland-Wright, Macfarlane, D. 
G., & Lynch, J. A. , 1992; S. R. Goldring, 2012; Hudelmaier, Wirth, Nevitt, & 
Eckstein, 2013).  
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Figure 2.4: Radiograph of a normal versus OA rat knee. (A) Normal knee (B) OA 
knee showing joint space loss and an increase in subchondral sclerosis. The articular 
surfaces look flattened (C. Buckland-Wright, 2004). 
At cellular level, it has been shown that the function of subchondral osteoblasts in 
production of inflammatory markers may be altered in OA patients compared to 
normal group (Massicotte et al., 2002). It has been reported that OA subchondral 
osteoblasts express higher levels of alkaline phosphatase (ALP)  compared tothose 
from normal people (L. H. Truong, Kuliwaba, Tsangari, & Fazzalari, 2006). Similarly, 
osteocalcin (OC) expression was elevated at the protein level in OA subchondral 
osteoblasts (Gevers et al., 1989; Hilal, Martel-Pelletier, Pelletier, Ranger, & 
Lajeunesse, 1998). Moreover, it has been reported that the growth factors such as 
insulin-like growth factor (IGF)-1,2 and transforming growth factor (TGF)-β levels 
are upregulated in OA subchondral osteoblasts (Hilal et al., 2001). In a study, the levels 
of ALP, Transglutaminases, C-terminal type 1 procolagen propeptide, OC, interleukin 
(IL)-6,8 and TGF-β1 were reported to be significantly elevated in sclerotic OA 
subchondral osteoblasts compared to non-sclerotic osteoblasts (Sanchez et al., 2008). 
These findings together suggest that the OA subchondral osteoblasts have increased 
osteogenic capabilities and produce abnormal cytokine and growth factors compared 
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to normal osteoblasts. In addition, it has been suggested that this abnormal osteoblasts’ 
behaviour can affect the overlying cartilage properties (Lajeunesse & Reboul, 2003). 
Indeed, the hypothesis that there is an interaction between subchondral bone 
osteoblasts changes and articular cartilage chondrocytes phenotype has been well-
demonstrated previously in our group study (Prasadam, Crawford, & Xiao, 2010; 
Indira Prasadam et al., 2010).  
 
2.1.1.3. Synovial membrane in the pathogenesis of OA 
The synovial membrane, or synovium, is a membranous structure that lies 
between articular capsule and joint cavity. The main function of synovium is to provide 
nutrients to cartilage and produce lubricants (synovial fluid) that are essential for 
normal joint movement (Firestein, Budd, O'Dell, Gabriel, & McInnes, 2012). The 
normal synovial membrane consists of two distinct structures: (1) intimal lining layer, 
comprised of synovial lining cells; (2) Synovial sublining, which consists of 
connective tissue containing blood vessels, fibroblasts, adipocytes, and a certain 
number of monocytes/macrophages and mast cells (M. Smith et al., 2003).  
In contrast to rheumatoid arthritis (RA), OA has long been described as a non-
inflammatory disease due to the absence of neutrophils (a marker of classical 
inflammation) in the synovial fluid, especially in hand and knee OA (Vlad, Neogi, 
Aliabadi, Fontes, & Felson, 2011). Despite this, there is increasing evidence that 
patients with OA have varying degrees of acute or chronic synovial inflammation, both 
in early and late OA; and synovitis has been recognized as a common feature in OA 
patients (Sandell & Aigner, 2001). The common features of chronic inflammatory 
arthritis include inflammatory cell infiltration and thickening of the lining layer, which 
are caused by hyperplasia of the lining cells with a dense cellular infiltrate mainly 
consisting of lymphocytes and monocytes/macrophages through to a synovial 
membrane (D. Loeuille et al., 2005; M. D. Smith, Triantafillou, Parker, Youssef, & 
Coleman, 1997). Histological studies have shown that, in some cases, OA synovial 
inflammatory infiltrates of mononuclear cells were indistinguishable from infiltration 
observed in RA (Goldenberg, Egan, & Cohen, 1982; Lindblad & Hedfors, 1987; 
Revell, Mayston, Lalor, & Mapp, 1988). Synovitis and synovial inflammation can be 
defined histologically by the pattern of synovial changes (Figure 2.5). It seems the 
accumulation of monocytes/macrophage induces hyperplasia of the lining cells and the 
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subsequence development of synovial membrane inflammation. The presence of 
increased numbers of macrophages in synovium (human, OA patients), infra-patella 
fat pad (bovine model), and subchondral bone (human, OA patients) are detected both 
in early and late OA (Bastiaansen-Jenniskens et al., 2012; Benito, Veale, FitzGerald, 
van den Berg, & Bresnihan, 2005; Lisignoli et al., 1999). Bondeson and colleagues 
tested synovial cells from human synovial specimens and suggested that inflammation 
of the synovial membrane is one of the main contributors to cartilage matrix 
destruction, and it is driven by the release of  cytokines through activated synovial 
macrophages (J. Bondeson, 2010).   
               
Figure 2.5: Microscopic features of the normal versus OA synovial membrane in 
mouse. (A) Normal synovial membrane composed of 1-4 layers of synovial lining 
cells, infiltration is moderate. (B) Hyperplasia of the lining cells with a dense cellular 
infiltrate (OA) (Damien Loeuille et al., 2005; Neuhold et al., 2001). The arrows point 
to the synovial membrane. Scale bar = 50 μm. 
 
 22 Chapter 2: Literature Review 
2.1.2 Animal models of OA 
Animal model methods provide one pathway to investigate OA pathophysiology, 
develop ‘disease-modifying’ therapeutic agents and biologic markers for diagnosing 
and/or prognosis of the disease. OA is a heterogeneous disorder causing reduced joint 
function and pain because of a structurally damaged joint. Therefore, it is difficult to 
determine an optimal model system for such a heterogeneous condition and various 
models engaging different species are currently in use. These consist of spontaneous 
and induced (surgically, enzymatically/chemically (injection), mechanically, and 
genetically) models (A. Bendele, 2001). In all animal models, surgical methods of OA 
induction work through a combination of joint destabilization, altered articular surface 
contact forces, and intra-articular inflammation. These methods create models 
intended to represent post-traumatic OA. The surgical models include meniscectomy, 
anterior cruciate ligament (ACL) transection, and osteotomy. ‘Intra-articular injection 
of mono-ido-acetate (MIA)’ is another method of OA induction that act by stimulating 
intra-articular inflammation, direct matrix damage, and chondrocyte toxicity. These 
methods are useful for studying matrix degeneration, but are limited in that the bulk 
death of chondrocytes is not representative of either spontaneous or post-traumatic OA 
progression (Teeple, Jay, Elsaid, & Fleming, 2013). Mechanically-induced OA is 
commonly used, and is related to the possibility of inducing lesions of various 
severities by techniques that include the combinations of ligament transection and 
menisectomy in mouse knee joints and is suitable for detecting early-stage 
modifications in whole joint tissues (Cohen-Solal, Funck-Brentano, & Hay, 2013). 
 
2.1.3 Different subtypes/phenotypes of OA 
OA is a “heterogeneous” disorder with several risk factors and consists of 
various phenotypes that ultimately lead to mutual radiographic and clinical 
manifestations (Castañeda, Roman-Blas, Largo, & Herrero-Beaumont, 2013). Several 
categorizations have been performed based on the stage of disease, the main 
underlying mechanisms, involved joints, clinically relevant patient characteristics,  
and degree of inflammation (Haynes, Hume, & Smith, 2002; Herrero-Beaumont, 
Roman-Blas, Castañeda, & Jimenez, 2009; MacGregor, Li, Spector, & Williams, 
2009; Scanzello et al., 2009). It has been proposed that the various patients with knee 
OA indeed consist of different phenotypes or subgroups (Driban, Sitler, Barbe, & 
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Balasubramanian, 2010; D. T. Felson, 2010). Recognizing different phenotypes of OA 
can be very important for treatment and prevention from disease development. 
Classifying OA joints as primary and secondary OA has been disputed recently, 
as OA is “multifactorial”, with intrinsic and extrinsic causes (K. D. Brandt, Dieppe, & 
Radin, 2008). Considering the significance of causative factors, it has been suggested 
that primary OA can be classified into three subsets: (1) type 1: genetically determined 
OA, (2) type 2: hormone-dependent OA, and (3) type 3: aging related OA (Herrero-
Beaumont et al., 2009). Trauma and congenital or developmental diseases induce 
secondary OA, although inappropriate biomechanics has been regularly linked to 
primary and secondary OA.  (Altman, 1986; Roach, Aigner, Soder, Haag, & 
Welkerling, 2007). Moreover, the extra-articular contributing factors (e.g., obesity, 
overloading of joints, etc.) also play a role through the OA progression (Figure 2.6). 
Apart from mechanical overload, changed adipokine levels also contribute to the OA 
development in overweight people. (D. T. Felson et al., 1997; Iannone & Lapadula, 
2003). Recently, metabolic OA has been suggested as a new OA phenotype (Sellam 
& Berenbaum, 2013; Velasquez & Katz, 2010; Qi Zhuo, Wei Yang, Jiying Chen, & 
Yan Wang, 2012). The metabolic syndrome (MetS) frequently happens in the general 
aged population, and is related to numerous metabolic and non-metabolic 
abnormalities that possibly give rise to cardiovascular risk (Lakka, 2002). The 
worldwide prevalence of MetS ranges from <10% to 84%, depending on composition 
(sex, age, race, and ethnicity) and the region of the people studied, and the syndrome 
definition (Desroches & Lamarche, 2007; Kolovou, Anagnostopoulou, Salpea, & 
Mikhailidis, 2007). Generally, the International Diabetes Federation (IDF) estimates 
that one-quarter of the world’s adult population has the MetS (IDF). However, E 
Bonora et al. reported that approximately one-third of examined individuals, who were 
randomly recruited from the general population, turned out to be affected by the 
syndrome when they applied the World Health Organization (WHO) criteria (Bonora 
et al., 2003).  
Among different OA phenotypes, metabolic syndrome can be easily modified. 
However, little research has been undertaken to address the mechanism underlying 
these changes. Therefore, more evidence supporting the mechanism by which these 
systemic factors alter the course of OA could be useful in directing OA patient targeted 
therapies. 
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Figure 2.6: Adopted pathogenic and clinically integrated view of OA 
progression (Castañeda et al., 2013). 
 
2.2 OSTEOARTHRITIS AND METABOLIC SYNDROME  
A growing body of evidence suggests that OA is not simply a disease related to 
traditional well-known risk factors of joints, but rather a "metabolic disorder" 
(Puenpatom & Victor, 2009). Although the metabolic syndrome definition is rather 
undefined, as many criteria have been suggested, it is seen as a combination of 
conditions that enhance the cardiovascular risk, including hypertension, dyslipidemia, 
insulin resistance or diabetes, and obesity (Alshehri, 2010). The link between 
metabolic syndrome and OA may be looked from two different perspectives. OA can 
be related to either metabolic syndrome or each of its components (glucose, lipids, 
hypertension).  
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Among the metabolic syndrome components, obesity has long been documented 
as a governing condition for OA development. The effect of obesity on OA is found 
mainly in weight-bearing joints, such as the knee and hip, and has to some extent been 
linked to mechanical trauma related to excess body weight. Though, there is also 
evidence of a metabolic link between OA and obesity in non-weight–bearing joints, 
suggesting that factors other than weight play an important role (Felson & Chaisson, 
1997; Grotle, Hagen, Natvig, Dahl, & Kvien, 2008; Woolf, Breedveld, & Kvien, 
2006). 
2.2.1 Obesity and incidence of OA in humans 
Obesity is considered one of the most important risk factors for OA in knee(s). 
A systemic review and meta-analysis by Blagojevic et al. examined 36 papers 
reporting on body mass index (BMI) and reported that all demonstrated obesity and 
being overweight to be risk factors for knee OA (Blagojevic, Jinks, Jeffery, & Jordan, 
2010). To summarize, many longitudinal studies have shown a strong association 
between obesity, defined as a BMI above 30, and radiographic knee OA, e.g., in the 
Framingham Study (D. T. Felson et al., 1997), the Chingford Study (Spector, Hart, & 
Doyle, 1994), the Baltimore Longitudinal Study of Aging (M. Hochberg et al., 1995), 
the John Hopkins Precursors Study (Gelber et al., 1999), and in longitudinal studies in 
UK (C. Cooper et al., 2000) and the Netherlands (Reijman et al., 2007). More recently, 
three large population based studies that documented the link between obesity and 
knee OA were published (M. Grotle, Hagen, Natvig, Dahl, & Kvien, 2008; L. S. 
Lohmander, de Verdier, M. G., Rollof, J., Nilsson, P. M., & Engström, G, 2009; 
Toivanen et al., 2010). Another recent study also found that there was a greater risk 
for knee OA with increasing duration of being overweight (Holliday et al., 2011). 
Thus, the World Health Organization (WHO) initiative on counteracting obesity also 
accepts OA as a consequence of obesity (Woolf, Breedveld, & Kvien, 2006). However, 
the link between obesity and OA in hip(s) and hand(s) are still debated (M. Grotle et 
al., 2008; Woolf et al., 2006) and a weaker association with hip OA has been reported 
(C. Cooper et al., 1998; M. Grotle, Hagen, K. B., Natvig, B., Dahl, F. A., & Kvien, T. 
K, 2008b). In another study, however, obesity was associated with more OA severity 
not only at the knee, but also at the hip, with earlier and more frequent hip replacement 
surgery in patients who had high body mass index (BMI) values (L. S. Lohmander, de 
Verdier, M. G., Rollof, J., Nilsson, P. M., & Engström, G, 2009). A strong link 
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between obesity and radiographic hip OA has been demonstrated in some cross-
sectional studies (C. Cooper et al., 1998; Hartz et al., 1986; Heliövaara et al., 1993; 
Tepper & Hochberg, 1993; Vingård, Alfredsson, & Malchau, 1997), as well as in 
longitudinal studies (Järvholm, Lewold, Malchau, & Vingård, 2005; Oliveria, 1999; 
Vingård, 1991). In large longitudinal studies of Gelber et al. (Gelber et al., 1999) and 
Reijman et al. (Reijman et al., 2007) high BMI was related to hip OA. Moreover, large 
cross-sectional studies have not found  a strong relationship between hand OA and 
obesity in either males or females (Bagge et al., 1991; M. A. Davis, Neuhaus, J. M., 
Ettinger, W. H., & Mueller, W. H, 1990; M. C. Hochberg, Lethbridge-Cejku, Scott, 
Plato, & Tobin, 1993), although some data have recognized that obese patients have a 
higher chance of developing hand OA (Carman, Sowers, Hawthorne, & Weissfeld, 
1994; Oliveria, 1999). 
 
Table 2.2: Summary of literature studying the association between obesity and 
OA in humans. 
                References Study 
design 
                           Results 
D. T. Felson & Chaisson 
(1997) 
Cohort High body mass was associated with 
increased risk of radiographic OA and 
weight loss is directly associated with 
the decreased risk of OA development. 
Spector et al. (1994) Cohort Obesity was an important factor 
correlated to OA incidence, 47% of 
women with high BMI had OA, 
compared with 10% in low BMI group. 
M. Hochberg et al. (1995) Cohort Women and men in the highest MBI 
group had a significantly increased 
chance of developing both definite and 
bilateral knee OA. 
Gelber et al. (1999) Cohort The incidence of knee, but not hip, OA 
was highly related to BMI index 
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evaluated at ages 20 to 29 years and 30 
to 39 years. 
G. M. Cooper (2000) Cohort The risk of incident radiographic knee OA 
was significantly higher among 
individuals with higher BMI index after 
adjusting for age and sex.  
Reijman et al. (2007) Cohort A high BMI was linked to incidence of 
knee OA, but not with incidence of hip 
OA. Similarly, a high BMI was correlated 
with knee OA progression. A significant 
link between hip OA progression and 
BMI was not found. 
L. S. Lohmander, de 
Verdier, Rollof, Nilsson, 
& Engström (2009) 
Cohort All measures of being overweight were 
related with the incidence of knee OA, 
with the strongest relative risk gradient 
detected for BMI. The incidence of hip 
OA revealed smaller but significant 
differences between normal weight and 
obesity. 
Toivanen et al. (2010) 
 
Cohort The risk of developing knee OA was 
significantly correlated with BMI after 
adjustment for age and gender and 
other variables, and compared with the 
normal BMI group (BMI < 25.0). 
M. Grotle et al. (2008) Cohort After adjustment for age, gender, work 
status etc., a high BMI (> 30) was 
strongly related to knee OA and a dose-
response association was found for this 
relationship. In addition, obesity was 
strongly associated with hand OA, but 
not with hip OA. There was no 
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statistically significant interface effect 
between BMI and gender, age, or the 
other variables. 
Holliday et al. (2011) Case-
control 
BMI was related to knee and hip OA. 
Those who became obese earlier in 
adulthood displayed higher risks of 
lower limb OA. 
C. Cooper et al. (1998) Case-
control 
Obesity and previous hip injury were 
independent risk factors for hip OA 
among men and women. 
M. C. Hochberg et al. 
(1993) 
Cohort Age was strongly correlated with hip OA; 
though, other sociodemographic factors, 
obesity, and fat distribution were not 
related to hip OA. 
Vingård et al. (1997) Case-
control 
The relative chance of hip OA incidence 
resulting in total hip replacement after 
the age of 50 was associated with an 
increased BMI.  
Oliveria (1999) Case-
control 
The body weight was a risk factor for the 
hand, hip, and knee OA incidence.  
Järvholm et al. (2005) Cohort The relative risk for hip OA was more 
than two times greater in individuals 
with a BMI of 20-24 than in people with 
a BMI 17-19.  
 
 
2.2.2 In vivo association between obesity and OA 
Although obesity is noticeably linked to clinical OA, only a few animal models 
have been used to study the link between OA and obesity (Griffin & Guilak, 2008). 
These animals are usually rodent models that are either developed with high-fat diet 
or are overweight/obese inbred strains that spontaneously develop OA. Obese mouse 
 Chapter 2: Literature Review 29 
models on a high-fat diet, specifically the C57BL/6J strain, have been widely used as 
animal models to study human obesity (S. Collins, Martin, Surwit, & Robidoux, 2004). 
C57BL/6J on a high-fat diet showed more severe phenotypical changes similar to OA 
at an earlier age than C57BL/6J mice on a low-fat control diet (Griffin et al., 2010; 
Silberberg, 1950b, 1960; Sokoloff, Mickelsen, Silverstein, Jay, & Yamamoto, 1960). 
During these animal model studies, the prevalence of OA is comparable in males and 
females (Silberberg, 1950b), and interestingly a lard-based fat diet develop more 
severe OA than vegetable-based fat diet (Silberberg, 1960; Sokoloff et al., 1960). 
High-fat diet is also able to initiate OA-like changes in rats (Silberberg, 1960; Sokoloff 
et al., 1960). The STR/Ort mouse and the Hartley guinea pig, which are inbred strains 
of spontaneous OA, may be considered obese animal models of OA in comparision to 
other mouse and guinea pig strains, respectively (Mason et al., 2001; Sokoloff et al., 
1960). Remarkably, a recent study has demonstrated that STR/ort mice have three 
chromosomal locations linked with body weight or fatty acid metabolism using 
quantitative trait studies (Jaeger et al., 2008). In another study, body weight control in 
the Hartley guinea pig by food restriction significantly decreased the severity of OA 
in the knee joints (A. M. Bendele & Hulman, 1991).  It has been reported that 
C57BL/6J mice on high-fat or low-fat fed diets with significantly increased body 
weights compared to diet-matched mice showed OA-like changes, confirming an 
association between OA and body weight. However, mice on a low-fat diet who did 
not develop OA and mice on high-fat diet  whodeveloped OA had comparable body 
weights, signifying that weight alone did not contribute to high-fat diet-induced OA 
(Silberberg, 1950a). 
All of the studies using these animal models of OA have suggested that body 
weight is a factor that facilitates the progress of spontaneous knee OA. However, 
recent studies in obese mice have reported that leptin-impaired mice, which developed 
morbidity obesity, did not exhibit knee OA (Griffin, Huebner, Kraus, & Guilak, 2009). 
Moreover, mice on extremely high-fat diet (60% fat measured by kilocalories) 
developed knee OA, which was moderately improved by exercise, without any weight 
loss (Griffin, Huebner, Kraus, Yan, & Guilak, 2012).  
This evidence suggests that adiposity (or weight) alone may not be a contributing 
factor for joint degradation, but that  inter-relationships amongst diet, joint loading and 
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local or systemic inflammation may play a role in OA development (Guilak et al., 
2004). 
 
Table 2.3: Summary of literature studying the association between obesity and 
OA in vivo  using animal models. 
             Authors    Animal model                         Results 
Silberberg (1950b) 
 
C57BL/6J mice The OA incidence in C57BL/6J 
mice fed a high-fat diet increased 
significantly two-fold with 
increasing age compared to 
animals fed a lower-fat control 
diet. 
Silberberg (1960) C57BL/6J mice In male C57BL mice, a stock diet 
enriched with 25% cottonseed oil 
did not adversely influence the 
course of OA compared with 
animals fed a stock diet enriched 
with 25% lard. 
Sokoloff et al. (1960) DBA/2JN 
C57L/HeN, 
STR/N mice  
Osborne-Mendel 
rats 
The highest fat content diet 
induced OA in two strains of mice 
and in the rat. Weight-gain 
induced with lower fat diets did 
not raise the OA incidence. 
DBA/2JN mice did not develop 
OA when fed the 60% vegetable 
fat diet. 
Griffin et al. (2010) C57BL/6J mice Dietary-induced obesity in mice 
was associated with increased 
knee OA changes and impaired 
musculoskeletal force generation 
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compared with controls. In 
addition, a high-fat diet caused 
symptomatic OA phenotype. 
Jaeger et al. (2008) STR/ort × C57BL/6J 
mice 
Elevated weight, serum cartilage 
oligomeric matrix protein (COMP) 
levels and knee OA changes in 
the F2 generation compared to 
C57BL/6 parental animals 
confirm Mendelian inheritance. 
Quantitative trait analyses 
revealed three weight-, one 
serum COMP- and one OA-locus. 
A. M. Bendele & 
Hulman (1991) 
guinea pigs The severity of the OA lesions 
was decreased by 40%, in 
combination with a 28% body 
weight reduction, in the diet-
restricted group. These results 
point out that body weight in 
guinea pigs, as in humans, is a 
significant risk factor for knee OA 
development. 
Griffin et al. (2009) leptin deficient 
(ob/ob) and leptin 
receptor deficient 
(db/db) mice 
Adiposity was increased 
approximately 10-fold in ob/ob 
and db/db mice compared to 
controls, but it was not related 
with more knee OA occurrence. 
In addition, serum cytokine levels 
were not altered in ob/ob and 
db/db mice compared to 
controls. Leptin impairment was 
correlated with decreased 
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subchondral bone thickness and 
increased trabecular bone 
volume in the tibia. 
Griffin et al. (2012) C57BL/6J mice Feeding mice with a very high-fat 
diet elevated knee OA scores. 
Wheel-running exercise 
decreased OA progression in the 
medial femur of obese mice.  
 
2.2.3 How does obesity influence OA development? 
The pathophysiology of obesity-induced OA is dependent on many different 
elements. The association between mechanical loading and the condition of the joint 
was highlighted in many in vivo studies, and proposed that the normal mechanical 
regulation of chondrocyte activity might be adversely affected by the presence of 
cytokines and pro-inflammatory mediators in the joint. Structural joint damage can 
occur due to mechanical factors, such as increased forces about the joint, decreased 
muscle strength, and changed biomechanics throughout daily activities (King et al., 
2008; Runhaar, Koes, Clockaerts, & Bierma-Zeinstra, 2011), and metabolic elements, 
such as obesity also raise the risk of OA development  in joints like the hands (M. 
Grotle, Hagen, K. B., Natvig, B., Dahl, F. A., & Kvien, T. K, 2008a; Oliveria, 1999; 
A. J. Teichtahl, Wluka, A. E., Wang, Y., Hanna, F., English, D. R., Giles, G. G., & 
Cicuttini, F. M, 2009).  
 
2.2.3.1. Biomechanical mechanism 
One obvious mechanism that obesity would contribute to the pathogenesis of 
OA is increased load and force on the weight-bearing joints as a consequence of 
obesity through additional mechanical load (D. T. Felson, 1996). These excess forces 
increase stress in articular cartilage and induce its final breakdown, which 
consecutively causes proliferation of periarticular bone and results in reduced joint 
space. 
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A recent study by Moyer et al. designated this linkage, presenting a link between 
dynamic knee joint loading and body weight (Moyer, Birmingham, Chesworth, Kean, 
& Giffin, 2010). Clinical and animal findings have demonstrated that excess loads can 
modify the configuration, structure, and mechanical properties of cartilage, resulting 
in the primary OA (Maly, 2005; Mündermann, 2005; Rejeski, Craven, Ettinger, 
McFarlane, & Shumaker, 1996; M. R. Sowers & Karvonen-Gutierrez, 2010). Gushue 
and colleagues completed a gait study and remarked that their “overweight group of 
children showed a significantly higher peak internal knee abduction moment in early 
stance” and that “these data suggest that overweight children may not be able to 
compensate for alterations in the frontal plane during gait, which may lead to increased 
medial compartment joint loads” (Gushue, Houck, & Lerner, 2005). In another study, 
a strong link between body weight and peak values of compressive forces, abduction 
moments , resultant forces,  and the medial rotation moments of the knee has been 
found; each pound of weight loss leads to a four-fold decrease in load per step through 
regular activities (Messier, Gutekunst, Davis, & DeVita, 2005).  
Recently, mechanoreceptors were found to exist on the surface of chondrocytes 
(A. J. Teichtahl, Wang, Wluka, & Cicuttini, 2008). Moreover, two studies also 
demonstrated that weight gain elevates the mechanoreceptors activation within the 
cartilage ‘(stretch-activated channels, a-5B1 integrin, CD44 on chondrocytes)’ (Guilak 
et al., 2004; Pottie et al., 2006). It has been hypothesised that the mechanical 
stimulation of these mechanoreceptors might increase the expression of growth 
factors, cytokines, and metalloproteinases, generating mediators such as nitrous oxide 
and prostaglandins (Guilak et al., 2004). Although it has not been well-studied, these 
series of actions may result in extra oxidative stress, inflammation, and the onset of 
cartilage degradation (Pottie et al., 2006).  
Another potential biomechanical mechanism that plays a role in the pathogenesis 
of obesity-induced OA involves muscle strength. Biomechanically, muscles and 
muscle forces strongly contribute in the load diffusion across the joint (M. R. Sowers 
& Karvonen-Gutierrez, 2010). It has been reported that obesity may lead to muscles 
weakness, which will possibly cause more stress on the articular cartilage, activating  
growing degradation of the joint (Segal, Zimmerman, Brubaker, & Torner, 2011). 
Amin et al. suggested that patients with stronger quadriceps have less degradative 
cartilage at the lateral compartment of the patellofemoral joint, along with less pain 
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and improved physical knee function at follow-up (Amin, 2009). Moreover, animal 
studies of muscle weakness suggested when muscle weakness was combined with a 
local inflammation there was a trend towards an increased rate of cartilage damage 
compared to muscle weakness alone (Egloff et al., 2014). Andersone et al. reported 
that non-invasive knee injury do not result in increased levels muscle weekness 
markers in injured mice compared to sham mice (Anderson et al., 2016). On the other 
hand, recent papers show that knee OA patients have the same (Meireles et al., 2016), 
or lower loading that healthy matched controls (Adouni and Shirazi-Adl, 2014; 
Wellsandt et al., 2016).  
 
2.2.3.2. Systemic inflammatory mechanism 
Another mechanism that plays a role in the pathophysiology of obesity-induced 
OA is systemic inflammation. Although clinically untreated RA has been well-known 
to stimulate the body’s inflammatory system, it has recently been proposed that 
untreated OA also shows clinical and joint tissue inflammatory response. Adipose 
tissue, which was believed to  beonly an energy store, is an endocrine organ that is 
able to secrete cytokines and cytokine-like molecules termed adipokines (Pottie et al., 
2006; M. R. Sowers & Karvonen-Gutierrez, 2010). Therefore, finding that stimulated 
macrophages inside adipose tissue release cytokines and adipokines influences other 
cells and tissues through the body led to new characterization of obesity as a mild, 
chronic inflammatory disorder.  
 Twospecific adipokines, leptin and adiponectin, are believed to be the most 
important molecules playing a role in the association of obesity and OA,  andhave been 
the focus of more recent studies (Weisberg et al., 2006; Weisberg et al., 2003; Xu, 
2003). It has been suggested that dysregulated adipokines levels in obese individuals 
might be mostly key mediators, as a biochemical environment results from obesity 
makes chondrocytes unable to respond to such challenges. As an example, 
chondrocytes from obese OA patients have been demonstrated to respond differently 
to leptin levels compared with normal or overweight patients (Stéphane Pallu, 2010). 
In another study, it has been shown that people with OA exhibit strongly increased 
levels of leptin and adiponectin than controls (de Boer et al., 2012); however, notable 
weight loss in obese individuals with knee OA showed reduced circulating levels of 
leptin, but an increase in adiponectin levels (Richette et al., 2011).  
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These findings suggest that the very high level of leptin in obese individuals have 
directed researchers to propose a leptin resistance syndrome as a similar concept to 
insulin resistance. Consistently, body mass is directly related to the level of leptin in 
OA people. Moreover, it has been identified that leptin and its receptor, which  is 
present in human chondrocytes, osteophytes (Dumond et al., 2003; Gegout, Francin, 
Mainard, & Presle, 2008), synovium, and infrapatellar fat pad (Presle et al., 2006), 
might influence growth factor metabolism and regulation. Analysis of cartilage, 
subchondral bone, and osteophytes evidence that  increased leptin expression is highly 
linked to the grade of cartilage degradation (Dumond et al., 2003; T. Simopoulou et 
al., 2007) and it has been reported that leptin and proinflammatory cytokines have a 
synergistic effect (Dumond et al., 2003). The direct pro-inflammatory and catabolic 
role of leptin in cartilage homeostasis was further confirmed when chondrocytes from 
OA patients, which stimulated with leptin, showed increased IL-1b, MMP-9, and 
MMP-13 levels (T. Simopoulou et al., 2007), suggesting leptin or its receptor as a new 
therapeutic target. Leptin may also contribute to the OA development through 
peripheral and central mechanisms that regulate bone mass  (Ducy et al., 2000; 
Kishida, 2005). In ob/ob mice, leptin deficiency lead to a mosaic bone mass phenotype 
with increased bone mass in the axial skeleton and decreased bone mass in the 
appendicular skeleton (Hamrick, Pennington, Newton, Xie, & Isales, 2004). In another 
animals study, the lack of the leptin gene, as perceived in ob/ob mice, elevated 
hypertrophic chondrocyte apoptosis and weakened endochondral ossification 
(Kishida, 2005). 
While there is growing evidence highlighting the association between leptin and 
OA, the functional role of adiponectin and joint damage, with both reported anti-
inflammatory and pro-inflammatory properties has been less investigated (Gomez et 
al., 2011; Tilg & Moschen, 2006). It has been reported that adiponectin induces 
metalloproteinase 1 expression in synovial fibroblasts in OA patients, signifying a 
potential catabolic character in cartilage homeostasis (Pottie et al., 2006). Conversely, 
another study has reported a possible protective role against OA for adiponectin (M. 
R. Sowers & Karvonen-Gutierrez, 2010). Therefore, further research will be needed 
to clarify the roles of these adiponectin in the OA pathogenesis. 
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2.2.3.3. Metabolic–related mechanism 
Apart from adipocytokines, obesity can cause other systemic impacts associated 
with OA, such as roles for dysregulated glucose and lipid metabolism (Manuel T. 
Velasquez 2010). Consequential metabolic alterations from insulin resistance and 
elevated glucose levels are closely associated with the production of pro-inflammatory 
cytokine, which is a typical feature of a chronic inflammation (Tamakoshi et al., 2003). 
Moreover, the generation of advanced glycation end products (AGEs), i.e. substances 
that can be a factor in speeding up oxidative damage to cells and in changing their 
normal behaviour under metabolic syndrome can be linked with changes in the 
mechanical properties of the cartilage extracellular matrix,  increased collagen 
stiffness, and reduced proteoglycan synthesis, thus probably leading to cartilage 
degradation (DeGroot, 2004). Remarkably, chondrocytes express the functional 
receptor for AGEs, which induces production of pro-inflammatory cytokines via 
stimulation with ligands (Loeser et al., 2005). 
These data propose that systemic metabolic change is a potential mechanism 
playing a part between obesity and OA. In a review study Sowers & Karvonen-
Gutierrez have summerized supporting evidence of metabolic relationship between 
OA and obesity (M. R. Sowers & Karvonen-Gutierrez, 2010). A recent study reported 
that mid-aged women who had BMI ≥30 kg/m2 (characterized as obese) and had two 
or more cardiovascular risk factors had a more than six times chance of having knee 
OA compared to non-obese females without cardiometabolic clustering. 
Cardiometabolic risk factor clustering includes the prevalence of two or more of the 
following factors: ‘HDL-c, LDL-c, triglycerides, blood pressure, waist: hip ratio, 
glucose, and C-reactive protein’. (M. Sowers et al., 2009).  
In a massive cohort study of the general US population, the incidence of 
metabolic syndrome was higher in OA patients even after adjustment for BMI and age 
(Puenpatom RA, 2009). A Japanese ROAD study found that the prevalence of having 
more metabolic-syndrome components was related to an accelerating risk of knee OA 
(Yoshimura et al., 2012). In another study, the incidence of obesity and at least two 
other metabolic-syndrome components in women was linked to an greater risk of knee 
OA compared to obesity itself (M. Sowers et al., 2009). The same synergistic results 
for hand OA were reported for accumulation of hypertension and diabetes over obesity 
(S. Dahaghin, Bierma-Zeinstra, S. M., Koes, B. W., Hazes, J. M., & Pols, H. A, 2007). 
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Radiological evidence has suggested that hypertension, hypercholesterolemia, and 
blood glucose are related to the incidence of knee OA independent of obesity 
supporting the conception that consequential systemic and metabolic component 
contribute to OA etiology (DEBORAH J Hart, DAVID V Doyle, & Tim D Spector, 
1995). Interestingly, it has been demonstrated that each of the components of 
metabolic syndrome may similarly be linked with OA (Qi Zhuo et al., 2012), although 
available data are rather inconsistent (Qi Zhuo et al., 2012).  Recently, Berenbaum et 
al., reviewed papers studying the role of diabetes in the initiation of OA  and 
showedthere were strong relationships between diabetes and OA from in vivo and 
epidemiological studies.  However, they suggested more in vitro and in vivo 
experimental models were needed to obtain a better understating of the underlying 
mechanism (Berenbaum, 2012). Back to the last century, the correlation between lipid 
abnormalities and OA was raised by the presence of increased levels of serum 
cholesterol in OA patients (DEBORAH J Hart et al., 1995; T. Stürmer et al., 1998). 
The levels of total fatty acids and arachidonic acid from OA cartilages have been 
shown to increase with greater severity of cartilage damage (Lippiello, Walsh, & 
Fienhold, 1991). Moreover, in OA cartilage, decreased expression of genes regulating 
for cholesterol uptake was detected (Aspasia Tsezou, Dimitrios Iliopoulos, 
Konstantinos N Malizos, & Theodora Simopoulou, 2010); althought; more in vitro and 
in vivo models are required to establish this correlation. As metabolic disorders have 
recently been regarded as new risk factors for OA, it is important to study the effect of 
each component of the syndrome (glucose, lipids, and hypertension) on joint tissues 
and cells. The most important concern resulting from current data is that few studies 
have investigated the effect of each MetS component independent of obesity. Such a 
component is hypercholesterolemia, which has been shown as possibly existing in non-
obese individuals with normal BMI (Giltay et al., 1998; Vikram et al., 2003). Although 
hypercholesterolemia’s role in the pathogenesis of different diseases is well-known, 
more confirmatory in vivo evidence is required to establish the role as a risk factor in 
the development of OA and for potential treatment options. 
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Table 2.4: Summary of literatures studying association between MetS and OA.  
            Authors         Study design                      Results 
M. Sowers et al. 
(2009) 
Cohort The knee OA prevalence in non-
obese women without 
cardiometabolic clustering was 
4.7%, compared to 12.8% in obese 
women without cardiometabolic 
clustering and 23.2% in obese 
women with cardiometabolic 
clustering. Non-obese women 
without cardiometabolic clustering 
were less likely to perceive 
themselves as limited compared to 
women in all other 
obesity/cardiometabolic groups. 
Puenpatom RA 
(2009) 
Cohort Each of the five cardiovascular risk 
factors that comprise MetS was 
more prevalent in the OA 
population versus the population 
without OA. Metabolic syndrome 
was more prevalent in subjects 
with OA regardless of sex or race. 
The association between OA and 
MetS was greater in younger 
subjects and diminished with 
increasing age.  
Yoshimura et al. 
(2012) 
Cohort Logistic regression analyses after 
adjusting for possible risk factors 
showed that the knee OA 
occurrence strongly increased 
according to the number of MetS 
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components present. In addition, 
progression of knee OA 
significantly increased based on 
the number of MetS components 
present. 
S. Dahaghin, Bierma-
Zeinstra, S. M., Koes, 
B. W., Hazes, J. M., & 
Pols, H. A (2007) 
Cohort The association between diabetes 
and hand OA was only present in 
people aged 55–62 years, but was 
absent in the total population or in 
other age groups.  
The association of hypertension 
with hand OA was weak, and 
disappeared when BMI was 
adjusted.  
There was no significant 
association between total/HDL 
cholesterol ratio and hand OA. The 
concurrent presence of 
overweight, diabetes and 
hypertension resulted in an even 
higher prevalence of hand OA 
compared with people without 
these conditions; this occurrence 
was higher in the youngers. 
DEBORAH J Hart et 
al. (1995) 
Cohort There were significant associations 
between bilateral knee OA and 
hypertension and both high and 
moderately elevated serum 
cholesterol. No correlation was 
found with elevated triglyceride or 
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HDL levels or with current systolic 
blood pressure.  
Berenbaum (2012) 
 
Review paper A number of epidemiological and 
experimental data support the 
hypothesis that diabetes might be 
a self-governing risk factor for OA 
bringing on the conception of a 
diabetes-induced OA phenotype. 
 
2.3 CHOLESTEROL 
Cholesterol is required by all mammalian cells for growth and maintenance and 
it functions as a stabilizing component of the bilaminar membranes of cells. It is also 
a component of the myelin sheath of nerves, a modified plasma membrane (PM), and 
is present in all plasma lipoproteins. The cholesterol in tissues and plasma may be in 
free (unesterified) or esterified form; however, most of the total cholesterol in the 
animal body is present as free cholesterol (Myant, 1990). Cholesterol also plays a role 
in intracellular transport, cell signalling and nerve transmission within the cell 
membrane (Hanukoglu, 1992; Simons & Toomre, 2000). 
There are the two potential sources of cholesterol in the organism: diet and 
synthesis. From a dietary perspective, cholesterol is noticeably found in animal fats, 
which are complex combinations of triglycerides. Therefore, all foods with animal fat 
contain cholesterol with different ranges (Christie, 2010). The cholesterol present in a 
specific tissue has either been synthesised de novo in the cells of that tissue, or was 
derived from circulating lipoprotein cholesterol. Approximately 20–25% of total daily 
cholesterol production takes place in the liver, while the reproductive organs, adrenal 
glands, and the intestines are other sites of high synthesis rates.The liver converts 
carbohydrates and fatty acids into triglycerides, which it packages into lipoproteins to 
deliver to tissue. The liver uses dietry source of sterol for lipoprotein synthesis, when 
that is available. When dietary cholesterol is inadequate, the liver synthesizes its own 
cholesterol (Clayton, 1998).  
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2.3.1 Cholesterol biosynthesis 
All cells produce cholesterol with corresponding manufacture rates for their use, 
differing by cell type and organ function. Cholesterol is derived from acetyl-CoA 
through the isoprenoid pathway in endoplasmic reticulum (ER) (Horton, Goldstein, & 
Brown, 2002). Most cellular cholesterol is produced from de novo synthesis in 
extrahepatic tissues (Dietschy & Turley, 2001), while hepatocytes (liver cells) find 
most of their cholesterol by receptor-mediated uptake of plasma lipoproteins including 
low-density lipoprotein (LDL). Following internalization of LDL by the LDL receptor, 
it is transported to lysosomes through the endocytic pathway, where hydrolysis of the 
core cholesteryl esters (CE) occurs. ‘Cellular cholesterol levels are also controlled by 
a cycle of cholesterol esterification mediated by acyl-CoA:cholesterol acyltransferase 
(ACAT) and hydrolysis of the CE, by cholesterol metabolism to bile acids and 
oxysterols, and by cholesterol efflux’ (Liscum, 2008). 
Figure 2.7 provides more detail regarding the cholesterol biosynthetic pathway. 
Sterols are manufactured from the two-carbon building block, acetyl-CoA. The acetyl-
CoA and acetoacetyl-CoA, which are converted to each other by soluble enzyme 
acetoacetyl-CoA thiolase, condensed later by 3-hydroxy-3-methylglutaryl (HMG)-
CoA synthase to procedure HMG-CoA. Using two molecules of NADPH, HMG-CoA 
reductase catalyses the reduction of HMG-CoA to mevalonate. HMG-CoA reductase 
is the rate-determining enzyme of the cholesterol biosynthetic pathway and, like 
HMG-CoA synthase, is tightly controlled by the source of cholesterol. This is the 
regulated, rate-limiting and irreversible step in cholesterol synthesis and is the site of 
action for the statin drugs (Panini, 1993; Vance & Vance, 2002). 
Mevalonate is decarboxylated to isopentenyl pyrophosphate, which is a main 
metabolite for several biological responses. Three molecules of isopentenyl 
pyrophosphate condense to make farnesyl pyrophosphate via the action of geranyl 
transferase. Two molecules of farnesyl pyrophosphate then condense to generate 
squalene by means of squalene synthase. Oxidosqualene cyclase then mediates 
squalene for the production of lanosterol. Lastly, cholesterol results from lanosterol 
through a series of oxidations, reductions, and demethylations (Kim, 2001; Vance & 
Vance, 2002). Apart from endogenous cholesterol biosynthesis, the exogenous source 
of cholesterol that comes from external dietary intake is another important proportion 
of circulating lipoprotein cholesterol. 
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Figure 2.7: Pathway of cholesterol biosyntheisis from Acyl-colA.  
 
2.3.2 Absorption of dietary cholesterol 
Dietary cholesterol is absorbed from bile salt in the proximal parts of the small 
intestine. During the past few years, the role that main proteins play in dietary 
cholesterol uptake has been recognized. It has been found that protein Niemann-Pick 
C1-Like 1 (NPC1L1) is one of the key proteins that contributes to this process (Aiello, 
Brees, & Francone, 2003). The NPC1L1 protein is critical for intestinal uptake of  
cholesterol and is localized to the brush-border membrane of enterocytes (H. R. Davis, 
Zhu, L. J., Hoos, L. M., Tetzloff, G., Maguire, M., Liu, J., . . . & Lund, E. G, 2004). 
Recent research also proposes that the cholesterol-lowering drug ezetimibe 
targets NPC1L1 protein (Garcia-Calvo et al., 2005; L. Yu et al., 2006). However, it is 
not clear whether the NPC1L1 plays a direct role as a typical cholesterol transporter 
via the plasma membrane or indirectly contributes to the process. Moreover, the family 
of ATP-binding cassette (ABC) transporters, i.e. cholesterol-to-bile half-transporters 
ABCG5 and ABCG8 (sterolin-1 and sterolin-2) form a functional components in 
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controlling sterol absorption (Graf et al., 2002; Turley & Dietschy, 2003). The ABCG5 
and ABCG8’s indirect role in dietary cholesterol absorption is to inhibit dietary 
cholesterol uptake by enterocytes, which triggers hepatic sterol excretion into the bile, 
and thus controls the bile-acid/sterol ratio, most likely to stimulate the secretion of 
absorbed sterols from the intestinal epithelium back into the gut lumen (D. Y. Hui & 
Howles, 2005). Therefore, it is important for the body to take different regulatory 
mechanisms to maintain a normal circulating cholesterol level.  
 
2.3.3 Cholesterol regulation 
The level of cholesterol synthesis in the liver is largely controlled by cholesterol 
intake, which is transported to cells throughout the body by lipoproteins. When the 
dietary intake of cholesterol is high, synthesis is reduced; and when the dietary intake 
is low, synthesis is increased (Goldstein & Brown, 2001). Conversely, cholesterol 
synthesised in other tissues is not controlled by such a mechanism, and therefore 
requires other regulatory molecules to maintain normal cholesterol levels. 
First of all, when cholesterol levels are increased in other tissues, there is a rapid 
response of esterification of excess cholesterol by an endoplasmic reticulum (ER) 
enzyme, acyl CoA:cholesterol acyltransferase (ACAT) (Chang, 1997). The ACAT 
activity as a cholesterol homeostatic sensor controlled by cholesterol levels (Tabas, 
2002). This regulation happens at the following levels: ACAT is allosterically 
regulated by cholesterol (Zhang et al., 2003), and accumulation of cholesterol in cells 
stimulates more prompt efflux of sterol from the plasma membrane (Wüstner, Mondal, 
Tabas, & Maxfield, 2005), which might promote the delivery rate to ACAT in the ER 
(Lange, Ye, & Steck, 2004).  
Many other genes contribute to cholesterol metabolism at the next level, which 
are controlled by SREBP (sterol regulatory element-binding proteins) (Brown & 
Goldstein, 1999). At the high cholesterol levels, SREBP and SCAP (SREBP cleavage-
activating protein) are reserved in the ER by binding to a resident ER protein, INSIG 
at the low cholesterol levels, the SREBP–SCAP complex leaves the ER, and SREBP 
is cleaved by two proteases. After this proteolytic leavage, the cytosolic domain of 
SREBP is released and transported into the nucleus, which then controls several genes 
transcription such as the LDL receptor and HMG-CoA reductase, the cholesterol 
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synthesis rate-limiting enzyme. Therefore, this process controls both the cholesterol 
synthesis and its absorption via lipoproteins. 
Cholesterol efflux within cells is a third mechanism of cholesterol regulation. 
Although the molecular mechanisms involved in cholesterol export have been 
investigated over the years, there are still important knowledge gaps regarding the 
function and regulation of these systems. High-density lipoproteins (HDLs) and one 
of their related apolipoproteins, ApoA-I are the most important extracellular molecules 
for cholesterol uptake (Tall, Costet, & Wang, 2002), whereas the ABC transporters 
deliver cholesterol and phospholipids to apolipoproteins, and any dysregulation during 
this transport results in different human disorders (Pohl, Devaux, & Herrmann, 2005). 
Moreover, it has been suggested that the lipid-bilayer properties of cell membrane 
effect cholesterol efflux, but the exact mechanisms undergoing this influence is not 
clear. In a study, expression of caveolin, the coat protein of caveolae, has been  
associated with cholesterol efflux and it has been suggested that these cholesterol-rich 
domains in membranes might be a cholesterol efflux site (Fielding & Fielding, 2001). 
In most peripheral tissues, cholesterol metabolism is a minor biological pathway. 
Most cells transform a small fraction of cholesterol to oxysterols (Schroepfer, 2000), 
which are key intracellular signalling molecules. For instance, excess cellular 
cholesterol activates the nuclear liver X receptor/retinoid X receptors (LXR/RXR), 
possibly using oxysterol intermediates, which initiates a ‘reverse cholesterol transport’ 
(RCT) system, including both efflux of cellular cholesterol and delivery of the effluxed 
cholesterol to the liver for bile discharge (Costet et al., 2003). Precisely, activation of 
LXR/RXR results in the induction of the efflux receptors ABCA1 (ATP-binding 
cassette transporter sub-family A member 1) and ABCG1(ATP-binding cassette sub-
family G member 1), the plasma lipid transfer proteins (CETP), the cholesterol-to-bile 
transporter ABCG5/G8 and the efflux enhancer apolipoprotein E (Chawla, Repa, 
Evans, & Mangelsdorf, 2001; Oram, 2002; Tall et al., 2002). Inside the liver, 
cholesterol is discharged into the bile both as free cholesterol and after alteration to 
bile acids.  
To maintain biophysical properties of the cell membrane, not only cholesterol 
regulation, but also the degree of the acyl chains unsaturation in phospholipids play a 
key role. The fatty acids are required for integration into phospholipids and their levels 
are regulated by many factors, such as their extracellular availability (e.g., via dietary 
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sources), as well as a network of metabolic regulatory systems. In addition to the 
SREBP role in cholesterol synthesis, it has important impacts on proteins levels 
contributing to fatty-acid synthesis and metabolism (Horton et al., 2002). Moreover, 
SREBP, along with other transcriptional regulators of fatty-acid metabolism including 
the LXRs, hepatocyte nuclear factor, and the peroxisome proliferator-activated 
receptors (PPARs) may all be regulated by polyunsaturated fatty acids (Horton et al., 
2002; Sampath & Ntambi, 2005). This regulatory system impacts the fatty acids levels 
within the cell, as well as their unsaturation, which is able to change the saturation of 
the fatty acids integrated into phospholipids in addition to cellular 
cholesterol:phospholipid ratio. Although this procedure facilitates the proper 
maintenance of cell membrane biophysical properties, it is not clear if membrane 
bilayer properties themselves directly contribute to the regulation of these pathways or 
not (Horton et al., 2002; Sampath & Ntambi, 2005). 
 
2.3.4 Cholesterol transport 
2.3.4.1. Intracellular cholesterol transport from the plasma membrane (PM) to the 
ER and from the ER to the PM 
Newly synthesised cholesterol has to move away from the ER to function. 
Therefore, it travels through a concentration gradient to get to the PM. One route from 
the ER to the PM is vesicular transport through the Golgi. Although vesicular transport 
via the Golgi can transport some newly synthesised cholesterol to the PM, it is not the 
main pathway (DeGrella & Simoni, 1982; Urbani & Simoni, 1990), as cholesterol 
transport from the ER to the PM is likely non-vesicular. Moreover, there are some 
adjacent physical membrane sites between the ER and the PM mediating this transport 
(Maxfield & Wüstner, 2002; Prinz, 2002). However, regardless of involvement of 
these sites, cytosolic transfer proteins such as the caveolin family are possibly involved 
(Puglielli et al., 1996). 
While cholesterol obviously moves from the PM to the ER using a more diverse 
method than newly synthesized cholesterol exiting the ER (Field, Born, Murthy, & 
Mathur, 1998), the mechanism underpinning cholesterol transport from the PM to the 
ER is not clear. Cholesterol might undertake vesicular transport to endosomes to get 
into the ER for esterification.  Apart from endosomes, reversing vesicular transport via 
the Golgi has been associated in PM-to-ER transfer as well (Neufeld, 1998); however, 
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PM to ER cholesterol transport is also mainly non-vesicular. Accordingly, cholesterol 
PM is believed to undergo a minimum of two routes for PM to ER transport: (1) a 
vesicular pathway through endosomes and/or Golgi; and (2) an substitute non-
vesicular pathway (Wojtanik & Liscum, 2003).  
It is thought that transport from the PM to the ER needs to be tightly regulated 
as some excess free cholesterol can remain on the large  surface  area  of the ER  
and synthesize phospholipids (Blanchette-Mackie, 2000; Tabas, 2002). It has been 
reported that excess PM cholesterol triggers an apoptotic response in mouse 
macrophages (Kellner-Weibel, Geng, & Rothblat, 1999); however, a recent study 
highly associated ER cholesterol to the apoptotic pathway (Feng et al., 2003). This 
association reveals a novel research area and highlights the significance of 
cholesterol regulation and transport from and to the ER. 
 
2.3.4.2. Cholesterol transport in plasma 
In plasma, cholesterol, regardless of its source, is transported within lipoproteins 
with water-soluble outward-facing and lipid-soluble inward-facing surfaces. Different 
forms of lipoproteins in the blood are identified based on their intensity: they are 
chylomicrons, very low density lipoprotein (VLDL), low density lipoprotein (LDL), 
and high density lipoprotein (HDL) (Brown, Kovanen, & Goldstein, 1981).  
Lipoprotein particles have some apolipoproteins that govern the start and end 
points of cholesterol transport to particular tissues by binding to specific receptors on 
cell membranes. Chylomicrons as the lowest density molecules in cholesterol transport 
have apolipoprotein E, apolipoprotein B-48 and apolipoprotein C  (Havel, 1986). The 
role of chylomicrons is to carry fatty acids from the intestine to other tissues to produce 
energy and fats. Unexploited cholesterol resides in more cholesterol-rich chylomicrons 
and the liver then transports them from these lipoproteins to the bloodstream (Ai, 
Tanaka, & Schaefer, 2014). 
VLDL particles are formed in the liver and have apolipoprotein E and 
apolipoprotein B100. On the blood vessel wall, lipoprotein lipase degrades VLDL 
molecules. The main cholesterol carriers in the blood are LDL molecules, which are 
identified by LDL receptors in peripheral tissues (Brown & Goldstein, 1986; Sugii, 
Reid, Ohgami, Du, & Chang, 2003). LDL receptors play a role during cholesterol 
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absorption as well, and its synthesis rate is controlled by the similar protein that 
regulates the de novo cholesterol synthesis, SREBP. When a cell has a high amount of 
cholesterol, the synthesis of LDL receptors is blocked to inhibit new cholesterol uptake 
by LDL particles. On the other hand, synthesis of LDL receptors continues if the 
cholesterol levels in the cells are not sufficient (Havel, 1986). Dysregulation of this 
process makes LDL particles appear in the blood without their receptor. After these 
LDL particles are oxidized, macrophages take them up leading to inflamed particles 
that form foam cells. Foam cells are regularly trapped in the blood vessels walls and 
involve formation of atherosclerotic plaque (Meir & Leitersdorf, 2004; Stemme et al., 
1995).  
It is well-known that HDL particles play a role in a RCT process in which 
cholesterol is transported back to the liver for excretion or for other tissues that produce 
hormones (Lewis & Rader, 2005; von Eckardstein et al., 1995). Moreover, high levels 
of HDL molecules have been linked with better health condition, while low HDL 
levels are correlated with development of atheromatous disease (Gordon et al., 1989; 
Vakkilainen et al., 2003). Therefore, it is not surprising that dysregulation in 
cholesterol metabolism and transport plays a remarkable pathogenic role in human 
diseases, particularly hypercholesterolemia.         
   
2.3.5  Hypercholesterolemia  
Hypercholesterolemia, also called dyslipidemia, is the existence of high levels 
of cholesterol in the blood. Elevated plasma triglyceride level in association with 
hypercholesterolemia is common and contributes an increased risk of heart disease. 
Typically such patients have elevated  VLDL and LDL cholesterol levels and 
decreased  HDL cholesterol levels (Sarwar, 2007). The normal range for total blood 
cholesterol in humans is between 140 to 200 mg per decilitre (mg/dL) of blood and 
above 240 mg/dl is classified as a high cholesterol level in blood (Daniels & Greer, 
2008), while a normal cholesterol range in rats is 40-130 mg/dL and in mice it varies 
between strains and gender (30-100 mg/dL) (Pritchett & Taft, 2006). 
Hypercholesterolemia is usually caused by a combination of genetic and 
environmental factors. Obesity and dietary intake are typical examples of 
environmental factors that induce hypercholesterolemia. However, 
hypercholesterolemia, in some cases such as in familial hypercholesterolemia, is 
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totally in control of genetic irregularities where one or more mutations in the 
autosomal dominant genes exists (Grundy Md, 1998). This condition affects 
approximately 1 in 500 people in most countries (Liyanage, Burnett, Hooper, & van 
Bockxmeer, 2011). While hypercholesterolemia itself is not symptomatic, a 
longstanding increase of serum cholesterol can cause atherosclerosis. A number of 
clinical trials with HMG-CoA reductase inhibitors (statins) have revealed significant 
risk reduction through LDL cholesterol lowering in patients with heart disease, mainly 
via increased LDL-receptor activity (Baigent et al., 2011; S. J. Nicholls et al., 2007; 
Nissen et al., 2006). The role of hypercholesterolemia, specifically in the development 
of coronary artery disease, has been well documented, and many studies have shown 
its deteriorating impact on atherosclerosis development (Göran K Hansson, 2005; 
Peter Libby, Ridker, & Maseri, 2002). However, its role in OA development as a 
metabolic syndromes component has not been fully investigated. 
 
2.3.6 Epidemiological link between hypercholesterolemia and OA 
Epidemiologic studies have developed different conclusions regarding the 
association between OA and cholesterol. Some have found a positive link between OA 
and increased serum cholesterol levels (Al-Arfaj, 2003; M. A. Davis et al., 1988; D. J. 
Hart et al., 1995; K. Martin et al., 1997; Sturmer et al., 1998), whereas others have 
found a negative correlation (Bagge et al., 1991). Many studies have proposed that 
lipids may contribute to the pathogenesis of OA. In early population studies, a positive 
correlation between hand OA and high serum cholesterol levels was reported 
(Kellgren, 1961). Many years later, the Chingford study found a link between 
hypercholesterolemia and knee OA in women and this link was stronger for bilateral 
knee OA independent of BMI (DEBORAH J Hart et al., 1995). The hypothesis that 
hypercholesterolemia is a metabolic risk factor for OA was further supported by the 
Ulm study, whereas a cross-sectional study of OA demonstrated a link between 
radiological OA in hand joints and high serum cholesterol levels (T. Stürmer, Sun, Y., 
Sauerland, S., Zeissig, I., Günther, K. P., Puhl, W., & Brenner, H, 1998). In another 
epidemiological study, Davies-tuck et al. showed total cholesterol and triglycerides are 
associated with the development of new bone marrow lesions in asymptomatic middle-
aged women (Miranda L Davies-Tuck et al., 2009). Lastly, Oliviero et al. 
demonstrated that even Apolipoprotein A1, a lipid transport protein that contains a 
 Chapter 2: Literature Review 49 
main component of HDL, is significantly increased in the serum of the OA group 
compared to healthy people (F. Oliviero, Sfriso, P., Baldo, G., Dayer, J. M., Giunco, 
S., Scanu, A., ... & Punzi, L, 2009), although it is dramatically reduced in the synovial 
fluid of OA group compared to RA individuals.  
 
2.3.7 Cholesterol regulation in healthy and OA chondrocytes 
In chondrocytes, the expression of proteins involved in cholesterol metabolism 
is strongly regulated. For example, the expression of Apolipoprotein A-I (ApoA-1) 
and ATP-binding cassette transporter (ABCA1) is high in differentiating 
chondrocytes, and reduces to a basal level when cells reach hypertrophy. In contrast, 
hypertrophic chondrocytes express the maximal level of Serum Amyloid A (SAA) 
mRNA (Gentili et al., 2005; Zerega et al., 2004). This suggests that the synthesis and 
use of cholesterol should be strongly controlled to inhibit hyperlipidemia and abnormal 
accumulation of cholesterol within cartilage tissues, which may lead to cartilage 
damage. This is further supported by a proteomic analysis study showing that several 
lipid metabolism-related proteins are diversely expressed in OA cartilage compared to 
normal (Iliopoulos, Malizos, Oikonomou, & Tsezou, 2008; Wu et al., 2007). 
Furthermore, Tsezou et al. detected oxidized low-density lipoprotein (Ox-LDL) in the 
synovial fluid and its receptor, lectin-like oxidized low-density lipoprotein receptor 1 
(LOX-1) in cartilage of weight-bearing and non-weight-bearing joints; however, 
LOX-1 was not expressed in normal cartilage (T Simopoulou, Malizos, & Tsezou, 
2007). These findings demonstrated that chondrocytes are definitely able to internalize 
lipids.  
Abnormal cholesterol accumulation occurs when cholesterol influx into the 
tissue wall (from apoB-containing lipoproteins) exceeds cholesterol efflux. A more 
recent study demonstrated that cholesterol transporting genes such as ApoA-1 and 
ABCA1 mRNA levels were significantly lower in OA cartilage compared to normal. 
Additionally, in the two subtypes of the Liver X receptor  (LXR), LXRα and LXRβ, 
mRNA levels were also found to be significantly lower in OA cartilage (A. Tsezou et 
al., 2010). Interestingly, the same group also showed a central role of up-regulated 
SREBP-2 in the pathogenesis of OA, as well as a potentially involving mechanism 
(Kostopoulou et al., 2012). The differential expression pattern of these cholesterol 
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efflux genes between normal and OA cartilage may signify a causal relationship of 
cholesterol related mechanisms to the development and/or progression of OA. 
 
2.3.8 In-vivo link between hypercholesterolemia and OA 
Although the association of hypercholesterolemia with coronary heart disease 
has been frequently reported (H Mabuchi, 1989), whether cholesterol levels influence 
the occurrence of OA is a matter of debate. A few researchers have recently studied 
the possible link between plasma high cholesterol levels and OA in-vivo. A study by 
Gierman et al. found an association between metabolic stress and spontaneous OA 
development in mice. A high-fat diet induced cartilage damage independent of body 
weight, and this effect might be eliminated by decreasing cholesterol levels (L. M. 
Gierman et al., 2012). Two years later, this group also showed that dietary cholesterol 
played a role in the development of OA in an ApolipoproteinE*3Leiden mice. To 
better study the particular role of cholesterol in OA development, they used the drug 
ezetimibe, which decreases intestinal cholesterol absorption, and consequently, 
decreases serum cholesterol levels in animals fed a cholesterol-rich diet. In that study, 
ezetimibe therapy did not reduce OA development, even when fed a cholesterol-rich 
diet, suggesting that the processes independent of cholesterol exposure also contribute 
to the OA development (L. Gierman et al., 2014). In both studies, the authors proposed 
that metabolic stress-induced inflammation may be more likely caused by cholesterol-
induced cartilage damage than mechanical overload, as anti-inflammatory medication 
suppressed the OA progression. They demonstrated that OA and atherosclerosis are 
both linked to the MetS and that the cell types that play a role in the atherosclerosis 
development (such as macrophages) (Peter Libby, Lichtman, & Hansson, 2013) also 
contribute to OA pathology (Jan Bondeson, Wainwright, Lauder, Amos, & Hughes, 
2006; Haywood et al., 2003). 
One of the hallmarks of hypercholesterolemia is elevated LDL levels (Koskinen 
et al., 2012). Contribution of LDL in OA pathology was evidenced in a mice animal 
model of the disease. Recently, Koskinen et al. found that elevated levels of LDL (by 
LDLR deficiency or a cholesterol-rich diet), in an inflammatory OA model induced 
pathology. In mice with high LDL levels, synovial production of S100A8 and TGF-β 
signalling were increased signifying synovial activation. Additionally, it has been 
found that enhanced levels of LDL caused more ectopic bone formation, both at the 
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bone margins and in the collateral ligaments (de Munter et al., 2013). Even though 
they suggested a definite role for oxLDL, the major emphasis of that study was the 
consequential impacts of elevated LDL levels on OA development. They suggested, 
that future experimental studies testing the effect of oxLDL or oxLDLRs on joint 
health will possibly provide evidence of oxLDL contribution. In another study, 
Triantaphyllidou et al., also showed that HDL (lipoprotein that carries cholesterol) 
metabolism was predisposed to OA (Triantaphyllidou et al., 2013). Despite the fact 
that the above studies have demonstrated important and complex interactions between 
cholesterol and OA, the mechanisms remain unclear. To better understand the 
mechanism involved in this interaction, further investigation to address the following 
potential issues is required. 
 
2.3.9 Hypercholesterolemia has common molecular mechanisms in 
developing OA and atherosclerosis 
Current information suggests that OA development can be associated with 
changed blood vessel function, similar to that observed in atherosclerosis (Conaghan 
et al., 2005; Katz et al., 2010; Saleh et al., 2007). As cholesterol is a major constituent 
of the cell membrane, any alterations could affect fluidity and function of the 
membrane so that they result in poor cell behaviour and cholesterol accumulation (N. 
Wang et al., 2000). It is possible that hypercholesterolemia can result in the deposition 
and oxidation of lipids in tissues, causing damage to the cartilage similar to that seen 
in diseases such as atherosclerosis (Sevin et al., 2013). A main contributing factor in 
the atherosclerotic lesion incidence is the possible imbalance between cholesterol 
influx and efflux regulation within the tissue (Schwenke & St Clair, 1993). The 
regulation of cholesterol is known to be mediated by a number of cell surface receptors, 
such as scavenger receptor class B type I (SR-BI), CD36 and ABCA1 (Ikonen, 2006). 
The first stage in reverse cholesterol transport is related to ABCA1, a transmembrane 
protein mediating lipid efflux from cells to apolipoproteins (Apo). It has been well-
established that ABCA1 plays a key role in cholesterol regulation and alterations in 
this gene have been linked to atherosclerosis (Rothblat et al., 2002; Soumian et al., 
2005). SR-BI, a member of the CD36 superfamily, is mostly expressed in the 
steroidogenic tissues and liver, where it facilitates selective cholesteryl ester uptake 
from HDL (Krieger, 1999; Marcil et al., 2006). SR-BI is also expressed in 
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macrophages, including tissue macrophages, monocyte-derived macrophages, and 
macrophages in atherosclerotic lesions (Pagler et al., 2006; Rinninger et al., 2003). 
SRBI deficiency is associated with de-regulation of cholesterol homeostasis in the 
arterial wall leading to an increased susceptibility to atherosclerosis (Van Eck et al., 
2003). CD36 has been known to bind and internalize oxLDL, but also a wide range of 
different ligands such as anionic phospholipids, apoptotic cells, long-chain fatty acids 
and other modified LDL (Adorni et al., 2012). CD36 distinguishes lipid moieties of 
oxLDL and function as the main scavenger receptor in oxLDL uptake (T. Q. Truong 
et al., 2010). Moreover, increasing evidence proposes that peroxisome proliferator 
activated receptors (PPARs) (Barbier et al., 2002; Xia et al., 2012) apply 
antiatherogenic effects by increasing cholesterol efflux via activation of LXR–ABCA1 
pathway (Bultel et al., 2008; Di et al., 2012; Hozoji-Inada et al., 2011; Ouvrier et al., 
2009). Therefore, it is possible that the same genes and molecular determinants could 
affect cartilage cholesterol homeostasis. This hypothesis is further supported by the 
study showing the expression of some of those genes in the cartilage tissue (A. Tsezou 
et al., 2010). Yet, further studies are required to support such a hypothesis. In another 
view, Findlay et al. proposed that blood vessel alterations can cause changed blood 
flow to the bone that underlies the cartilage in joints.  As a results, the bone and 
cartilage are deprived of blood, oxygen, and nutrients, which induce the whole tissue 
to degenerate (Findlay, 2007). As cholesterol is known to be a predominant factor that 
influences altered blood vessel function, it is possible that the above chain of events 
can lead to OA.   
 
2.3.10 The role of inflammation in hypercholesterolemia-induced OA 
Obesity and related metabolic syndromes are associated with chronic low-grade 
inflammation and systemic tissue damage (Gregor & Hotamisligil, 2011). Continuous 
accumulation of lipoproteins, primarily LDL, in the extracellular matrix of cartilage 
can trigger the inflammatory process. C-reactive protein (CRP) is a very sensitive 
marker of inflammation. The presence of inflammation in OA individuals were 
proposed by a finding demonstrated increased levels of CRP and IL-6 in OA groups. 
In this respect, the fact that CRP is associated with obesity is noteworthy. A positive 
association between circulating CRP has been demonstrated in patients with obesity, 
metabolic syndrome and OA. Interleukin-6 (IL-6) is a proinflammatory cytokine 
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produced by many cells, including chondrocytes. Expression studies have also shown 
increased levels of IL-6 mRNA in the OA specimens. IL-6 has in fact been shown to 
be the main stimulus for the CRP production. Moreover, IL-6 seems to be associated 
with visceral obesity and insulin resistance. Recent studies clearly highlight the close 
link between inflammation and cholesterol homeostasis through mechanisms in which 
ABCA1 appears to be a major factor. For example, increased intracellular free 
cholesterol concentration in ABCA1 KO macrophages is accompanied by enhanced 
inflammatory response in macrophages. 
Another molecule assumed to play a viatal role in lipid-induced inflammation is 
the ‘transcription factor nuclear factor-κB (NF-κB)’. Its essential role is regulating 
inflammation and immune responses by activation of  different genes, including those 
that encode growth factors, adhesion molecules, and cytokines. ‘NF-κB is redox 
sensitive and activated by radicals’. A large number of different radicals may be 
generated by oxidation of lipoproteins, signifying that lipid-induced inflammation in 
the vascular wall can be mediated by the pro-inflammatory NF-κBactivation by 
radicals drived from oxidized lipids. Indeed, induction of hypercholesterolemia in 
mice, rabbits, pigs, and many other animals leads to activation of vascular 
inflammation (Faggiotto & Ross, 1984; Faggiotto et al., 1984; H. Li et al., 1993). 
 
2.3.11 Statins’ role in preventing OA  
The growing list of interconnections between cholesterol and OA indicate that 
statins that inhibit de-novo cholesterol synthesis may have a disease modifying effect. 
Unfortunately, statins have not yet been evaluated in OA in a placebo-controlled trial 
with solid end points. In one study Clockaerts et al. demonstrated that the use of statins 
was related to a decrease in OA progression in the knee, but not of the hip in a 
population based study (Clockaerts et al., 2012) . In addition to its effects on lipid 
metabolism, several anti-inflammatory effects have been ascribed to statins. Leung et 
al. found that simvastatin significantly restrained not only developing, but also 
established collagen-induced arthritis in a mouse model (Leung et al., 2003). It has 
been demonstrated that the intra-articular injections of statin during OA development 
decreased the infiltration of inflammatory cells and the expression of matrix-degrading 
enzymes, hence, controlling cartilage degradation (Akasaki, Matsuda, & Iwamoto, 
2009). The same authors, in another study, showed that intra-articular administration 
 54 Chapter 2: Literature Review 
of HMG-CoA reductase inhibitor (e.g. statin) decreases inflammatory cell infiltration 
and matrix-degrading enzyme expression, therefore, preventive cartilage degradation 
(Akasaki, Matsuda, Nakayama, et al., 2009). Simopoulou et al. suggested that in vitro 
loading of atorvastatin in OA cultured chondrocytes may have potential 
chondroprotective effects, mostly by reducing cartilage degradation protein MMP13 
(Theodora Simopoulou, Malizos, Poultsides, & Tsezou, 2010). Furthermore, it has 
been demonstrated that mevastatin upregulates the mRNA levels of bone 
morphogenetic protein-2, collagen type II and aggrecan, along with enhancing 
proteoglycan synthesis in rat chondrocytes (Hatano, Maruo, Bolander, & Sarkar, 
2003), while Yudoh and colleague’s findings proposed that statins may be capable of 
inhibiting the catabolic stress-induced chondrocyte disability and aging detected in 
articular cartilage of STR/OrtCrlj mice that spontaneously develop OA (Yudoh & 
Karasawa, 2010). By virtue of the various immunomodulatory and chondroprotective 
functions exerted by statins, they may be able to reduce the damage. However, a few 
questions remain, and the most important uncertainty is to what extent cholesterol 
should be reduced to nullify any off-target effects and to maintain the levels required 
for cartilage homeostasis.  
 
2.3.12 Cholesterol triggers mitochondrial function 
It has been shown that in some pathological states, mitochondria are enriched 
with high levels of cholesterol, suggesting that cholesterol play a role in mitochondrial-
induced pathological conditions (Echegoyen et al., 1993; Rouslin, MacGee, Gupte, 
Wesselman, & Epps, 1982; W. Yu et al., 2005). Regardless of the physiological role 
of cholesterol in mitochondria, the mechanisms underlying trasnport to this organelle 
are not fully studied. It has been observed that the relative amount of fatty acids chains 
and the interactions between phospholipid and cholesterol, as important constituents 
of biological membranes, may influence permeability and physical resistance of 
membranes, including mitochondrial membrane (Phillips, 1972). Recent observations 
have reported the activity of cholesterol-transporting polypeptides, including the 
steroidogenic acute regulatory protein (StAR) that contribute to the mitochondrial 
intermembrane trafficking of cholesterol (Hall et al., 2005; Soccio & Breslow, 2003).  
There is growing evidence documening that cholesterol enrichment in 
mitochondria can impair specific mitochondrial components accounting, in part, for 
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the mitochondrial dysfunction described in cells (Colell et al., 2003; Crain, Clark, & 
Harvey, 1983; Feo, Canuto, Garcea, & Gabriel, 1975). The mechanisms by which free 
cholesterol overloading triggers these events may be conducted by direct membrane 
effects or by activation of death-promoting molecules or both (W. Wang, Yang, & 
Huang, 2007; Yao & Tabas, 2001). This may be of potential relevance as recent 
strategies target mitochondria in different cholesterol-associated disease therapy 
(Galluzzi, Larochette, Zamzami, & Kroemer, 2006; W. Yu et al., 2005). these 
theraputical approaches trigger alterations in the mitochondrial apoptotic pathways 
(Yao & Tabas, 2001),  mitochondrial membrane permeability (MMP) and 
mitochondrial membrane potential and ATP synthesis levels (Bosch et al., 2011) 
which contribute to different cholesterol-induced pathogenesis. 
This thesis aims to determine whether high levels of cholesterol mimic human 
hypercholesteremic can trigger the changes of cartilage cell’s mitochondrial function 
and morphology.  
 
2.4 MITOCHONDRIA 
Mitochondria are small membrane-enclosed bean-shape organelles that are 
present in large numbers in cells of all eukaryotic organisms. They have their own 
maternally inherited, ~16-kb extra-chromosomal DNA, the mitochondrial genome 
(mtDNA), implying that mitochondrial function is regulated by both nuclear and 
mitochondrial transcripts (Lanza & Nair, 2010). Mitochondria are of great importance 
in cellular metabolism, survival, differentiation, and homeostasis. Mitochondria not 
only contribute to energy production, but also to other cellular activity, such as calcium 
buffering, signal cascade, apoptosis induction, and so forth (M. T. Lin & Beal, 2006). 
2.4.1 Mitochondrial structure 
Mitochondria were one of the first subcellular organelles studied using electron 
microscopy. Sjostrand and Palade were the first researchers who found that 
mitochondria contained more than one membrane in the early 1950s; however, their 
initial three-dimensional models of mitochondria structure were not the same. 
Sjostrand (Sjöstrand, 1956) identified that mitochondria have a third membrane apart 
from the outer and inner boundary membranes (IBM), forming septa separating the 
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matrix into several parts. In Palade’s model (Palade, 1952), mitochondria also had 
outer and IBM, but the inner membrane coiled inward to shape baffles that he called 
cristae. The current mitochondrial structure in textbooks is based on Palade’s model, 
in which the mitochondrial boundary is identified with the smooth outer membrane 
and much larger constant closed inner membrane accommodated inside the space 
determined by the outer membrane generating wide folds to form cristae. The inner 
and outer membranes in the “baffle” model consist of two internal compartments: the 
intermembrane space between the two membranes and the matrix within the inner 
membrane. The space inside the cristae folds is not basically defined as a distinct 
compartment; however, it is extended through intermembrane space interacting via 
broad openings. This mitochondrial structure is the most currently accepted model 
(Frey & Mannella, 2000; Perkins & Frey, 2000) (Figure 2.8). The inner membrane 
possesses several enzymes performing as a barrier, which is poorly permeable to many 
molecules (Mitchell, 1979). However, there are some transporters in this membrane 
permitting the entrance of endogenous compounds such as pyruvic acid, fatty acid, and 
glutathione. The mitochondrial membranes may lose their structural and functional 
integrity in some pathophysiological conditions, specifically when the mitochondrial 
permeability transition pores (MPTP) are opened. Apart from numerous drugs and 
toxic composites, high levels of few endogenous products (e.g., calcium, fatty acids, 
and bile salts) may open MPTP (Bernardi et al., 2006).   
 
Figure 2.8: Mitochondria structure. A schematic mitochondrial structure. 
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The mitochondria have relatively different shapes and sizes, with a remarkable 
difference in the cristae number and structure. Though it is known that the cristae 
function increases the inner membrane surface area, the cristae shape still remains 
undefined even after viewing its cross sections under the electron microscope. 
Recently, advanced 3-dimensional images of outer and inner mitochondrial 
membranes and cristae have been obtained using electron tomography, but the 
importance of new discoveries (cristae junctions) require great elucidation. The 
number and morphology of mitochondria as dynamic organelles may alter inside a cell 
through development, the cell cycle, and several toxic challenges. Visualizing living 
cells labelled by key fluorescent probes including Rhodamine 123 and JC-1 that 
precisely label mitochondria further supported the concept that mitochondria are 
extremely dynamic organelles with many shape alterations (Bereiter‐Hahn & Vöth, 
1994; L. B. Chen, 1988; Rizzuto, Simpson, Brini, & Pozzan, 1992). 
A new interesting  field  of study is  related to mitochondrial dynamics shape 
and the distribution of mitochondria within specific cells (Okamoto & Shaw, 2005). It 
has been found that mitochondria have to constantly fiss and fuse with each other in 
many in many organisms and their interface with the cytoskeleton reassures their 
distribution in differentiating and dividing cells along with their ideal localization 
within cells (Chan, 2006; H. Chen et al., 2003; T. J. Collins & Bootman, 2003).  
 
2.4.2 Mitochondrial function 
Mitochondria are unique organelles as they contain their own DNA called 
mitochondrial DND (mtDNA). Several copies of the mitochondrial genome exist in 
each mitochondrion (G. M. Cooper, 2000).  Mitochondria play multi-factorial roles 
within the cell. In addition to their central bioenergetic task of adenosine triphosphate 
(ATP) regeneration, the organelles are the main source of both reactive oxygen species 
(ROS) and of the cell’s anti-oxidant defences and mediate apoptosis (Cadenas & 
Davies, 2000; Gibson, 2005; J. T. Liu et al., 2010), while the properties of the Ca2+ 
transport pathways in the inner mitochondrial membrane are such that the organelles 
can avidly accumulate the cations under conditions of elevated local cytoplasmic Ca2+ 
(D. Nicholls & Åkerman, 1982). 
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Mitochondrial oxidative phosphorylation (OXPHOS) produces ATP via a series 
of reactions where macronutrients are oxidized, oxygen is converted to water, and 
adenosine diphosphate (ADP) is phosphorylated to ATP to form energy for cells. 
Carbon substrates come into the tricarboxylic acid cycle and are then oxidized to make 
decreasing counterparts in the form of NADH and FADH2, providing electron drift 
through respiratory chain complexes I (NADH dehydrogenase) and II (succinate 
dehydrogenase). Electrons flow from complexes I and II and come together in complex 
III (ubiquinone-cytochrome c reductase), in addition to electrons transported in from 
electron transferring flavoproteins (beta oxidation), via the mobile electron carrier 
coenzyme Q. Cytochrome c as a next mobile electron carrier  shuttles electrons into 
complex IV (cytochrome c oxidase) where they are eventually shifted to oxygen, 
generating water. A proton gradient through the inner mitochondrial membrane is 
formed due to electron flow through complexes I, III, and IV. Complex V (ATP 
synthase) phosphorylates ADP to ATP using the potential energy of this gradient 
(Hebert, Lanza, & Nair, 2010; Lanza & Nair, 2010). 
ROS are formed at complex I and complex III in addition to the OXPHOS 
process producing ATP. ROS are very sensitive molecules that can damage nucleic 
acids, lipids, and proteins by overproduction. mtDNA is believed that greatly 
endangered of oxidative damage caused by ROS. The mitochondrial-induced aging 
concept suggests that ROS plays a key role in oxidative damage to mitochondria and 
mtDNA results in aging (Harman, 1972; Linnane, Ozawa, Marzuki, & Tanaka, 1989). 
The main idea of this theory is that a brutal mitochondrial damage cycle leading to 
dysfunction induces the aging procedure.  
The ROS generated through OXPHOS can damage mtDNA, lipids, and proteins. 
Therefore, damaged and mutated mtDNA can result in mutations that may occur 
within the cell as a result of unrepaired oxidative damage may cause dysfunctional 
proteins formation. These proteins themselves lead to more generation of ROS that 
will worsen this vicious cycle (Gibson, 2005). A growing body of data proposes that 
the production of ROS mainly depends on the mitochondrial membrane potential (Δψ). 
While membrane potential is high, mitochondrial redox potential is high, permitting 
more potential for electrons backflow over complexes I and III (Balaban, Nemoto, & 
Finkel, 2005). It has been demonstrated that low mitochondrial membrane potential 
and mitochondrial depolarization are in charge of  pro-apoptotic proteins release from 
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the mitochondria inducing apoptosis (Bossy‐Wetzel, Newmeyer, & Green, 1998; 
Kroemer, Zamzami, & Susin, 1997). 
 
2.4.3 The role of mitochondria in apoptosis 
Programmed cell death, orapoptosis, is a cellular self-destruction mechanism 
palys a role in different biological events, including tissue homeostasis, the removal 
of unwanted cells, and developmental sculpturing. Excessive or insufficient apoptosis 
contributes to numerous diseases and is involved in the growth and regression of 
tumours (Kerr, Wyllie, & Currie, 1972; Saikumar et al., 1999). Mitochondrial 
dysfunction, which is induced by DNA damage and other genotoxic factors, results in 
an irreparable event, apoptotic cell death (Green, 1998). The mitochondria perform at 
the core of the apoptotic pathway providing many essential factors, such as those that 
induce caspase, a group of cysteine proteases that can cleave many cellular substrates 
to dismantle cell contents (Salvesen & Dixit, 1997), activation, and chromosome 
fragmentation (Adams, 2003). Mitochondrial fragmentation during apoptosis was 
associated with the loss of the mitochondrial membrane potential (ΔΨm) that was 
considered an irreparable point in the death cascade (Zamzami et al., 1995). 
In most, but definitely not all apoptotic pathways, mitochondria play an early 
role releasing cytochrome c from the intermembrane space and possibly the intracristal 
space as a result of one or more different signals such as presence of oxidants, high 
[Ca2+], ceramide and pro-apoptotic proteins. Cytochrome c release activates 
apoptosome (Acehan et al., 2002) assembly from ATP, apoptotic protease-activating 
factor-1 (Apaf-1) and procaspase-9, which triggers effector caspase-3 and caspase-7, 
resulting in oligonucleosomal DNA fragmentation (Baliga & Kumar, 2003; Bao & 
Shi, 2007).  
Release of cytochrome c from the intermembrane space requires large openings 
in the outer membrane to allow the cytochrome c to pass. Two mechanisms have been 
suggested to influence cytochrome c release. The first is dependent on the swelling of 
the mitochondrial matrix to an extent that its external pressure breaks the outer 
membrane discharging all of the intermembrane space substances (Bernardi, 1996). 
Some stimuli, including high [Ca+] and/or oxidants, can open a high conductance 
channel in the inner membrane of isolated mitochondria leading to loss of the 
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electrochemical proton gradient, and the hyperosmolarity of the matrix makes it 
expand to the point that it can rupture the outer membrane (Green, 1998). However, 
the findings that cytochrome c is able to leave mitochondria before loss of the inner 
mitochondrial membrane potential proposes another mechanism, the generation of 
enough large pore in the outer membrane to permit cytochrome c to move into the 
cytosol (Pavlov et al., 2001). The membrane permeability transition pore (PTP) is 
regulated by pro-apoptoic and anti-apoptotic Bcl-2 family proteins including Bax, 
Bak, Bcl-2 and Bcl-xL (Harris & Thompson, 2000; Kelekar & Thompson, 1998). 
Through early steps of apoptosis, the pro-apoptotic proteins Bax translocates to the 
outer mitochondrial membrane (OMM) and, almost immediately after translocation, 
gather into submitochondrial punctate foci (Nechushtan, Smith, Lamensdorf, Yoon, & 
Youle, 2001). Moreover, Bak co-localizes with Bax in these foci. It has been 
demonstrated that Bax and Bak triggers cell death through mitochondrial outer 
membrane permeabilization (MOMP) that results in small pro-apoptotic molecules 
release including cytochrome c (X. Liu, Kim, Yang, Jemmerson, & Wang, 1996), 
second mitochondria-derived activator of caspase/direct IAP (inhibitor-of apoptosis) 
binding protein with low pI (Smac/Diablo) (Du, Fang, Li, Li, & Wang, 2000), 
Omi/HtrA2 (Hegde et al., 2002), apoptosis- inducing factor (AIF) (Susin et al., 1999), 
and endonuclease G (EndoG) (L. Y. Li, Luo, & Wang, 2001) from the mitochondrial 
intermembrane space to the cytosol and consequent induction of the caspase-activating 
pathways in apoptotic cell death pathways (Donovan & Cotter, 2004) (Figure 2.9).  
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Figure 2.9: Modified apoptosis signalling through mitochondria: Stimuli can start 
apoptosis via the mitochondrial pathway. After stimulation of mitochondria, 
cytochrome c (Cyt c) releases into the cytosol and forms apoptosome by binding to 
apoptotic protease activating factor 1 (APAF1). Initiator caspase-9 is stimulated at 
apoptosome and conducts apoptosis. Anti-apoptotic proteins such as the anti-apoptotic 
BCL2 family members and inhibitors of apoptosis proteins (IAPs), which are 
controlled by SMAC/DIABLO (second mitochondria-derived activator of 
caspase/direct IAP binding protein with low pI) are able to inhibit mitochondria 
apoptosis at different levels. An alternative way is via survival signals, such as 
cytokines and growth factors, that trigger the phosphatidylinositol 3-kinase (PI3K) 
pathway (Igney & Krammer, 2002). 
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2.4.4 Mitochondrial dysfunction in the course of OA progression 
ROS, a major by-product of OXPHOS, can play a positive role as signalling 
molecules. Mitochondrial oxidative pathways produce ROS to synthesise ATP for 
energy to maintain normal cartilage homeostasis when subject to physiological 
mechanical strains, with the signal cascade stimulated by mechanical distortion of the 
mitochondria (Brouillette et al., 2014; Montagne et al., 2014; Wolff et al., 2013). 
However, overproduction of ROS can induce oxidative damage in the form of lipid 
peroxidation and mtDNA damage. It is possible that mitochondrial dysfunction results 
in a signal cascade associated with programmed cell death, or apoptosis. The damage 
to mitochondrial membrane phospholipids, DNA, or proteins can differently influence 
mitochondrial function, such as increased permeability of mitochondrial membranes, 
decreased activity of the mitochondrial respiratory chain complex, loss of the 
mitochondrial components (e.g., cytochrome c) and dissipation of mitochondrial 
membrane potential (Δψm). Apoptosis is a physiological procedure, not only to 
maintain both embryogenic and adult tissue homeostasis, but it also contributes to 
articular cartilage degradative disorders such as OA. 
It has been shown that the protein expressions of BCL-2 and BAX were 
increased in cartilage from OA patients. BCL-2 and BAX are two factors that play a 
vital role in mitochondria-related apoptosis. Increased synthesis or translocation of 
BAX, a pro-apoptotic protein, can cause the mitochondrial membrane potential 
depolarization, increasing the cytochrome c discharge. Interestingly, Li et al. used an 
ingenuity pathways analysis (IPA) to identify mitochondria-related pathways involved 
in the pathophysiology of OA. They presented the first evidence displaying that 
canonical pathways involved in oxidative phosphorylation, pyruvate metabolism and 
apoptosis signalling are associated with the mitochondrial dysfunction found in OA 
patients, in addition to evidence for the underlying mechanism of mitochondrial 
dysfunction in the cartilage of OA patients. In their study, genes and pathways that are 
related to apoptosis pathways were significantly up-regulated in OA, which can lead 
to extreme chondrocyte apoptosis and abnormal expression of the apoptosis-related 
genes in articular cartilage (C. Li et al., 2012). 
Cytochrome c has recently been recognized as a main mediator in apoptotic 
pathways and is generally used as a marker of the mitochondrial apoptotic procedure 
in the cells. When Cytochrome c releases from mitochondria into the cytoplasm 
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activates caspase-9 and 3, and eventually results in cell apoptosis. Liu et al. reported 
that OA articular chondrocytes demonstrated significantly decreased complex II, III, 
IV and V activities, loss of mitochondrial membrane potential, but showed an 
increased mitochondrial mass compared to normal chondrocytes. Moreover, findings 
from cultured OA chondrocytes revealed a decrease in ATP levels and an increase in 
percentage of cells with de-energized mitochondria. Moreover, it has been observed 
that a release of mitochondrial cytochrome c and stimulation of capase-9 and 3 
occurred in OA samples. Thus,  chondrocytes from OA patients showed more positive 
apoptotic cells than the healthy controls (J. T. Liu et al., 2010).  
More recently, Gavriilidis et al. proposed that mitochondrial dysfunction in OA 
is related to superoxide dismutase 2 (SOD2) down-regulation . SOD2, a subfamily of 
superoxide dismutase (SOD), acts as a defence against ROS. Increased levels of ROS 
may elevate levels of mtDNA damage, lipid peroxidation, as well as activation of 
signalling pathways, all of which may intensify cartilage degradation, cleavage of 
collagen, and hyaluronan. All SODs are expressed at lower levels in OA cartilage 
comparing normal control cartilage at both the messenger RNA (mRNA) and protein 
level (Gavriilidis, Miwa, von Zglinicki, Taylor, & Young, 2013), which suggests that 
decreases in the SOD2 levels in OA human articular chondrocytes may induce an 
increase in mitochondrial superoxide levels, and additionally, mitochondrial 
dysfunction.  
 
2.4.5 Cholesterol triggers oxidative stress  
Mitochondrial dysfunction is known to be induced by hypercholesterolemia, 
hyperglycemia, hypertriglyceridemia, and even the process of aging (Lee & Wei, 
2012; Puddu et al., 2005).  Numerous studies havefound a link between increased 
cholesterol oxidation products (oxysterols) and mitochondrion-derived oxidative 
stress, which typically leads to overproduction of mitochondrial reactive oxygen 
species (mtROS) (Lordan et al., 2009). Excessive and continuous accumulations of 
oxidised cholesterol particles tend to bind to ‘sulphate-containing proteoglycans, 
where they aggregate and become oxidatively modified’ (Eva Hurt-Camejo & 
1997).The factors in charge of these changes are not fully known, but apart from ROS, 
different membrane and extracellular tissue-associated enzymes were reported to be 
involved. There are numerous defence systems, such as antioxidant vitamins and 
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enzymes that inhibit oxidative damage of accumulated lipoproteins, but in conditions 
of a constant lipid overload these defence mechanism may ultimately not function, 
causing the activation of stress signalling pathways (Oliveira et al., 2005). ROS is 
typically produced under optimal conditions by mitochondria and are neutralized by 
the mitochondrial cellular defence systems. When ROS is overproduced, it induces 
deterioration of mitochondrial oxidative stress defences, causes irreversible harm at 
the cellular and molecular levels in vulnerable cells, and contribute to pathologic 
conditions via c-Jun N-terminal kinase (JNK) pathway activation (Kamata, 2005). 
ROS may also harm DNA, cellular lipids, and proteins, increasing lipid peroxidation, 
a condition that may more induces mtDNA damage (Fosslien, 2001). It has been 
shown that increased ROS production, particularly, radicals and superoxide, has been 
related to cartilage dysfunction in human (Ostalowska et al., 2006) and animal models 
of disease (Johnson et al., 2004), and there is growing evidence of an association 
between oxidative stress and cartilage degradation in humans (Afonso et al., 2007; 
Regan et al., 2005). These observations led to our hypothesis that accumulation free 
cholesterol increases superoxide anion levels, induces oxidative stress, and activates a 
transient inflammatory response causing permanent damage to the joint tissues. 
However, whether the high cholesterol levels trigger the mitochondrial dysfunction in 
cartilage needs further investigation. 
Thus, the study objectives are as below: 
1. To test the effect of excess cholesterol on primary chondrocytes in vitro 
using a 3D pellets culture method and determine how cholesterol may 
challenge chondrocytes under this condition. 
- This objective help author to find out if high cholesterol levels challenge 
cartilage andchondrocytes function and phenotype or not. 
- Chondrocytes 3D pellet culture is well-stablished method mimcs cartilage 
condition and used to define how cholestreol change OA-like marker in 
chondrocytes.  
2. To study the link between hypercholesterolemia and osteoarthritis using two 
different animal models (ApoE-/- mice and dietary-induced 
hypercholesterolemia [DIHC] rats) mimicking the human 
hypercholesterolemia condition. 
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3. Using these two animal models will help to investigate possible association 
between hypercholesterolemia and OA. ApoE-/- mouse is a well-stablished 
model to study hypercholesterolemia-related condition. Moreover, using 
dietary rat model will help to test the effect of dietary high cholestreol intake 
on OA.To study the effect of high levels of cholesterol on chondrocytes 
mitochondrial function both in vitro. 
- Using 3D culture model of chondrocytes, we are going to investigate effet of 
high cholesterol levels on chondrocytes’ mitochondrial function. Different 
well-stablished functional methods will be used to study chondrcoytes’ 
mitochondrial changes under cholestreol challenge 
4. Study the effect of cholesterol-lowering drug and mitochondrial protector 
(anti-oxidants) on cartilage using in vivo (ApoE-/- mice and DIHC rats) and 
in vitro models. 
We are going to use statin as a positive cholesterol-lowering drug in our in vivo and in 
vitro models. New anti-oxidant drug will be used to protect mitpochondrial from 
oxidative damge caused by high cholesterol levels. Following anti-oxidants drug 
administration, I will investigate joint biology to figure out the theraputical effect of 
this drug..
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Chapter 3: Research Design 
3.1 ETHICS 
Ethics approval for human cartilage collection was granted by Queensland 
University of Technology and Prince Charles Hospital Human Research Ethics 
Committees (approval ethics number: HREC/14/QPCH/186) and informed consent 
was given by all patients involved. 
Ethics approval for the rats’ study was granted by Queensland University of 
Technology, University Animal Ethics Committee (UAEC) (approval ethics number: 
1300000283) and the ApoE-/- mice study was approved by the Xiangya Hospital, the 
Central South University of China (approval ethics number: 2013-053). 
 
3.2 METHODOLOGY 
3.2.1  Articular cartilage sample collection  
OA cartilage (n= 24) were sourced from the main defective area of the medial 
compartment cartilage showing degenerative changes (Figure 3.1). The average age of 
OA patients used in this study was 65.20 ± 15.4. Normal  cartilageswere obtained from 
OA patients (n=24), where smooth knee tissue was available. To eliminate early OA 
symptoms, samples showing any evidence of cartilage changes were excluded for 
normal cartilage collection. These macroscopic changes included softening of the 
hyaline articular cartilage, thinning and fibrous dislocation, ulcerations of the cartilage, 
and light sclerosis of the subchondral bone. At the microscopic level, cartilage was 
classified according to the Mankin score (H. J. Mankin et al., 1971) based on saffranin-
O and H&E histology staining, where a score of 0-4 (Grade1) indicated normal 
cartilage and a score over 10 (Grade 4) indicated advanced degenerative OA cartilage. 
Due to limition of OA research in accessing normal human cartilage from healthy 
donors, Grad 1 cartilage is used for control group. 
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Figure 3.1: Tibia plateau collected from patients undergoing knee replacement.  
The right panel represents OA cartilage pieces with a rough degenerated surface and 
normal cartilage with a smooth surface under gross examination. 
 
3.2.2 Primary articular cartilage chondrocytes (ACCs) isolation 
Chondrocytes from the cartilage tissues were isolated following a method 
described previously with minor modifications (Schnabel et al., 2002). Briefly, 
cartilage was dissected into small pieces using a sterile scalpel, and washed several 
times with 1X PBS (phosphate buffered saline). Chondrocytes were released by 
digesting the tissues in 0.2% collagenase type II mixed in high glucose DMEM at 37°C 
for 16 hrs. The cell suspension was filtered (70µm mesh) and centrifuged at 1000g for 
10 min and resuspended in complete Dulbecco’s Modified Eagle Medium (DMEM, 
Gibco-Invitrogen,VIC, Australia) containing 10% fetal bovine serum (FBS, Thermo 
Scientific, VIC, Australia) and 50u/ml penicillin and 50µg/ml streptomycin (Gibco-
Invitrogen, VIC, Australia) and plated at a density of 2500 cells/cm2. Only early 
passage ACCs, showing a strong expression of type II collagen (COL2) and aggrecan 
(ACAN) were used for subsequent experiments.  
 68 Chapter 3: Research Design 
 
3.2.3 Cell culture 
The obtained primary ACCs from the protocol described above were seeded into 
the tissue culture flasks containing DMEM supplemented with 10% FBS and 1% 
penicillin/streptomycin and incubated at 37°C in humidified CO2 incubator. The cells 
were passaged at approximately 80% confluence by trypsinization and expanded 
through a maximum of two passages for this study.                  
      
3.2.4 Chondrocyte pellet culture 
Cell culture systems known to preserve the chondrocyte phenotype were used in 
the co-culture studies. Chondrocytes pellet culture was performed as described 
previously in our research group (Prasadam et al., 2010). Two x 105 cells of ACCs 
were trypsinized and resuspended in a serum free chondrogenic media (serum-free 
medium-high glucose DMEM) (Invitrogen, Mt Waverley, VIC, Australia) 
supplemented with 10 ng/mL transforming growth factor-β3 (Bio Scientific, Gymea, 
NSW, Australia), 10nM dexamethasone, 50 mg/mL ascorbic acid, 10 mg/mL sodium 
pyruvate, 10 mg/mL proline, and an insulin+transferrin+selenium supplement (final 
concentration: 10 µg/mL insulin, 5.5 µg/mL transferrin, 5 ng/mL sodium selenite, 0.5 
mg/mL bovine serum albumin and 4.7 µg/mL linoleic acid) and centrifuged at 600 g 
for 20 minutes to form a pellet. Pellets were allowed to differentiate for two weeks in 
3-dimensional conditions in 15 mL Falcon tubes, in a chondrogenic medium, which 
was replenished every two to three days. After two weeks of chondrogenesis ACCs 
pellets (Figure 3.2) were processed for histological analysis, immunofluorescence 
staining, western blotting and qRT-PCR.  
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Figure 3.2: ACCs in 3-D pellet chondrogenic culture. 
 
3.2.5 Bovine explant culture 
Bovine tibia cartilage has previously been validated as a model relevant to human 
disease (W. Hui, Barksby, H. E., Young, D. A., Cawston, T. E., Mckie, N., & Rowan, 
A. D, 2005) and was cultured as previously described (Morgan, 2006).  Three bovine 
cartilage explants were harvested from the proximal femoral condyle of joint of three 
one-year-old animals from local butchery and animals were not killed for the purposes 
of this study. 6mm discs of bovine knee cartilage (Figure 3.3) were taken using a 
biopsy punch. Cartilage discs were washed twice with PBS and stabilized for 48 hours 
in Dulbecco’s Modified Eagle Medium (DMEM, Gibco-Invitrogen, VIC, Australia) 
supplemented with 10% fetal bovine serum (FBS, Thermo Scientific, VIC, Australia), 
and 1% (v/v) penicillin/streptomycin (Gibco-Invitrogen, VIC, Australia) at 37◦C in a 
humidified CO2 incubator. The medium was then removed and replaced with serum-
free medium supplemented with cholesterol and without cholesterol as a control for 
seven days. The medium was changed every three days and supernate was collected 
each time and kept at -80◦c to quantify Sulfated glycosaminoglycan (sGAG) content 
during the bovine explant culture. Bovine cartilage discs release proteoglycans into a 
culture medium when they loos their cellular GAG. Therefore, storing supernate from 
bovine explant culture would enable us to quantify the sGAG content of bovine explant 
cartilage under cholesterol challenge. 
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Figure 3.3: 6mm discs of bovine cartilage explant. 
 
3.2.6 Cholesterol, atorvastatin, and mito-TEMPO loading in vitro 
Cholesterol was delivered to chondrocytes by using Chol:MβCD complex 
(Sigma-Aldrich, #C495, NSW, Australia). Cyclodextrins (CD) have been used 
extensively as drug delivery vehicles and chemically modified β-CDS, such as 
methylated β- cyclodextrins (MβCD) have been made to form soluble inclusion 
complexes with cholesterol, thereby enhancing its solubility in aqueous solution. In 
vitro, β-CDs have a high affinity for cholesterol as compared to other lipids, which 
may make this compound quite effective in modifying cholesterol metabolism. This 
method has been widely used to successfully deliver cholesterol in a variety of cell 
types (Choi & Toyoda, 1998; Christian, Haynes, Phillips, & Rothblat, 1997; Pucadyil 
& Chattopadhyay, 2004).  
Human articular chondrocytes (ACCs) were isolated and differentiated in 3D 
pellets as described above. The pellets were treated with different doses of 
Chol:MβCD (5,10,30μg/ml) in 0.2% (w/v) BSA for 14 days. Pellets incubated with 
0.2% BSA without Chol:MβCD treatment served as controls. Similarly, cartilage disks 
were harvested from the femoropatellar grooves of one year old bovine calf knee joints 
(obtained from a local butcher) as previously described and treated with Chol:MβCD 
complex for seven days as described above.  
Mito-TEMPO (Sigma-Aldrich, #SML0737, NSW, Australia) treatment was 
performed following cholesterol loading in ACCs pellets. Mito-TEMPO treatment 
(10μM) was performed for 14 days in cholesterol-stimulated (30μg/ml) ACCs pellets 
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after pre-incubation for one hour at the dose of 5μM. Media was changed every three 
days and stored in -80◦c to perform sGAG assay. The same method was used to treat 
bovine explants by mito-TEMPO for seven days. Media was changed every three days 
and stored in -80 ◦c to be used for sGAG assay. Chol:MβCD treatment in both ACCs 
pellet and bovine discs served as controls. 
3.2.7 Sulfated glycosaminoglycan (sGAG) assay 
sGAG assay was performed based on a protocol provided in the Blyscan Sulphated 
Glycosaminoglycan assay kit (Biocolor, life science assays, UK). Supernant from 
chondrocytes pellet culture and bovine explant cultured were collected every three 
days and immediately stored at -80◦c. On the day of the experiment, supernant was 
thawed and sGAG were precipitated, drained, and recovered. sGAG content was 
measured at the wavelength of 595 nm by a microplate spectrophotometer (Benchmark 
Plus, Tacoma, Washington, USA). sGAG content was determined by measuring 
sulphated glycosaminoglycan content compared to a chondroitin sulphate standard and 
expressed as μg/ml since each ml of condition media contained similar amounts of 
bovine cartilage and ACCs pellets. 
 
 
3.2.8 Histological Haematoxylin and Eosin (H&E) staining 
The knee samples were fixed in 4% paraformaldehyde (PFA) and decalcified in 
10% Ethylenediaminetetraacetic acid (EDTA) for three-four weeks. Decalcified 
samples were then embedded in paraffin and 5 μm thick serial sections were cut from 
paraffin blocks with a microtome. Selected slides from each sample were stained with 
H&E (HD Scientific, Wetherill Park, NSW, Austalia). Briefly, following dewaxing 
and hydration, Maye’s haematoxylin was used to stain the cell nucleus. After 
dehydration in increasing alcohol concentrations, the cell plasma and extracellular 
matrix were stained with eosin. Images of the stained slides were captured using Axion 
software under a light microscope (Carl Zeiss Microimaging GmbH, Gottingen, 
Germany). 
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3.2.9 Histological Safranin O staining 
The knee and chondrocytes 3D pellet cultured samples were fixed in 4% 
paraformaldehyde (PFA) and decalcified in 10% Ethylenediaminetetraacetic acid 
(EDTA) for three-four weeks. Decalcified samples were then embedded in paraffin 
and 5 μm thick serial sections were cut from paraffin blocks with a microtome. 
Selected slides from each sample were stained with safranin O staining method. 
Briefly, following dewaxing of sections in xylene (6 minutes) and hydration in a 
descending ethanol series (100%, 90% and 70%) for 3 minutes in each, Weigert’s iron 
haematoxylin working solution (Sigma-Aldrich, NSW, Australia) was applied for 
nuclei staining for two minutes, fast green solution for cytoplasm (five minutes), and 
Safranin O solution for cartilage staining for 10 minutes. After dehydration in 
increasing alcohol concentration, slides were mounted in Depex mounting medium. 
Images of the stained slides were then captured using Axion software under a light 
microscope (Carl Zeiss Microimaging GmbH, Gottingen, Germany), and OA severity 
in the tibia plateau was evaluated according to a modified Mankin’s histological 
grading system (Mankin’s score, 0-14) (H. J. Mankin et al., 1971). This scoring system 
is mainly focused on the Safranin O staining intensity, chondrocytes’ cellularity, and 
cartilage structure integrity. Accordingly, 0 points implies normal healthy cartilage, 
whereas 14 points represents the most severe cartilage lesions. 
 
3.2.10 Histological Alcian blue staining 
The chondrocytes 3D pellet cultures were fixed in 4% paraformaldehyde (PFA), 
embedded in paraffin and 5 μm thick serial sections were cut from paraffin blocks 
using a microtome. Selected slides from each sample were stained with alcian blue 
(Sigma-Aldrich, NSW, Australia). Briefly, following dewaxing of sections in xylene 
(6 minutes) and hydration in a descending ethanol series (100%, 90% and 70%) for 3 
minutes in each, alcian blue and fast red solutions were applied for 
Glycosaminoglycans (GAGs) and nuclei staining respectively. After dehydration in 
increasing alcohol concentration, slides were mounted in Depex mounting medium. 
Images of the stained slides were then captured using Axion software under a light 
microscope (Carl Zeiss Microimaging GmbH, Gottingen, Germany). 
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3.2.11 OCT embedding and Cryostat microtome 
The fresh cartilage tissue samples were collected from patients undergoing knee 
replacement. Cartilage pieces classified to normal and OA using gross view 
examination of macroscopic changes included softening of the hyaline articular 
cartilage, thinning and fibrous dislocation, ulcerations of the cartilage, and light 
sclerosis of the subchondral bone. Then, cartilage pieces were frozen in liquid nitrogen 
and embedded in optimal cutting temperature compound (OCT). A frozen block of 
tissue was sectioned using cryostat microtome. Frozen sections were collected by 
touching the glass slide directly onto each section. The slides were then kept at room 
temperature to air dry. Slides were then fixed by dipping the slides into acetone five 
times. Fixed slides were stained with Oil Red O staining to compare lipid distribution 
between normal and OA cartilage. 
 
3.2.12 Histological Oil Red O staining 
Serial 5μm sections were incubated with Oil Red O solution for 10-20 minutes 
at room temperature. Stained slides were washed very gently by dipping two-four 
times in distilled water, followed by air drying. Finally, slides were mounted in Depex 
mounting medium. Images of the stained slides were then captured using Axion 
software under a light microscope (Carl Zeiss Microimaging GmbH, Gottingen, 
Germany). 
 
3.2.13 Histochemical staining for cholesterol  
Cellular cholesterol staining was performed based on a protocol provided in the 
cholesterol assay kit (Sapphire Bioscience Pty. Ltd). Wells of a 96-well plate were 
seeded with 2x104 cells/well. Cells were left overnight to attach. The next day, culture 
medium from the wells was removed and cells were fixed with cell-based assay 
fixative solution and stained with Filipin III solution, incubating in the dark for 30-60 
minutes. Samples were analysed using a fluorescent microscope (Carl Zeiss 
Microimaging GmbH, Gottingen, Germany) under an excitation of 340-380 nm and 
emission of 385-470 nm. 
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3.2.14 Immunohistochemistry 
Tissue slices were dewaxed and hydrated. Endogenous peroxidases were blocked by 
incubation in 0.3% peroxide for 15 minutes. Non-specific proteins were removed with 
the incubation of 10% swine serum for one hour. Sections were then incubated with 
an optimal dilution of primary antibody overnight at 40C, followed by incubation with 
a biotinylated swine-anti-mouse, rabbit, goat antibody (DAKO Multilink, CA, USA) 
for 15 minutes, and then incubated with horseradish perioxidase-conjugated avidin-
biotin complex for 15 minutes. Antibody complexes were visualized by the addition 
of a buffered diaminobenzidine (DAB) substrate for three minutes. Sections were 
counterstained with Mayer's haematoxylin for 10 seconds each, and rinsed with 
running tap water. A list of antibodies sources and dilutions used for this study are 
summarized in Table 3.1. To conduct semi-quantitative data analysis, the positive cells 
from different fields of observation were counted and normalized to the cell number 
per 100 total cells in each group. 
                 Table 3.1: Antibodies Used for Immunohistochemistry (IHP) 
Antibody Source Dilution 
Anti-MMP-13 Labvision, ThermoFisher 
Scientific, VIC, Australia 
1:50 
Anti-Aggrecan (ACAN) Merck Millipore, VIC, Australia 1:500 
Anti-Collagen-X (COL10) Abcam, Sapphire Bioscince, 
NSW, Australia 
1:500 
Anti-DIPEN Kind gift from Prof Amanda 
Fosang 
1.6μg/ml 
Anti-NITEGE Kind gift from Prof Amanda 
Fosang 
5μg/ml 
Anti-Malondialdehyde (MDA) Abcam, Sapphire Bioscince, 
NSW, Australia 
1:500 
Anti-Cytochrome C (CYCS) Cell signalling Technology, 
Genesearch, QLD, Australia 
1:100 
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3.2.15 Immunofluorescence staining  
Tissue slices were dewaxed and hydrated. Sections were heat-treated at 94°C for 
four minutes in 10mM sodium citrate solution (pH 6.0) using the decloaking chamber, 
then incubated with 0.1% (w/v) hyaluronidase (Sigma-aldrich, NSW, Australia) at 
room temperature for 30 minutes. Non-specific proteins were removed with the 
incubation of 2% BSA/PBS solution for one hour. Sections were then incubated with 
optimal dilution of primary antibody in blocking buffer overnight at 40C, followed by 
incubation with fluorescence-labelled goat anti-mouse and anti-rabbit secondary 
(dilution range of 1:500-1:800 in blocking buffer) antibody (Alexa Fluor® 488, 
Invitrogen, Austraila) for one hour. Sections were mounted using Prolong® Gold 
antifade reagent (Invitrogen, Australia) and visualized using a confocal microscope 
(Carl Zeiss Microimaging GmbH, Gottingen, Germany). To conduct semi-quantitative 
data analysis, the positive cells from different fields of observation were counted and 
normalized to the cell number per 100 total cells in each group. 
 
3.2.16 RNA extraction and quantitative real time -PCR (qRT-PCR) 
Total RNA was isolated from ACCs pellets with TRIZOL reagent (Invitogen,VIC, 
Australia), DNase treated and column purified using an RNeasy Mini Kit (QIAGEN 
Pty Ltd, VIC, Australia) as described previously in our research group (Prasadam et 
al., 2010). Complementary DNA was synthesized using Superscript III (Invitrogen) 
from 1 µg total RNA following the manufacturer’s instructions. PCR primers (Table 
3.2) were designed based on cDNA sequences from the NCBI Sequence database 
using the Primer Express® software and the primer specificity was confirmed by 
BLASTN searches. RT-qPCR was performed on an ABI Prism 7300 Thermal Cycler 
(Applied Biosystems, Scoresby, VIC, Australia) with SYBR Green detection reagent. 
Briefly, 2 µL of template cDNA, 20 pmol of gene-specific primers and 10 μL of 1x 
Master Mix were used in a 20 μL reaction volume; each sample was performed in 
duplicate. The thermo cycling conditions were as follows: one cycle of 10 minutes at 
95°C for activation of the polymerase, 40 cycles of 10 seconds at 95°C and one minute 
at 60°C for amplification. Dissociation curve analysis was carried out to verify the 
absence of primer dimers and/or non-specific PCR products. The relative expression 
of the genes of interest was normalized against the α-tubulin housekeeping genes by a 
comparative cycle of threshold (Ct) value method (ABI user bulletin # 2). The 
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difference between the mean Ct values of the gene of interest and the housekeeping 
gene was labelled ΔCt, and the difference between ΔCt and the Ct value of the 
calibrator sample was labelled ΔΔCt. The log2 (ΔΔCt) gave the relative value of gene 
expression. 
 
Table 3.2: Primers Pairs Used in the qRT-PCR 
Genes Primer sequences 
MMP13 FORWARD: 5'- CATTTGATGGGCCCTCTGGCCTGC-3'         
REVERSE: 5'- GTTTAGGGTTGGGGTCTTCATCTC -3'    
ACAN FORWARD: 5'- TGAGGAGGGCTGGAACAAGTACC- -3'         
REVERSE: 5'- GGAGGTGGTAATTGCAGGGAACA -3'  
SREBF-2 FORWARD: 5’-GTCAGCTGCCAAGGAGAGTC -3’ 
REVERSE: 5’- TCATAACCCCCACAGAGTCC -3’ 
NPC1L1 FORWARD: 5’- CATCTTTGCCACCAGCTACA -3’ 
REVERSE: 5’- GAAAGGAACCACTTGCAGGA -3’ 
ABCA1 FORWARD:5’- TGGCAGTGTCCAGCATCTAA -3’ 
REVERSE: 5’- AGCATGTTCCGGTGTTTCTC -3’ 
NR1H3 FORWARD:5’- GAGAGGCTGCAGCACACATA -3’ 
REVERSE: 5’- AGACGCAGTGCAAACACTTG -3’ 
Beta-actin FORWARD: 5’ -  CAGGTCATCACYATYGGCAATGAGC- 
-3’  
REVERSE: 5’-  CGGATGTCMACGTCACACTTCATGA -3’ 
RUNX2 FORWARD: 5'- ACTTTGACAATAACTGTCCT -3'         
 REVERSE: 5'- GACACCTACTCTCATACTGG-3'    
BAX FORWARD: 5'- CTGAGCTGACCTTGGAGC -3'         
 REVERSE: 5'- GACTCCAGCCACAAAGATG-3'    
CYCS FORWARD: 5'- GCTGGTGGTGACTTTCTCT -3'         
 REVERSE: 5'- GCTTGCTTCACTGCTGCCAT -3'    
SOX9 FORWARD: 5'- TGAATCTCCTGGACCCCTTC -3'         
 REVERSE: 5'- TGCTGGAGCCGTTGACGCG -3'    
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3.2.17 Protein extraction and western blotting 
Total protein was harvested by lysing the ACCs pellets in a lysis buffer 
containing 1 M Tris HCl (pH 8), 5 M NaCl, 20% Triton X-100, 0.5 M EDTA and a 
protease inhibitor cocktail (Roche, Dee Why, NSW, Australia). The cell lysate was 
clarified by centrifugation and the protein concentration determined by a bicinchoninic 
acid (BCA) protein assay (Sigma-Aldrich Pty. Ltd., NSW, Australia). 10 g of protein 
was separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis on a 12% 
gel.  The protein was transferred to a nitrocellulose membrane, and blocked in a Tris-
Tween buffer containing 5% non-fat milk. The membranes were incubated with 
primary antibodies against ACAN (1:2000, rabbit anti-human/mouse; Cell Signaling 
Technology, Massachusetts, USA), MMP-13 (1:2000, Rabbit anti-human/mouse; 
Abcam-Sapphire Bioscince Pty. Ltd., NSW, Australia), phospho-ERK1/2 (1:2000) 
and phospho-JNK (1: 1000) and α-tubulin (1:5000, Rabbit anti-human/mouse; Abcam-
Sapphire Bioscince Pty. Ltd., NSW, Australia) overnight at 4ºC. The membranes were 
washed three times in TBS-Tween buffer, and then incubated with an anti-rabbit 
secondary antibody at 1:2,000 dilutions for one hour. The protein bands were 
visualized using the ECL Plus™ Western Blotting Detection Reagents (GE 
Healthcare, Rydalmere, NSW, Australia) and exposed on x-ray film (Fujifilm, 
Stafford, QLD, Australia).  Immunoblot negatives were analysed by densitometry 
using Image J software. 
 
3.2.18 MTT assay 
Normal chondrocytes were seeded in a 96-well tissue culture plate at the density 
of 5000 cells per well. After 24 hours’ incubation, the culture medium was removed 
and replaced with DMEM supplemented with 0.2% (w/v) BSA and Chol:MβCD 
(30μg/ml) for 24 hours. Cells incubated with 0.2% BSA without Chol:MβCD 
treatment served as controls. MTT [(3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide] assay was applied to test the overall metabolic activity 
and cell viability. 20μL of 5mg/ml MTT (Sigma-Aldrich, NSW, Australia) solution 
was added into each well. After incubation for four hours, the DMEM-MTT solution 
was carefully removed and replaced by 100μL of DMSO (dimethyl sulfoxide) to 
dissolve the formazan crystals. The absorbance was read at the wavelength of 595 nm 
by a microplate spectrophotometer (Benchmark Plus, Tacoma, Washington, USA). 
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3.2.19 ATP assay 
Passage 0 freshly plated primary chondrocytes that retain chondrogenic 
phenotype were plated on T75 flasks. On the day of experiment, growth medium was 
removed and replaced with serum free DMEM supplemented with 30 µM Chol:MβCD 
for 24 h. Cells incubated with 0.2% BSA (vehicle) without Chol:MβCD served as 
controls. Next day, Chondrocytes with 1x104 cells/ml density were cultured on a 96-
well plate and the cellular ATP content of the chondrocytes was determined by a 
bioluminescence assay based on the luciferase requirement for ATP in producing 
emitted light, according to the protocol for the CellTiter-GloRLuminescent Cell 
Viability Assay Kit (Promega, Madison, USA). Briefly, plates with its content were 
equilibrated at room temperature for 30 minutes. Then, 100 μl of CellTiter-Glo reagent 
was added to each well. The content of each well was mixed for two minutes in an 
orbital shaker to induce the cell lysis. The plate was incubated at room temperature for 
10 minutes to allow the luminescence signals to be stabilized. Luminescence was 
recorded using a Luminometer.  
 
3.2.20 Rhodamine 123 assay (RH-123)  
Passage 0 freshly plated primary chondrocytes were plated on T75 flasks and 
treated with 30 µM Chol:MβCD for 24 h. Cells incubated with 0.2% BSA (vehicle) 
without Chol:MβCD served as controls. Chondrocytes were first washed with 
phosphate-buffered saline (PBS) and then centrifuged (10000 g, 4 min) twice. 
Following measurement of viable cells using trypan blue, 90 μl of suspended 
chondrocytes (1 X 106 cells/ml) in a sodium citrate buffer and 10μl of Rhodamine 123 
solution (500μM) (Sigma-Aldrich Pty Ltd, NSW, Australia) were incubated for 10 min 
at 37°C in the dark. After incubation, stained cells were centrifuged for one minute at 
10 000g and the pellet was suspended in a HEPES buffer (Gibco-Invitrogen, VIC, 
Australia). 20μl of stained sample was read using a fluorescent plate reader at 505 nm 
excitation and 534 nm emission wavelengths.  
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3.2.21 Cellular ROS detection 
Cell Cellular ROS detection assay was performed according to the protocol for 
the 2’,7’ –dichlorofluorescin diacetate (DCFDA) Cellular ROS Detection Assay Kit 
(Abcam, Sapphire Bioscience Pty. Ltd., NSW, Australia). Passage 0 freshly plated 
primary chondrocytes were seeded on the T75 flasks and left overnight to attach. On 
the day of experiment, growth medium was removed and replaced with serum free 
DMEM with 30 µM Chol:MβCD for 24h. Cells incubated with 0.2% BSA (vehicle) 
without Chol:MβCD served as controls.  After 24 h, 1.5x107cells were resuspended in 
DCFDA mix and incubated at 37◦C for 30 minutes in the dark. Cells were washed in 
buffer solution by centrifugation and resepended in the supplemented buffer. 1x105 
stained cells/50μL were seeded per well in a 96-well dark plate. The fluorescence was 
read using a fluorescence plate reader to perform an endpoint read at 485 nm excitation 
wavelength and 535 nm emission wavelength.  
 
3.2.22 JC-1 staining 
Mitochondrial electrochemical potential gradient (∆Ψ) was assessed using 
fluorescent dye 5,5’,6,6’-tetrachloro-1,1’,3,3’ tetraethylbenzimidazolylcarbocyanine 
iodide (JC-1). Chondrocytes were cultured at 0.2x106 cells/ml and incubated 
overnight. The next day, media was removed and replaced with DMEM supplemented 
with 0.2% (w/v) BSA and Chol:MβCD (30μg/ml) for 24 hours. Cells incubated with 
0.2% BSA without Chol:MβCD treatment served as controls. Cells were incubated 
with JC-1 dye (Sigma-Aldrich, NSW, Australia) for 20 minutes at 37◦C in a humidified 
atmosphere containing 5% CO2. JC-1 aggregates were visualized under fluorescence 
microscope (Carl Zeiss Microimaging GmbH, Gottingen, Germany) using FITC/Cy3 
filters. Mitochondrial depolarization is indicated by a shift from red to green 
fluorescence. 
 
3.2.23 Transmission electron microscopy (TEM) 
TEM is a microscopy technique, whereby a beam of electrons is transmitted 
through an ultra-thin specimen, interacting with the specimen as it passes through. 
TEMs are capable of imaging at a significantly higher resolution than light 
microscopes and suited to study small cell organelles such as mitochondria. 
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Chondrocytes with 2x104 cells/ml density were cultured on 6-well plate. After 
overnight incubation, the medium was removed and replaced with DMEM 
supplemented with 0.2% (w/v) BSA and Chol:MβCD (30μg/ml) for 24 hours. Cells 
incubated with 0.2% BSA without Chol:MβCD treatment served as controls. After 
treatment with cholesterol, cells were immediately fixed with glutaraldehyde. As a 
second fixative procedure, osmium tetroxide was used to crosslink and stabilize lipids 
in cells and organelle membrane. Fixation was followed by dehydration of the tissue 
in ethanol, followed by embedding in resin. Thin sections were cut from resin blocks 
and stained. Images of the stained slides were then captured using a transmission 
electron microscope. 
 
3.2.24 In situ cell death detection (apoptosis) using TUNEL 
Chondrocytes apoptosis was assessed principally at the single cell level, based 
on labelling of DNA strand breaks (Terminal deoxynucleotidyl transferase dUTP nick 
end labelling or TUNEL technology) using an In Situ Cell Death Detection Kit, 
Fluorescein (Roche, Germany) according to manufacturer's protocol. TUNEL positive 
chondrocytes were visualized under a fluorescence microscope (Carl Zeiss 
Microimaging GmbH, Gottingen, Germany). 
 
3.2.25 Micro-CT analysis 
Micro-CT analysis was performed as described previously in our group (Afara, 
Prasadam, Crawford, Xiao, & Oloyede, 2013). Briefly, intact joints were scanned in a 
7- or 12-mm sample tube on a micro CT (Scanco 40, Switzerland) with an isotropic 
voxel size of 18 μm after tissues were fixed in 4% paraformaldehyde (PFA) in PBS as 
a scanning medium. The x-ray tube voltage was 55 kV and the current was 145μA, 
with a 0.5 mm aluminium filter. The exposure time was 1180 m. In the medial part of 
each tibia, a volume of interest was selected with an automatic contouring method. 
The circles were located in the middle of the load-bearing and non-load bearing sites 
of subchondral bone areas. Selected areas contained a subchondral plate, but did not 
contain a subchondral trabecular bone or growth-plate tissue. A total of 30 consecutive 
tomographic slices were analysed from the proximal part of the medial tibia plateau. 
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The meaningful subchondral bone plate measurements such as bone volume (mg 
HA/ccm) and BV/TV (%) were analysed using inbuilt software.  
 
3.3 ANIMAL STUDY  
3.3.1 Animal models 
ApoE−/− mice were purchased from the Animal Resource Centre (Laboratory 
Animal Cenre of Central South University, China). Experiments were performed in 
accordance with protocols approved by the Xiangya Hospital, the Central South 
University of China (ethics number: 2013-053). The mice were fed either 
standard/control rodent chow (CD) or a high cholesterol diet (HCD) (normal diet with 
1.25% cholesterol, 0.5% sodium cholate; Specialty Feeds, WA, Australia) diet two 
weeks prior to OA induction to raise the hypercholesterolemia phenotype in mice (9 
mice per group). 
In dietary induced hypercholesterolemia (DIHC) rat model, animals were 
purchased from the Animal Resources Centre (Perth, Western Australia) and 
experiments were performed in accordance with animal ethics approved by 
Queensland University of Technology (ethics number: 1300000283). Standard/control 
diet (CD) was substituted with high cholesterol diet (HCD) (10% fat, 2% cholesterol 
and 0.5% cholate; Specialty Feeds, WA, Australia) four weeks prior to OA induction 
(6 rats per group). Body mass and food consumption were measured each week and 
blood samples taken to assess serum lipid profiles (total cholesterol) using 
commercially available kits to confirm the hypercholesterolemia (HC) phenotype. 
To investigate whether statin and anti-oxidant treatment can reduced OA 
changes in ApoE−/− mice and DIHC rats, atorvastatin (Merck Millipore, VIC, 
Australia) and Mito-tempo/MitoQ (Sigma-Aldrich Pty Ltd, NSW, Australia) drug 
administration started three weeks prior to the mice and rats sacrifice. Animals were 
given 3mg/kg/day atorvastatin orally and mito-TEMPO-MitoQ was injected to both 
models subcutaneously at 1.5mg/kg dose every second days. 
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3.3.2 Induction of OA in mice and rats 
To induce OA in mice, the right knee is opened via a medial parapatellar 
approach and by dissecting the medial meniscus ligament to achieve destabilization of 
medial meniscus in the right knee joint for DMM model as described previously (Yang 
et al., 2010). Mice in the control group underwent a sham surgery that did not dissect 
the medial meniscus ligament. OA in rats was induced by medial menisectomy surgery 
for MSX model as described previously in our group (I. Prasadam, X. Mao, W. Shi, 
R. Crawford, & Y. Xiao, 2013; I. Prasadam et al., 2012; I. Prasadam, Y. Zhou, W. Shi, 
R. Crawford, & Y. Xiao, 2014)(Hulth A, 1970; Indira Prasadam"_ENREF_215" \o 
"Hulth A, 1970 #317" Hulth A, 1970; Indira Prasadam, Xinzhan Mao, Wei Shi, Ross 
Crawford, & Yin Xiao, 2013; Indira Prasadam et al., 2012; Indira Prasadam, Yinghong 
Zhou, Wei Shi, Ross Crawford, & Yin Xiao, 2014). These animals were then 
euthanized at five and eight weeks after surgery. Knee joint tissues were processed for 
histological evaluation. 
 
3.3.3 Flourchrome injection 
To assess subsequent new bone formation and turnover, fluorescence labelling 
dyes were injected to DIHC rats intraperitoneally. Alizarin red S (Sigma-Aldrich Pty. 
Ltd., NSW, Australia) (25mg/kg, three days before sacrifice) and Calcein (Sigma-
Aldrich Pty. Ltd., NSW, Australia) (10mg/kg, 10 days prior to alizarin injection) were 
administered and the animals were euthanized. Knee samples were collected and fixed 
in 4% PFA followed resin embedding procedure. 
 
3.3.4 Resin embedding 
Undecalcified tissue samples were dehydrated through a graded ethanol series 
(70%, 80%, 90%, and 100%) for one week each and processed through three clearing 
in of xylene for four hours. Samples were then infiltrated with Methyl methacrylate 
(MMA) and subsequently incubated with a mixture of MMA and polyethylene glycol 
(PEG) as previously described in our research group (Jaiprakash et al., 2012). To 
initiate the polymerisation process, the catalyst Perkadox (0.3%) was added to a 
MMA/PEG (3%) solution. Samples were fully covered with the MMA/PEG/Perkadox 
solution and incubated at 50ºC for 10 minutes. Specimens were put to rest until fully 
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polymerised. Embedded samples were placed under a vacuum adhesive press and 
grinded to face the sample parrallel to the slide. Final mounted slides were cut into thin 
sections using an automated sledge microtome. The section was positioned in the 
grinding system and ground to a final thickness using an electronic measuring system.  
 
3.3.5 Total cholesterol analysis 
Blood samples were collected in Ethylenediaminetetraacetic acid (EDTA) 
coated tubes after four hours of food deprivation by tail incisions at eight weeks post 
surgeries. Blood smaples were centrifuged for 10 minutes at 600 rpm, and then plasma 
was separated and collected for total cholestreol analysis. For this purpose, plasma of 
each group was measured following cholesterol assay kit protocol (Abcam-Sappaire 
Bioscience pty. Ltd., NSW, Australia) and analysed for total cholesterol levels. 20μL 
of each smaple was added to each well of 96-well plate and adjusted to 50μl with assay 
buffer. Next, 50μL of total cholesterol reaction mix was added to each well and mixed 
well. Smaples were incubated at 37 c◦ for 60 minuets protected from light following 
measurement immediately on a microplate reader (Benchmark Plus, Tacoma, 
Washington, USA) at 570 nm wavelength.  
 
3.3.6 Faxitron x-ray radiography 
The Faxitron MX20 (Faxitron X-Ray, USA) is a commercially available x-ray 
machine designed for animal irradiation. After sacrificing the DIHC rats, both legs 
were dissected and radiographic images of both legs were taken using a Faxitron x-ray 
machine by placing the legs in a direction to have a frontal view of the knee.  
3.4 STATISTICAL ANALYSIS 
Six rats and nine mice per group were used for in-vivo study and all in-vitro 
experiments were performed on cells that were isolated from the tibia plateau of 
twenty-four different patients aged 48-79 undergoing knee replacement. In vitro, three 
samples were used for histology investigation while six samples were used for 
quantifying experiments. Three cartilage discs from three bovines were used for 
bovine explants culture. Data are expressed as means ± standard deviations (SDs). 
Analyses were carried out on the three replicate samples. Data were analyzed using 
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un-paired student t-test or one-way ANOVA with Dunnet’s post-test when we had 
normal distribution between data or Kruskal-Wallis non-parametric ANOVA with a 
Dunnet’s post hoc test, when contribution was not normal between two or more sets 
of data. I performed statistical analyses using GraphPad Prism version 5.01 (GraphPad 
software, Inc.). A probability (p) value <0.05 was considered statistically significant.
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4.1  CHOLESTEROL DISTRIBUTION IN CARTILAGE FROM OA 
PATIENTS AND CHOLESTEROL REGULATION IN 
CHONDROCYTES IN-VITRO. 
Data are expressed as means ± standard deviations (SDs). Analyses were carried out 
on the three replicate samples. Data were analyzed using un-paired student t-test using 
GraphPad Prism version 5.01.  
Oil Red O staining of normal and OA cartilage 
Oil red O staining was performed to investigate lipid distribution in OA and 
normal human cartilage tissues. Fresh human cartilage was obtained from patients 
undergoing knee replacement (n=3). Normal and OA cartilage were separated from 
the tibia plateau as mentioned in Section 3.2.1. Normal histological procedure on 
sections obtained from paraffin blocks consists of ethanol hydration and dehydration 
steps prior to staining which resolves the lipid content of tissue. Therefore, our 
intention to perform the oil red staining on fresh frozen samples was to record the lipid 
profile of the cartilage tissue during the histological procedure. Serial 5μm sections 
were cut from fresh cartilage as detailed in Section 3.2.1. Histological oil red O 
staining was performed as per Section 3.2.12. This histological method was used to 
characterize the lipid content of OA cartilage compared to normal and allowed for easy 
estimation of tissue lipid distribution. We compared normal and OA cartilage to 
characterize the lipid content of OA cartilage against normal cartilage. Oil Red O 
staining of normal and OA cartilage showed a different lipid profile of OA cartilage 
compared to normal (Figure 4.1). Using this method, we detected more lipid droplets 
in OA cartilage tissue than normal cartilage, which may represent excess lipid 
accumulation in OA cartilage compared to normal. This may suggest that excess lipid 
accumulation in peripheral tissue is a feature of metabolic syndromes. Higher lipid 
distributions in OA cartilage compared to normal tissue indicates an abnormal lipid 
profile of OA patients. These findings suggest that a high lipid profile may play a role 
in the initiation and/or development of OA. 
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Figure 4.1: Oil Red O staining of normal (left) versus OA (right) human cartilage 
tissue.  Fresh cartilage was obtained and classified to normal and OA (n=3). Cartilage 
tissues were frozen in liquid nitrogen and embedded in OCT medium. Embedded 
samples in OCT blocks were stored at -80 ◦c freezer for cryostat microtomy and 
sections were fixed by being dipped into acetone a few times. Oil Red O staining was 
performed to characterize lipid distribution in cartilage tissue, comparing normal and 
OA. Red staining represents lipid accumulation and droplets and purple 
counterstaining represents the nuclei. There are higher lipid extents (red droplet) in 
OA cartilage compared to normal. Percentages of total positive cells in OA cartilage 
was significantly higher compared to normal. *P<0.05 versus normal.  Scale 
bars=50μm. 
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Histochemical filipin staining  
Based on Oil red staining experiment, we found higher lipid distribution in OA 
cartilage compared to normal. Therefore, we carried out cholesterol staining technique 
to test specifically where cellular cholesterol is located in the cultured OA and normal 
ACCs. Primary normal and OA ACCs (n=3) were isolated form human cartilage as 
outlined in Section 3.2.2 and cells were cultured according to Section 3.2.3. Next, we 
tested if we could detect cholesterol location and distribution in cultured ACCs by 
comparing normal and OA ACCs. For this purpose, cells were cultured according to 
Section 3.2.3, we then performed filipin staining on cultured ACCs according to 
Section 3.2.13. Under normal conditions, 80-90% of total cholesterol is present at the 
cell membrane. Within cells, intracellular cholesterol may move to different 
compartments through cholesterol trafficking (efflux and efflux) pathways. Defects in 
these transport pathways can alter cholesterol metabolism resulting in pathological 
states. We used a filipin probe to visualize a cholesterol location by comparing OA 
and normal ACCs. Our results showed more intracellular cholesterol in OA ACCs 
compared to normal ACCs, whereas most cholesterol presented in cell membranes 
(Figure 4.2). In normal ACCs, most cholesterol presented in the cell walls, which are 
indicated with a yellow arrow; however, OA ACCs staining demonstrated a movement 
of cholesterol from the cell wall to the intracellular space where cholesterol 
accumulated forming a droplet shape, as indicated by red arrow. This observation 
indeed demonstrates that intracellular accumulation of cholesterol may highlight a 
dysregulated cholesterol metabolism in OA ACCs as a characteristic of OA obtained 
from OA patients. This result supports the contention that high lipid levels are present 
in OA cartilage. 
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Figure 4.2: Histochemical filipin staining of normal versus OA chondrocytes. 
ACCs were isolated form cartilage tissue obtained from patients undergoing knee 
replacement (n=3). Two x 104 cells/well were fixed by Cell-based Assay Fixative 
solution and incubated with a filipin fluorescence probe in the dark. Cholesterol 
location was visualised using a Carl Zeiss fluorescence microscope under an excitation 
of 340-380 nm and emission of 385-470 nm. There is more intracellular cholesterol in 
OA ACCs (red arrow) compared to normal ACCs. The location of cholesterol in 
normal ACCs is mostly at the plasma membrane (yellow arrow). Percentages of total 
positive cells for pilipin staining in OA chondrocytes was significantly higher than 
normal cells. *P<0.05 versus normal. Scale bars=50μm. 
Cholesterol Influx and efflux genes mRNA expressions level (qRT-PCR) 
SREBP-2 is best known as a regulator of genes involved in cholesterol 
biosynthesis and uptake. NPC1L1 protein is an important efflux gene plays a critical 
role in the absorption of intestinal cholesterol. The liver X receptors (LXRs) act as 
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cholesterol sensors: when cellular oxysterols accumulate as a result of accumulative 
concentrations of cholesterol, LXR triggers the transcription of genes that defend cells 
from cholesterol overload. LXRα (NR1H3) and LXRβ (NR1H2) are two isoforms of 
LXR, which regulate gene expression. ABCA1 is another pivotal regulator of 
cholesterol efflux from cells to apolipoproteins. 
Our findings demonstrated abnormal cholesterol and lipid accumulation at 
cellular and tissue levels in OA samples compared to normal (figure 4.2). In order to 
investigate molecular mechanism underlying this dysregulated cholesterol metabolism 
and distribution, we tested cholesterol regulatory genes expression in normal and OA 
ACCs pellets and cartilage. To assess the mRNA expression of cholesterol regulation 
genes, we extracted RNA from human cartilage tissue (n=6) and ACCs pellets (n=6) 
followed by qRT-PCR as outlined in Section 3.2.16.  
The expression of influx genes (SREBF-2 and NPC1L1) was increased in the 
OA group of both cartilage and ACCs pellets compared to normal (Figure 4.3). Influx 
genes control cholesterol absorption into intracellular space and an increase in 
expression of SREBF2 and NPC1L1 genes points to excess intracellular accumulation 
of cholesterol (Figure 4.3). Expression of efflux genes NR1H3 was significantly 
decreased in both OA cartilage tissue and OA ACCs pellets, whereas expression of the 
other efflux gene ABCA1 was increased in the OA cartilage tissue and decreased in 
OA ACCs pellets, which did not reach statistical significance (Figure 4.4).  
Abnormal cholesterol accumulation occurs when cholesterol influx into the tissue wall 
exceeds cholesterol efflux. Here, we found cholesterol influx genes such as SREBF2 
and NPC1L1 mRNA levels were significantly higher in the OA group compared to 
normal. Moreover, cholesterol efflux genes such as NR1H3 and ABCA1 mRNA levels 
were lower in OA group compared to normal. The differential expression pattern of 
these cholesterol efflux and influx genes between the normal and OA groups may 
suggest a link between cholesterol related mechanisms and development and/or 
progression of OA. In the other word, these findings indicate that these cholesterol 
regulatory pathways are altered in OA patients. The results obtained from first aim 
support this study’s hypothesis that abnormal levels of cholesterol govern signalling 
molecules, which may play a role in initiation and/or development of OA. 
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Figure 4.3: Expression of cholesterol influx genes is up-regulated in OA cartilage 
and ACCs pellets: mRNA was extracted from normal and OA cartilage and ACCs 
pellets. qRT-PCR was performed to determine the mRNA expression of cholesterol 
influx genes at both tissue and cellular levels (A) The mRNA expression of SREBF-2 
and NPC1L1 was significantly increased in OA cartilage tissue compared to the 
normal group (n=6). Data are shown as mean ± SD. *P<0.05 versus normal. (B) The 
NPC1L1 expression was significantly up-regulated in OA ACCs pellets compared to 
normal (n=6). Data are mean ± SD.  P0-P2 ACCs pellets were used for all the 
experiments. *P<0.05 versus normal. Quantitative measurements were determined 
using the (2−ΔΔCt); method and beta-actin expression were used as endogenous 
housekeeping genes. All samples were performed in triplicate. The data is normalised 
to normal ACCs pellets arbitrarily set to 1. 
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Figure 4.4: Expression of cholesterol efflux genes is down-regulated in OA 
cartilage and ACCs pellets: mRNA was extracted from normal and OA cartilage and 
ACCs pellets. qRT-PCR was performed to determined mRNA expression of 
cholesterol efflux genes at both tissue and cellular levels. (A) The mRNA expression 
of NR1H3 was significantly elevated in OA cartilage tissue compared to normal; 
however, an increase in the expression of ABCA1in OA cartilage did not reach a 
significant level (n=6). Data are mean ± SD. *P<0.05 versus normal. (B) Similar to 
cartilage efflux gene expression, the mRNA expression of NR1H3 was significantly 
increased in OA ACCs pellets compared to normal. In contrast, there was no 
significant difference in the expression of ABCA1 in OA and normal ACCs pellets 
(n=6). Data are mean ± SD.  P0-P2 ACCs pellets were used for all the experiments. 
*P<0.05 versus normal. Quantitative measurements were determined using the 
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(2−ΔΔCt); method and beta-actin expression were used as endogenous housekeeping 
genes. All samples were performed in triplicate. The data is normalised to normal 
ACCs pellets arbitrarily set to 1. 
 
 
4.2 ABNORMAL CHOLESTEROL CHALLENGES THE CARTILAGE 
PHENOTYPE AND MITOCHONDRIAL FUNCTION IN-VITRO. 
In-vitro effect of cholesterol stimulation on ACCs pellets: 
Upon completion of our first aim of this project, we already found that the 
differential expression of genes, which are responsible for cholesterol regulation, 
might be the most likely explanation for abnormal cholesterol distribution in OA 
samples compared to normal. Therefore, we hypothesized that those abnormal levels 
of cholesterol which were found in OA samples might be a contributor to initiation 
and/or development of OA. In orther to test our hypothesis, we performed a set of in 
vitro expriments to test the effect of abnormal cholesterol levels on chondrocytes. 
To examine the effect of cholesterol stimulation in vitro, we performed a well-
stablished ACCs 3D pellet culture model as outlined in Section 3.2.4 and ACCs pellets 
were treated with different doses of cholesterol, i.e. 5, 10, 30μg/ml of MβCD/chol for 
14 days as detailed in Section 3.2.6. Cholesterol-stimulated pellets were stained using 
Safranin O staining and Alcian blue staining methods as per Section 3.2.9 and Section 
3.2.10 respectively.  
Safranin o and Alcian blue staining are two well-stablished methods used for 
histological analysis of proteoglycans. Cartilage and matrix were stained red and the 
background was stained green using Safranin O staining, whereas the matrix was 
stained blue in Alcian blue staining.  
Proteoglycans are a major component of extracellular cartilage matrix and loss 
of proteoglycan leads to cartilage damage, which is a common incidence during OA 
progression. Histological observation showed a cholesterol dose dependent 
proteoglycan loss in both staining methods (Figure 4.5A). Proteoglycans of the matrix 
were remarkably lost after a high dose of cholesterol stimulation in the in-vitro ACCs 
pellet model. Moreover, Safranin O staining showed that ACCs pellets stimulation 
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with a high dose of cholesterol can damage the pellet’s surface, representing cartilage 
degradation in OA development.  
To quantify proteoglycans that were released from the ACCs pellets into the 
medium during the cholesterol stimulation, we performed a sGAG assay as per Section 
3.2.7. We used condition media from ACCs 3D pellet culture to quantify the amount 
of sGAG. The sGAG release was determined by measuring sulphated 
glycosaminoglycan content compared to a chondroitin sulphate standard and 
expressed as μg/ml since each 1 ml of condition media contained similar amounts of 
cells per pellets.  The amount of proteoglycans detected by the collected medium 
during the experiment is in line with the results obtained from the histological staining 
(Figure 4.5B). This experiment points to a destructive effect of a high dose of 
cholesterol on ACCs in-vitro. 
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Figure 4.5: Effect of cholesterol stimulation on ACCs in 3D pellet culture. ACCs 
were isolated and differentiated in a chondrogenic media supplemented with 0.2% 
(w/v) BSA and with different doses of MβCD/chol (5, 10, 30μg/ml) for 14 days. ACCs 
pellets incubated with 0.2% BSA (vehicle) without Chol:MβCD served as controls. 
The media was collected to quantify sGAG deposition form pellets. (A) Representative 
Safranin O and alcian blue staining of ACCs pellets which were stimulated with 
different doses of cholesterol. There was a dose dependent proteoglycan loss in 
cholesterol–treated ACCs pellets compared to the control. At the very high doses of 
cholesterol (30μg/ml), pellets surface degradation was observed compared to the 
control. (B) sGAG content in condition medium of ACCs pellets. Deposition of sGAG 
increased with an acceleration in the dose of cholesterol. P0-P2 ACCs pellets were 
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used for all experiments (n=6). All samples were performed in triplicate. Scale 
bar=100μm. Data are mean± SD. *P<0.05 versus +vehicle. 
 
Effect of cholesterol stimulation on bovine explants culture: 
To test the impact of high cholesterol stimulation in vitro, we also performed a 
bovine explant culture in accordance with Section 3.2.5 as our second in vitro model. 
Bovine explant culture is widely used as an in-vitro model to study the collagens and 
proteaglycans network of the cartilage tissue (Bascoul-Colombo et al., 2015; Seol et 
al., 2014).  
Bovine cartilage disks were stimulated with 50μg/ml cholesterol as outlined in 
Section 3.2.5 and the amount of sGAGs released form bovine disks into the medium 
were quantified using sGAG assay as per Section 3.2.7. Quantified sGAG levels 
showed a significant proteoglycan release from bovine cartilage; however, the \ from 
Saranin O staining of bovine explants did not show remarkable difference (Figure 4.6). 
The most possible justification for our histological observation is that the collagen 
degradation is typically a slower event and typically occurs subsequent to GAG release 
in cartilage explant models (Little et al., 2002; Shingleton, Jones, Xu, Cawston, & 
Rowan, 2006).  
   
                                                          
Figure 4.6: Effect of cholesterol stimulation on bovine explant culture. Bovine 
cartilage discs were cultured in serum free media supplemented with 0.2% (w/v) BSA 
and 50μg/ml Cholesterol/MβCD. Bovine discs incubated with 0.2% BSA (vehicle) 
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without Chol:MβCD served as controls. The media was collected to quantify sGAG 
deposition form bovine explants. (A) Safranin O staining of bovine disk stimulated 
with 50μg/ml of cholesterol. (B) sGAG content in the condition medium of the bovine 
explant culture (n=3). All samples were performed in triplicate. Scale bar=100μm. 
Data are shown as mean± SD. *P<0.05 versus +vehicle. 
 
Immunofluorescence staining of ACCs in the 3D pellet culture 
As demonstrated in figure 4.5, high level of cholesterol has a destructive effect 
of ACCs pellets. Here, we investigate molecular expression of genes, which are 
responsible for OA-like changes. To analyse the OA-like marker expression under the 
effect of the high cholesterol stimulation in vitro, we performed 3D ACCs pellet 
culture as outlined in Section 3.2.4 and stimulated the pellets with 30μg/ml cholesterol 
as described in Section 3.2.6. To assess the expression of COL10 (cartilage 
hypertrophy marker), MMP13 (cartilage degradation marker) and aggrecan (ACAN; 
cartilage chondrogenic marker), we performed immunofluorescence staining as per 
Section 3.2.15.  
Similar to the in vivo results obtained from the immunofluorescence staining of 
the ACCs pellets in vitro, cholesterol stimulation increased COL10 and MMP13 
expression in histological sections of ACCs pellets, while it decreased ACAN 
expression (Figure 4.7). The percentages of total positive cells stained for these 
markers were significantly changed after cholesterol stimulation (Figure 4.7). 
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Figure 4.7: Immunofluorescence staining of chondrocytes. Immunofluorescence 
staining of COL10, ACAN, and MMP13 after cholesterol stimulation (30μg/ml) in 3D 
cultured ACCs. ACCs pellets incubated with 0.2% BSA (vehicle) without Chol:MβCD 
served as controls. Percentage of total positive cells was used as a standard measure to 
quantify. Percentages of total positive cells stained were increased for MMP13 and 
COL10, but significantly decreased for ACAN. P0-P2 chondrocytes pellets were used 
for all of the experiments (n=3). Scale bars = 75μm 
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ACCs 3D pellet mRNA expression after cholesterol stimulation (RT-qPCR) 
Histological immunofluorescence staining of the ACCs pellets revealed 
increased altered expressions of COL10, ACAN, and MMP13. To further analyse 
whether excess cholesterol effected chondrocytes mRNA expression in vitro, 3D 
ACCs pellet culture was performed as outlined in Section 3.2.4 and ACCs pellets were 
treated with 30μg/ml cholesterol as described in Section 3.2.6. After completion of the 
cholesterol treatment, RNA was extracted from the ACCs pellet and qRT-PCR was 
used to assess gene expression of MMP13, ACAN, runt-related transcription factor 2 
(RUNX2) and transcription factor SOX-9 (SOX9) at the mRNA level as outlined in 
Section 3.2.16.  It has been well-demonstrated that MMP13 and RUNX2 mRNA 
expression levels were up-regulated, whereas ACAN and SOX9 expression were 
decreased in OA cartilage. MMP13 is a cartilage degradion enzyme, which breaks 
cartilage extracellular matrix (ECM) genes such as ACAN during OA development 
(Iwamoto et al., 2003; Pullig et al., 2000; Rengel, Ospelt, & Gay, 2007). RUNX 2 is a 
chondrocyte hypertrophy marker and is used to assess cartilage phenotypical changes 
as an increased expression of chondrocyte hypertrophy markers has been observed in 
OA cartilage. Chondrogenic transcription factor SOX9 is essential for cartilage ECM 
formation and is important in maintaining chondrocytes phenotypes. Therefore, we 
used this marker to evaluate the cartilage chondrogenic homeostasis. 
At the RNA level, cholesterol treatment significantly up-regulated MMP13 and 
RUNX2 expression and down-regulated SOX9 expression compared to the control 
(Figure 4.8; P<0.05). There was a trend toward decreased ACAN mRNA expression 
in cholesterol-treated ACCs compared to the control, but this did not reach statistical 
significance. This may relate to the compensatory mechanism of ACCs to maintain 
cartilage homeostasis (Figure 4.8; P<0.05). Overall, our findings demonstrate the 
ACCs molecular changes under the effect of excess cholesterol, which are similar to 
those in OA progression.  
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Figure 4.8: ACCs 3D pellet mRNA expression after cholesterol stimulation (RT-
qPCR). The mRNA expression of MMP13, RUNX2, ACAN, and SOX9 after 
cholesterol stimulation (30μg/ml) in 3D cultured ACCs (n=6). ACCs pellets incubated 
with 0.2% BSA (vehicle) without Chol:MβCD served as controls. Data are mean ± 
SD. P0-P2 chondrocytes pellets were used for all the experiments. *P<0.05  
versus +vehicle. Quantitative measurements were determined using the (2−ΔΔCt); 
method and beta-actin expression were used as endogenous housekeeping genes. All 
samples were performed in triplicate. The data is normalised to control ACCs pellets 
(+vehicle) arbitrarily set to 1. 
 
Expression of chondrocytes haemostasis marker altered after cholesterol 
stimulation in ACCs 3D pellet culture (Western blot) 
As qRT-PCR showed an altered mRNA expression for the OA-like marker, we 
also examined the effect of excess cholesterol on protein expression in vitro. We 
performed an ACCs 3D pellet culture as outlined in Section 3.2.4 and ACCs pellets 
were treated with 30μg/ml cholesterol as detailed in Section 3.2.6. At the end of the 
experiments, protein was extracted from ACCs pellets and an active MMP13 and 
ACAN protein expression was evaluated by Western blot analysis performed as per 
Section 3.2.17. As MMP13 plays a key role in cartilage matrix destruction and ACAN 
is the most native extracellular matrix proteoglycan, we tested the protein expression 
of these markers to examine ACCs homeostasis. 
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A single band near 50 kDa and 110 kDa corresponded to the molecular mass of 
active MMP13 and ACAN, which were observed in our samples respectively  (Figure 
4.9). The ACAN antibody we used detected 110 kDa bands; however, the ACAN 
predicted molecular weight is 210-250 kDa. Consistant with our qRT-PCR results, 
MMP13 protein expression level is higher in cholesterol-treated ACCs pellets than 
control. In contrast, the ACAN protein expression level was higher in the control 
ACCs (non-treated) than cholesterol-treated ACCs pellets. This may suggest that post-
transcriptional processing of ACAN occurs in ACCs pellets treated with cholesterol, 
even though the mRNA expression trend is similar (Figure 4.9).     
                           
 
Figure 4.9: Expression of chondrocytes haemostasis marker altered after 
cholesterol stimulation in ACCs 3D pellet culture (Western blot). Western blot 
analysis of MMP13 and ACAN expression after cholesterol stimulation in 3D ACCs 
pellets culture (n=6). ACCs pellets incubated with 0.2% BSA without Chol:MβCD 
served as controls. P0-P2 ACCs pellets were used for this experiment. 
 
Excess cholesterol altered mitochondrial function  
Our above results demonstrate that cholesterol has a destructive role in cartilage 
homeostasis. Therefore, one potential mechanism that may play an essential role in 
this pathogenesis is mitochondrial dysfunction. In this experiment, we investigated the 
effect of high cholesterol levels on ACCs mitochondrial function. 
Diverse functional assessments were performed to evaluate the mitochondrial 
function under excess cholesterol (30μg/ml) conditions. We measured four 
parameters: the MTT [(3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium 
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bromide)] assay for mitochondrial dehydrogenase activity as outlined in Section 
3.2.18, RH-123 intensity for mitochondrial membrane potential as detailed in Section 
3.2.20, fluorescent probe (DCFDA) assay for ROS detection as explained in Section 
3.2.21, and luciferase-based assay for ATP production as per Section 3.2.19, 
respectively.  
These four experiments are essential for evaluating mitochondrial function and 
morphology under excess cholesterol. The MTT assay is based on conversion of MTT 
to formazan crystal by living cells that determine mitochondrial activity. As for most 
cells populations the total mitochondrial activity is related to total number of viable 
cells, this assay is widely used to measure the in vitro cytotoxic effects of drugs on 
primary cells. RH-123 distributes electrophoretically into the mitochondrial matrix in 
response to the electric potential across the inner mitochondrial membrane and is used 
to measure the mitochondrial electric potential (Δψ) (Baracca et al., 2003). Changes 
of Δψ are induced, directly or indirectly, by the proton transport occurring across the 
mitochondrial inner membrane during oxidative phosphorylation (ATP synthesis). Our 
hypothesis is that intracellular cholesterol overloadinf would alter mitochondrial 
membrane properties, which leads to the loss of Δψ and mitochondrial dysfuntion. 
Measuring Rh-123 levels and APT production rates in cholesterol-treated ACCs is a 
useful tool to test mitochondrial function. ROS is a major by-product of oxidative 
phosphorylation. Measuring the production rate of ROS in response to excess 
cholesterol is another way to further examine the mitochondrial function. 
 The presence of decreased mitochondrial dehydrogenase activity shown by 
MTT assay (Figure 4.10A; P<0.05), a decrease in ATP generation (Figure 4.10B; 
P<0.05), a breakdown of mitochondrial membrane potential as suggested by RH-123 
assay (Figure 4.10C; P<0.05) and increased ROS production level in cholesterol-
treated ACCs compared to non-treated ACCs, (Figure 4.10D; P<0.05) are all 
consistant with functional impairment of mitochondria after cholesterol stimulation.  
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Figure 4.10: Excess cholesterol altered mitochondrial function. Four types of 
mitochondrial functional assays: (A) MTT, (B) ATP generation, (C) RH-123 intensity, 
and (D) ROS level were assessed in 30μg/ml cholesterol-treated ACCs after 24 h 
(n=6). ACCs incubated with 0.2% BSA (vehicle) without Chol:MβCD served as 
controls. P0-P2 chondrocytes were used for all the experiments. All samples were 
performed in triplicate. Data are mean ± SD. *P < 0.05 versus +vehicle. 
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Excess cholesterol changed mitochondrial morphology under TEM 
Mitochondria are dynamic organelles that can change in number and 
morphology within a cell during development, the cell cycle, or when faced with toxic 
conditions. It is well-known that mitochondrial morphology is closely associated with 
mitochondrial function (Bereiter‐Hahn & Vöth, 1994; L. B. Chen, 1988; Rizzuto et al., 
1992).. In an attempt to further verify that mitochondria are involved in the 
pathophysiology of cholesterol-induced OA-like phenotype, we carried out 
morphological studies on ACCs pellets by electron microscopy as outlined in Section 
3.2.23.  
As demonstrated in Figure 4.11, chondrocyte from the control group showed 
intact, healthy mitochondrial structures with clear cristae and a lack of fragmentation. 
However, mitochondria in the cholesterol-treated group were characterized by 
fragmented double membrane and cristae disruption (yellow arrow), which are the 
definitive features of involvement of mitochondria in the apoptosis pathway. In 
addition, we found enlarged mitochondria with altered size in cholesterol-treated 
ACCs compared to the control group (Figure 4.11). Alteration in mitochondrial size 
and mass might be a mechanism by which cholesterol-treated ACCs compensate for 
the electron transfer deficiency resulting from mitochondrial dysfunction shown in 
Figure 4.11     
Figure 4.11: Excess cholesterol changed mitochondrial morphology. Transmission 
electron microscopy (TEM) of cholesterol-treated ACCs after 24 hour treatment (n=3). 
ACCs incubated with 0.2% BSA (vehicle) without Chol:MβCD served as controls. 
Scale bars= 200nm. 
 Chapter 4: Results 105 
Excess cholesterol altered mitochondrial membrane potential (Δψ) 
Mitochondrial membrane potential plays a role in both mitochondrial 
morphology and function. To specifically assess Δψ changes and mitochondrial 
function, we carried out JC-1 staining as detailed in Section 3.2.22. In normal cells, 
due to the electrochemical potential gradient, the dye concentrates in the mitochondrial 
matrix, where it forms red fluorescence. Imaging of living cells stained with JC-1 
demonstrated a noticeable shift from red fluorescence (normal Δψ) to green 
fluorescence (altered Δψ) in cholesterol-treated ACCs compared to the control group 
(Figure 4.12). Excess cholesterol dissipated the accumulation of the JC-1 dye in the 
mitochondria, and thus, the dye was dispersed throughout the entire cell, leading to a 
shift from red to green fluorescence, suggesting the mitochondrial membrane was 
depolarised and lost in cholesterol-treated group. In contrast, there are more 
chondrocytes possessing normal mitochondrial polarization (red fluorescence) in the 
control group (Figure 4.12). 
   
Figure 4.12: Excess cholesterol altered mitochondrial membrane potential.  JC-1 
staining of live ACCs after cholesterol treatment for 24 hours. ACCs incubated with 
0.2% BSA (vehicle) without Chol:MβCD served as controls. Scale bars= 50μm. 
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Excess cholesterol increased mitochondrial apoptotic marker’s expression  
We demonstrated that excess cholesterol leads to the mitochondrial damage and 
dysfunction. Next, to test whether excess cholesterol alters mitochondria-related 
apoptotic markers, we measured the expression level of BAX, CYCS, and CASP9 
mRNA expression. For this purpose, we performed 3D ACCs pellet culture and treated 
them with a high dose of cholesterol as outlined in Sections 3.2.4 and 3.2.6. We then 
extracted RNA from the ACCs pellets and performed qRT-PCR as detailed in Section 
3.2.16 to quantify expression levels of the mitochondrial-related apoptotic markers. 
BAX is widely used as the mitochondrial-related marker that initiates the 
apoptosis pathway by triggering cytochrome c release from mitochondria and down-
stream activation of Caspase-9 cascades through oxidative stress-induced cell death (J. 
T. Liu et al., 2010). Expression of the pro-apoptotic protein, BAX was significantly 
increased in ACCs pellets treated with cholesterol compared to the control group  
(Figure 4.13; P<0.05). As expected, BAX translocation to the mitochondria during 
excess cholesterol challenge led to marked up-regulation of cytochrome c and 
Caspase-9 expression in downstream apoptotic events (Figure 4.13; P<0.05). This 
suggests that the high cholesterol levels play a role as exogenous oxidative stimuli for 
mitochondria that govern chondrocytes apoptosis at the molecular level. 
                                                                                                                                 
Figure 4.13: Excess cholesterol changes in mitochondrial apoptotic marker’s 
expression. The mRNA expression of BAX, CASP9, and CYCS after cholesterol 
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stimulation in ACCs pellets (n=6). ACCs pellets incubated with 0.2% BSA (vehicle) without 
Chol:MβCD served as controls. Data are mean ± SD. P0-P2 chondrocytes pellets were used 
for all the experiments. *P<0.05 versus +vehicle. Quantitative measurements were determined 
using the (2−ΔΔCt); method and beta-actin expression were used as endogenous 
housekeeping genes. All samples were performed in triplicate. The data is normalised 
to control ACCs pellets (+vehicle) arbitrarily set to 1. 
 
Excess cholesterol induced mitochondrial oxidative stress-activated pathway  
Our previous results showed that high cholesterol levels directly induced 
oxidative stress environment via ROS overproduction, which itself activates 
mitochondrial-related apoptosis (Fleury, C. et al., 2002). Apart from this, there are 
other molecular pathways that indirectly drive oxidative stress-related apoptosis 
independent of mitochondria, such as extracellular signal-regulated kinases (ERK) and 
c-Jun N-terminal kinases (JNK) pathways (Kamata, 2005). We carried out ACCs 
pellets and treated the pellets with a high cholesterol dose as detailed in Sections 3.2.4 
and 3.2.6. Protein was extracted from the ACCs pellets and the expression of 
phosphorylated-JNK (p-JNK) and phosphorylated-ERK (p-ERK) were analysed using 
Western blot as outlined in Section 3.2.17.  JNKs consist of different isoforms among 
which JNK1 and JNK 2 are upstream kinases following JNKs activation and found in 
all cells and tissues. JNK signal activation occurs through dual phosphorylation of 
these proteins. They are activated in response to stress stimuli such as changes in ROS 
level and play a role in the cellular apoptotic pathway (C. Li et al., 2012). I proposed 
that high levels of cholesterol may activate oxidative stress-related pathways such as 
ERK and JNK via overproduction of ROS and mtDNA damge. 
Another signal that contributes to apoptosis in response to stress stimuli is ERKs, 
which belong to mitogen-activated protein kinase (MAPK) cascade. ERKs have two 
isoforms, ERK1 and ERK2, which are called ERK1/2 collectively. ERK1/2 is 
activated by oxidative stress following phosphorylation of these proteins. Though it 
has been reported that ERK1/2 play a pro-apoptotic role in cellular death signalling, 
ERK1/2 can also function as an anti-apoptotic factor after oxidative stress stimuli  
(Pearson et al., 2001). 
Western blot analysis revealed that the expression of p-JNK1/2 signals were up-
regulated in ACCs pellets after cholesterol treatment compared to non-treated ACCs. 
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In contrast, the expression of p-ERK1/2 pathway in ACCs was decreased after 
cholesterol stimuli, which may signify an anti-apoptotic function of p-ERKs cascades 
in response to excess amount of cholesterol (Figure 4.14). 
              
                                                                                                         
Figure 4.14: Excess cholesterol induced mitochondrial oxidative stress-activated 
pathway. Western blot analysis of p-JNK1/2 and p-ERK1/2 expression after 
cholesterol stimulation in 3D cultured ACCs (n=6). ACCs pellets incubated with 0.2% 
BSA (vehicle) without Chol:MβCD served as controls. P0-P2 chondrocytes pellets 
were used for all the experiments. Data are mean ± SD.  
 
4.3 HIGH CHOLESTEROL LEVELS LEAD TO OA DEVELOPMENT IN 
APOE-KNOCKOUT (APOE-/-) MICE AND DIETARY-INDUCED 
HYPERCHOELSTROLEMIC (DIHC) RAT MODELS. 
Characteristics of ApoE-/- mice model fed a control diet (CD) or high cholesterol-
diet (HCD): 
In order to study effect of high cholesterol levels on joint health, we developed 
two in vivo models: ApoE-/- mice and DIHC rat models. ApoE-/- mice, with sham or 
DMM surgery, are a promising small animal model, which helps to develop 
spontaneous hypercholesterolemia in vivo covering both the genetic and 
environmental determinants of hypercholesterolemia (Plump et al., 1992). The high-
cholesterol diet that we used for this study was previously used to develop 
hypercholesterolemia in ApoE-/- mice model (L. Gierman et al., 2014). 
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To assess the effect of mechanical loading, the body mass of ApoE-/- mice, 
developed as per Sections 3.3.1 and 3.3.2 were measured and showed no significant 
changes compared to the control diet (CD) and high-cholesterol diet (HCD) groups 
during this study (CD ApoE-/- mice 21.61 ± 1.37 g versus HCD ApoE-/- mice 21.81 
± 1.24 g) (Figure 4.15A; P<0.05).  We monitored the animals’ body mass to confirm 
that feeding a HCD does not increase mice body mass, which would affect joint health 
regardless of diet. 
We also performed lipoprotein analysis as per Section 3.3.5 to ensure that HCD 
induced high plasma cholesterol levels. The HCD group had significantly higher 
cholesterol levels than the CD group (Figure 4.15B; P<0.05). Our results show that 
HCD is able to increase the plasma cholesterol levels in ApoE-/- mice compared to CD 
fed animals. Normal serum cholesterol in mice varies based on strains and gender (30-
100 mg/dL).  
 
Figure 4.15: Characteristic of ApoE-/- mice on CD or HCD. (A) Body mass (g) of 
ApoE-/- mice (n=9 per group). Data are mean± SD. (B) Total serum cholesterol level 
in ApoE-/- mice fed a HCD and CD at the end week of the study (five weeks post-
surgery). Data are mean± SD. All samples were performed in triplicate. *P<0.05.   
 
H&E staining of knee joints from ApoE-/- mice model fed a CD or HCD: 
The knee joint of ApoE-/- sham and DMM mice models developed as outlined in 
Sections 3.3.1and 3.3.2 respectively, were histologically assessed to examine the 
structural changes from HCD. We performed H&E staining, as per Section 3.2.8, on 
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the knee joint sections obtained from the ApoE-/- mice fed either a HCD or CD. Sham 
ApoE-/- mice fed a HCD showed narrowing of the joint space, which is a common 
phenotype in OA patients, compared to CD group. Five weeks post-surgery, when 
DMM-induced OA was accompanied with HCD, OA ApoE-/- mice demonstrated 
significant cartilage damage and extreme joint space narrowing, while sham HCD 
mice still had a normal healthy structure (Figure 4.16). 
 
 
Figure 4.16: H&E staining of knee joints form ApoE-/- mice model fed a CD or 
HCD. HCD modified articular cartilage and joint space (black arrow) in both sham 
and OA ApoE-/- mice (n=3). Scale bar= 20μm. 
  
Hypercholeterolemia induced OA-like changes in ApoE-/- mice fed a CD or HCD: 
The knee joint of ApoE-/- sham and DMM mice models were histologically 
assessed to examine the effect of HCD on OA development. The knee joint sections 
of ApoE-/- mice were stained by Safranin O staining technique as per Section 3.2.9. 
Safranin O staining is a well-stablished method used to detect and characterize 
cartilage in terms of proteoglycans amount and cartilage thickness and structure. In 
this method, the cartilage is stained red, the nuclei are stained black and the 
background is stained green. Sham ApoE-/- mice fed a HCD showed more degradative 
changes compared to the CD group. Cartilage degradation was assessed based on 
cartilage structure and intensity of Safranin O staining representing proteoglycan 
content in cartilage. Five weeks post-surgery, when OA accompanied HCD, OA ApoE-
/- mice demonstrated significantly aggravated cartilage damage, while sham HCD mice 
still had a smooth cartilage surface (Figure 4.17A). At this time point, the Mankin 
score in ApoE-/- mice fed a HCD was significantly higher than the CD group.  Mankin 
scoring was performed by a blind person according to Table 2.1. This scoring system 
is mainly focused on the Safranin O staining intensity, chondrocytes’ cellularity, and 
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cartilage structure integrity. Accordingly, 0 points implies normal healthy cartilage, 
whereas 14 points represents the most severe cartilage lesions (Figure 4.17B; P<0.05).   
 
Figure 4.17: Hypercholesterolemia induced OA-like changes in APOE-knockout 
(ApoE-/-) mice. (A) Safranin O staining of sagittal sections of the tibia medial 
compartment of ApoE-/- mice fed a HCD or CD, proteoglycan (red) and background 
(green). Black arrows indicate loss of proteoglycan at five weeks after sham and DMM 
surgery. Scale bar=100μm. (B) Total Mankin score after OA surgery at five weeks in 
ApoE-/- mice. n=6 per group. Data are mean± SD. *P<0.05. 
 
Micro-CT scanning of ApoE-/- mice tibia plateau 
To assess potential subchondral bone changes in response to HCD, the tibia 
plateau of sham ApoE-/- mice model developed as outlined in Section 3.3.1 were 
scanned in a Micro-CT scanner as per Section 3.2.25 to evaluate subchondral bone 
changes. We used the proximal part of the medial tibia plateau to assess the ratio of 
bone volume over tissue volume (BV/TV). According to the Micro-CT analysis, there 
were significant changes in bone volume fraction (BV/TV) in the tibia plateau of the 
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ApoE-/- mice fed a HCD compared to CD. The ApoE-/- mice fed a HCD showed a 
decrease in bone volume fraction compared to the CD group (Figure 4.18; P < 0.05). 
 
Figure 4.18: Micro-CT scanning of ApoE-/- mice tibia plateau. Micro-CT three-
dimensional reconstructions of ApoE-/- mouse tibia plateau and bone volume/tissue 
volume ratio (BV/TV, %) measurements in the proximal part of tibia plateau (n=3). 
Scale bar =100μm. Data are mean ± SD. All samples were performed in triplicate. 
*P<0.05 versus CD. 
 
Hypercholesterolemia altered synovial membrane thickness in ApoE-/- mice 
To assess the effect of a HCD on the synovium, knee sections obtained from 
sham ApoE-/- mice were histologically stained as outlined in Section 3.2.9. In CD mice, 
histological examination showed proliferation of synovial lining cells, in places to 
more than five layers, associated with fibrous and disorganized intima. In the 
subintimal region, the reappearance of adipocytes was observed. In the ApoE-/- mice 
fed a HCD, the intima showed multi-layered lining cells, with an increase in the 
number of synoviocytes. Superficial synoviocytes were perpendicular rather than 
parallel with the joint space. Fibrosis of the normal adipose tissue was observed. 
Further measuring the synovial thickness, HCD mice revealed dramatic thickening of 
the synovial membrane. The synovium of CD ApoE-/- group was 23.6±5.4μm thick on 
average, compared to the average thickness of the HCD ApoE-/- mice, which was 50.28 
± 17.2μm thick (Figure 4.19).  
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Figure 4.19: Hypercholesterolemia altered synovial membrane thickness in 
ApoE-/- mice. (A) Representative histological images of the synovium showing 
thickened lining layer and signs of synovitis in HCD ApoE-/- mice. (B) Overall 
thickness of synovial membrane (n=6). Scale bar=50μm. Data are mean ± SD. *P<0.05 
versus CD. 
 
Hypercholesterolemia induced the inflammatory infiltrate in ApoE-/- mice  
To further test the potential inflammatory response to a HCD in the synovial 
membrane of ApoE-/- mice, we performed immunofluorescence staining for expression 
of F4/80 marker as described in Section 3.2.15. F4/80 is a well-characterized and 
extensively referenced mouse macrophage marker.  
ApoE-/- mice fed a HCD showed more expression of macrophages general F4/80 
marker compared to the CD group (Figure 4.20A). In the HCD group, there was a 
significant increase in positive stained cells compared to the CD mice (Figure 4.20B). 
Our results may signify that HCD in ApoE-/- mice model led to macrophage infiltration 
in the synovial membrane.  
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Figure 4.20: Hypercholesterolemia induced the inflammatory infiltrate in ApoE-
/- mice. (A) Expression of macrophages in ApoE-/- mice (n=6). Scale bar=50μm. (B) 
Percentage of total positive macrophages stained for F4/80. Data are mean ± SD. *=P 
＜0.05. 
 
Hypercholesterolemia induced OA-like marker expression in ApoE-/- mice 
Safranin O staining results demonstrated that HCD induce OA-like phenotype 
in ApoE-/- mice. In this experiment, we investigated the expression of some OA-like 
molecular markers in response to HCD in ApoE-/- mice. To this end, we performed 
immunohistochemistry staining as explained in Section 3.2.14 on sections obtained 
form ApoE-/- mice knee. The first marker was Collagen 10 (COL 10), which is 
expressed in hypertrophic chondrocytes. During OA development, COL 10 increases 
above the calcified zone and diffuses through the calcified matrix (Pullig O., et al., 
2002). However, OA may damage superficial cartilage and induce chondrocyte 
hypertrophic phenotype in the superficial zone as well (G. Murphy & Nagase, 2008). 
DIPEN and NITEGE are two neoepitope antibodies that detect N or C terminus of 
Aggrecan degradation products. DIPEN distinguishes MMP- driven aggrecan loss and 
NITEGE distinguish aggrecanase (ADAMTS-4, 5)-driven aggrecan loss in the late-
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stage disease. It has been well-demonstrated that aggrecan is degraded either with 
MMPs or aggercanase during OA development (Arner, 2002; Glasson et al., 2005; G. 
Murphy & Nagase, 2008). Our results demonstrate that the expression of COL10, 
NITEGE, and DIPEN in ApoE-/- mice fed a HCD was higher compared to the CD 
group, suggesting a cartilage degradative role for HCD. The total percentage of 
positive chondrocytes for these markers showed that only the DIPEN expression was 
significantly increased in the HCD group compared to control (Figure 4.21).  
                                                                
Figure 4.21: Hypercholesterolemia induced OA-like marker expression in ApoE-
/- mice. Immunohistochemistry staining of COL10, NITEGE, and DIPEN five weeks 
after surgery in ApoE-/- mice fed a CD and HCD. Percentage of total positive cells for 
OA-like markers were increased after HCD feeding and achieved a significant level 
for DIPEN expression. Scale bars = 50μm. 
 
Characteristics of DIHC rat model fed a CD or HCD: 
We developed a dietary induced hypercholesterolemia (DIHC) rat model as 
described in Sections 3.3.1 and 3.3.2 to further test the effect of HCD on OA 
development without genetic deficiency. To characterize the DIHC rats, the body mass 
of the DIHC rats were measured and showed no significant changes compared to the 
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control diet (CD) and high-cholesterol diet (HCD) groups during this study (CD rats 
304.16 ± 7.16 versus HCL rats 319.01 ± 12.81) (Figure 4.22A; P<0.05). Confirming 
that there was no significant body mass difference between the CD and HCD rats, we 
excluded the effect of excess mechanical loading from this study. 
Food consumption of the DIHC rats was also measured. There was no significant 
difference in food intake of DIHC rat model (CD 16.85 ± 0.79 versus HCD 17.83 ± 
0.74) (Figure 4.22B; P<0.05). 
Plasma cholesterol levels of the DIHC rats were measured eight weeks post-
surgery (mmol/l). The HCD group indicated significantly higher cholesterol levels 
than the CD group (Figure 4.22C; P<0.05). We performed this experiment to ensure 
that the HCD was able to increase the plasma cholesterol level significantly reaching 
a hypercholesterolemic condition. A normal serum cholesterol level in rats is 40-130 
mg/dL. 
 
Figure 4.22: Characteristic of DIHC rat model on a CD or HCD. (A) Body weight 
(g) of rats (n=6 per group). Data are mean± SD. (B) Food consumption (g/day) of 
DIHC rats fed a CD or HCD. Data are mean± SD (C) Total serum cholesterol level in 
DIHC rats fed a HCD and CD at the end week of the study. Data are mean± SD. All 
samples were performed in triplicate. *P<0.05 versus CD.   
 
Faxitron x-ray radiography of DIHC rats’ knee joints 
One of the radiographicall hallmarks in human OA patients is joint space loss. To 
radiographically assess the knee joint of DIHC rats, we performed x-ray radiographic 
as detailed in Section 3.3.6. Eight weeks after surgery, radiographs of knee joints were 
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obtained using the Faxitron MX20 x-ray system and semi-quantitative data obtained 
using Image J software and student t-test method used for statistcs. To adequately 
assess the joint space, x-ray images were taken from sham-operated rats fed either a 
CD or HCD. The non-uniform joint space narrowing, which is the radiographic 
hallmark of primary OA, was observed in rats fed a HCD compared to the CD group. 
Joint space in HCD fed animals was significantly decreased compared to CD. 
Moreover, the articular surface appears flattened in HCD group compared to CD group 
(Figure 4.23). 
 
  
 
 
Figure 4.23: Faxitron X-Ray radiography of DIHC rat model. X-ray images of rats 
fed a CD or HCD at eight weeks post-surgery (n=6). 
 
Safranin O staining and Mankin Score of tibia plateau from DIHC rat model fed a 
CD or HCD: 
We developed a dietary induced DIHC rat model as described in Section 3.3.1 
and investigated test the effect of HCD on OA development in cartilage. The knee joint 
of DIHC rats were histologically assessed using Safranin O staining as outlined in 
Section 3.2.9. The cartilage was characterized based on Safranin O staining for 
proteoglycans amount and cartilage thickness and lesions. Sham rats fed a HCD 
showed more degradative changes compared to CD group. Eight weeks post-surgery 
when OA was accompanied with HCD, OA rats demonstrated significant aggravated 
cartilage damage, while sham HCD rats still had a smooth cartilage surface (Figure 
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4.24A). At this time point, Mankin scoring was performed by a blind person according 
to Table 2.1. Mankin Score in both OA and sham DIHC rats fed a HCD was 
significantly higher than corresponding CD groups (Figure 4.24B; P<0.05).   
  
Figure 4.24:  Hypercholesterolemia induced OA-like changes in DIHC rat model. 
(A) Top, gross appearance of tibia in the sham and MSX groups fed a CD or HCD at 
eight weeks after surgery. Black arrows indicate the surface of the cartilage in the 
middle region of the medial tibia. Bottom, Safranin O staining of sagittal sections of 
the tibia medial compartment of rats fed a HCD or CD, proteoglycan (red) and bone 
(blue). Black arrows indicate the loss of proteoglycan at eight weeks after sham and 
MSX surgery. Scale bar, 100μm. (B) Total Mankin score after OA surgery at eight 
weeks in the dietary rat model. n= 6 per group. Data are mean± SD. *P<0.05. 
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Micro-CT scanning of DIHC rat’s tibia plateau 
In this experiment, we investigated the effect of high cholesterol levels on 
subchondral bone. Therefore, the tibia plateau of the DIHC rat model developed as 
outlined in Section 3.3.1 were scanned in a Micro-CT scanner as described in Section 
3.2.25 to evaluate subchondral bone changes in this animal model. We used the 
proximal part of the medial tibia plateau to assess the ratio of bone volume over tissue 
volume (BV/TV). Our Micro-CT analysis showed that there were significant changes 
in the bone volume fraction (BV/TV) in the tibia plateau of the DIHC rats fed a HCD 
compared to the CD. Subchondral bone volume was calculated using the Micro-CT 
scanning.  Micro-CT assessment showed significant changes in BV/TV ratio in the 
tibia plateau of the rats on HCD. The rats fed a HCD showed a decrease in bone volume 
fraction compared to CD group (Figure 4.25; P < 0.05).  
 
Figure 4.25: Micro-CT tibia plateau scanning of DIHC rat model. Micro-CT three-
dimensional reconstructions of DIHC rats and bone volume/tissue volume ratio 
(BV/TV, %) measurements in the tibia plateau (n=3). Scale bar = 100μm. Data are 
mean± SD. All samples were performed in triplicate. *P<0.05 versus CD.   
 
Hypercholesterolemia increased bone formation and remodelling 
To further evaluate new bone formation and mineralization as well-known 
subchondral bone changes during the course of OA, the DIHC rat model developed as 
per Section 3.3.1 was subjected to fluorescence labelling as described in Section 3.3.3. 
Fluorochromes are fluorescent labels with calcium affinity, the most used being 
alizarin and calcein. When different types of fluorochromes are injected into the 
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animals at different moments of ossification, they bind to the available calcium that is 
precipitating in the mineralization areas. With the aid of filters that catch specific 
wavelengths for each fluorochrome, it is possible to visualize the mineralized areas in 
different colours for each period. Analysis of bone formation and mineral apposition 
are based on the distance between the two labels and percentage and/or intensity of 
bone labels exhibiting mineralizing activity.  
Our results showed that there were more bone formation and mineralization in 
the subchondral bone area of the DIHC rat’s model fed a HCD compared to the CD. 
The fluorescence band’s percentage and intensity in the HCD group were higher in 
comparison to the CD group (Figure 4.26A). An increase in subchondral bone 
remodelling and mineralization in rats fed a HCD represents the subchondral bone 
changes occurred in OA patients.  
We also found bone marrow like lesions in the subchondral bone area of DIHC 
rats fed a HCD compared to the CD; however, further investigation is needed to 
confirm this phenomenon (Figure 4.26B). Bone marrow lesions are a common 
symptom among OA individuals. 
                            
Figure 4.26:  Hypercholesterolemia increased bone formation and remodelling. 
(A) Calcein and alizarin red fluorescence labelling; representative subchondral bone 
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remodelling in rats fed a CD or HCD at eight weeks after surgery (n=6). Scale bar = 
100μm. (B) Bone marrow lesions in subchondral area of rats fed a HCD shown by 
yellow arrows. Scale bar = 50μm. 
 
Hypercholesterolemia altered synovial membrane thickness in DIHC rats 
To evaluate the effect of HCD on synovium, we performed the histological 
staining as described in Section 3.2.9 on the knee sections obtained from the DIHC 
rat’s model. In rats fed a HCD, synoviocyte hypertrophy, increased number of lining 
cells and thickened synovial membrane was observed. The intima was fibrous and 
disorganized, and in the subintimal region, reappearance of adipocytes was presented 
in synovial membrane of HCD rats. In the CD group, the synovial membrane showed 
no pathological changes as indicated by the typical palisading structure of the intimal 
lining layer and few proliferative lining layer cells. The thickness of synovium was 
also decreased, compared to rats with HCD (CD = 5 ± 2.7μm thick versus HCD= 
14±3.1μm thick) (Figure 4.27). 
                               
 
Figure 4.27: Hypercholesterolemia altered synovial membrane thickness in 
DIHC rats. (A) Representative histological images of the synovium showing 
thickened lining layer and signs of synovitis in HCD rats. (B) Overall thickness of 
synovial membrane (n=6). Scale bar=50μm. Data are mean ± SD. *P<0.05 versus CD.   
Hypercholesterolemia induced the inflammatory infiltrate in DIHC rats  
To further test the potential inflammatory response to a HCD in the synovial 
membrane of DIHC rats, we performed immunofluorescence staining for the 
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expression of CD68 marker as described in Section 3.2.15. CD68 is a classical 
inflammatory marker for rats that is expressed in monocyte/macrophages. 
 Immunofluorescence analysis of sections from rats showed a similar expression 
pattern to the mice. Rats fed a HCD had a higher CD68 fluorescence intensity 
compared to the CD group (Figure 4.28A). Moreover, there were significantly more 
CD68 positive macrophages (38.1%) in the lining cell layer and synovium of HCD 
rats compared to CD rats (Figure 4.28B). 
                                                                                                                   
Figure 4.28: Hypercholesterolemia induced the inflammatory infiltrate in DIHC 
rats. (A) Expression of different macrophages in DIHC rats (n=6). Scale bar=50μm. 
(B) Percentage of total positive macrophages. Data are mean ± SD. *=P ＜0.05. 
 
 
Hypercholesteremic induced OA-like marker expression in DIHC rat model 
To assess the effect of a HCD on the expression of OA-like molecular markers, 
we performed immunohistochemistry staining as outlined in Section 3.2.14 on the 
knee sections obtained from the DIHC rat model. We tested COL10, DIPEN, and 
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NITEGE expression under the effect of HCD. Although rats fed a HCD showed 
increased NITEGE, COL10 and DIPEN expression compered to CD,groups (Figure 
4.29).  
                                                                                         
 
Figure 4.29: Hypercholesteremic induced OA-like marker expression in the 
DIHC rat model. Immunohistochemistry staining of COL10, NITEGE, and DIPEN 
eight weeks after surgery in rats fed a CD and HCD. Percentages of total positive cells 
for OA-like markers, in particular NITEGE and DIPEN, were significantly increased 
in HCD compared to the CD group. Scale bars = 50μm. 
 
 
Expression of oxidative stress markers in ApoE-/- mice and rat model fed a HCD 
Lipid peroxidation is an oxidative degeneration of lipids results in cell and even 
tissue damage. In order to demonstrate whether hypercholesterolemia induces lipid 
peroxidation in our animal models fed a HCD, we detected the production of 
Malondialdehyde (MDA), a sensitive oxidative stress marker, using 
immunohistochemistry as outlined in Section 3.2.14. Proteins may be modified under 
oxidative stress either directly by ROS or indirectly by autoxidation of lipids. Such a 
protein is MDA, which also termed advanced lipoxidation end products. Localization 
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of MDA is closely related to oxidative process and is independent evidence of local 
oxidative stress. In the knee cartilage of animals fed a HCD, in particular in the DIHC 
rat model, more positive stained MDA were found in comparison with the CD group 
(Figure 4.30), suggesting that hypercholesterolemia induces lipid peroxidation and 
oxidative stress pathway.  
In order to determine whether oxidative stress induction triggers mitochondrial 
cytochrome C release, animals fed a HCD were immunohistochemically stained for 
cytochrome C expression as described in Section 3.2.14. The release of cytochrome c, 
one of the most important respiratory-chain proteins, from the mitochondria into the 
cytosol is the hallmark of cells passing through apoptosis. The intensity of staining in 
cytosol in HCD group, which represented the quantities of cytochrome c, was higher 
than those in CD group, specifically in our ApoE-/- mice model. The release of 
cytochrome c into the cytosol specifies the molecular basis of apoptosis, which can be 
induced in both ApoE-/- mice and DIHC rats fed a HCD compared to CD group (Figure 
4.30). 
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Figure 4.30: Expression of oxidative stress marker in HCD animals. 
Immunohistochemistry staining of CYCS and MDA, oxidative stress marker, seven 
and 12 weeks after HCD or CD in ApoE-/- mice and DIHC rats respectively. Scale 
bars= 50μm. 
 
Hypercholesterolemia lead to apoptosis  
We performed TUNEL staining assay as described in Section 3.2.24 to examine 
DNA fragmentation as a result of mitochondrial-induced cell death in ApoE-/- mice 
and DIHC rats fed a HCD. We used this method to further confirm a mechanism by 
which HCD induced cartilage damage (previously shown in Figures 4.17 and 4.24) in 
ApoE-/- mice and DIHC rat’s models.  
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Apoptosis as a mechanism that leads to cell death can run its course very quickly, 
from minutes to hours. Due to this, and the focal nature of cell death, apoptosis is 
unusually unobtrusive in tissue sections. However, we observed more TUNEL-
positive chondrocytes in the HCD groups of both animal models than the CD groups 
(Figure 4.31, green). Consistent with immunihistochemstry results (Figure 4.31), high 
levels of choelstreol targeted oxidative-induced apoptosis pathway from the most up-
stream incident, CYCS release to cytosol, down to cell death and DNA damge.                          
           
Figure 4.31: Hypercholesterolemia leads to apoptosis. Fluorescence detection 
(FITC) of TUNEL positive cells in ApoE-/- mice and DIHC rats seven and 12 weeks 
after HCD feeding, respectively. Scale bars= 50μm. 
 
Cholesterol-lowering drug (atorvastatin) reduced plasma cholesterol levels 
To study whether using cholesterol-lowering drugs could reverse cartilage 
degeneration, animals fed a HCD were subjected to atorvastatin oral treatment for 
three weeks prior to the animal’s euthanasia as outlined in Section 3.3.1. Total serum 
cholesterol was measured in the HCD groups and HCD plus atorvastatin groups. In 
both ApoE-/-  mice and DIHC rats, high cholesterol levels due to HCD were 
significantly reduced after atorvastatin treatment (Figure 4.32; P<0.05). This result 
confirmed that using oral atorvastatin in this study was efficient in decreasing plasma 
cholesterol levels. Accordingly, .this help us to rely on cholesterol-lowering effect of 
atorvastatin for further joint changes examination. 
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Figure 4.32: Cholesterol-lowering drug (atorvastatin) reduced plasma cholesterol 
levels. Total serum cholesterol level in ApoE-/- mice and DIHC rats received 
atorvastatin (+Ator) (n=6). Data are mean ± SD. *P<0.05 versus +HCD. 
 
Atorvastatin as positive control attenuated cartilage damage 
After confirmation of a cholesterol-lowering effect of atorvastatin administration 
in our animal models, the knee joint of ApoE-/- mice and DIHC rat models developed 
as per Sections 3.3.1 and 3.3.2 were histologically assessed with Safranin O staining 
to examine the inhibitory effect of atorvastatin on OA development as outlined in 
Section 3.2.9. Three weeks after atorvastatin administration, ApoE-/- mice showed less 
cartilage degenerative changes compared to the non-treated group, even with incidence 
of OA surgery. The Mankin score in atorvastatin-treated APOE-/- mice was also 
significantly lower than the control group (-Ator) (Figure 4.33; P<0.05). This may 
highlight the cartilage protective effect of atorvastatin during a course of 
hypercholesterolemia development.  
Interestingly, consistent results were obtained from HCD rats treated with 
atorvastatin. We found less proteoglycan loss, better cartilage surface structure and 
significantly lower Mankin scores in rats treated with atorvastatin compared to the 
control group (Figure 4.33; P<0.05).  
In general, we have demonstrated that the cartilage structure looks healthier, 
even in OA animals, when we diminish the impact of a HCD on joints using 
atorvastatin. 
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Figure 4.33: Atorvastatin attenuated cartilage damage. Safranin O staining and 
Mankin score of HCD ApoE-/- mice and DIHC rats who received atorvastatin (+ Ator) 
for three weeks. Cartilage damage caused by HCD was restored in ApoE-/- mice and 
DIHC rats after atorvastatin administration. This was in line with allied Mankin score 
graph showing a significant decrease in cartilage damage in atorvastatin-treated 
animals compared to the non-treated animals (-Ator). Scale bars= 100μm. Data are 
mean± SD. *P<0.05 versus - Ator. 
 
Atorvastatin treatment did not change subchondral bone volume  
The tibia plateau of ApoE-/- mice and DIHC rat models developed as outlined in 
Sections 3.3.1 and 3.3.2 were scanned in a Micro-CT scanner as described in Section 
3.2.25 to evaluate subchondral bone changes after atorvastatin treatment in animals. 
We used the proximal part of the medial tibia plateau to assess the ratio of bone volume 
over tissue volume (BV/TV). We also have to aknowledge that due to number of 
animals per each group (n=3), we might have statistical analysis limitation and our 
Micro-CT results had low statistical power. 
Micro-CT analysis showed that there were no significant changes in bone 
volume fraction (BV/TV) in the tibia plateau of the ApoE-/- mice and DIHC rats treated 
with atorvastatin compared to non-treated group (control). Subchondral bone volume 
was calculated using Micro-CT scanning. Micro-CT assessment did not show 
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significant changes in BV/TV ratio in the tibia plateau of the ApoE-/- mice and DIHC 
rats who received atorvastatin. As our previous Micro-CT assessment showed, in mice 
and rats fed a HCD, bone volume fraction was markedly decreased compared with CD 
group (Figures 4.18 and 4.25; P<0.05). Nevertheless, atorvastatin treatment did not 
significantly affect BV/TV in animals, but it tended to increase BV/TV (Figure 4.34; 
P< 0.05).        
 
Figure 4.34: Micro-CT scanning of tibia plateau of ApoE-/- mice and DIHC rats 
who received atorvastatin. Micro-CT three-dimensional reconstructions of ApoE-/- 
mice and DIHC rats who received atorvastatin and bone volume/tissue volume ratio 
(BV/TV, %) measurement in the tibia plateau (n=3). Using Micro-CT analysis, no 
significant changes were observed after atorvastatin treatment (+Ator) in the ApoE-/- 
mice and DIHC rats compared to non-treated groups (-Ator). Scale bar = 100μm. Data 
are mean ± SD.  
Atorvastatin reduced intensity and expression of OA-like markers 
To assess the effect of atorvastatin on the expression of OA-like molecular 
markers, we performed immunohistochemistry staining as described in Section 3.2.14 
on sections obtained form ApoE-/- mice and DIHC rat models developed as per 
Sections 3.3.1 and 3.3.2. We used the same OA-like marker that we used in our 
previous experiments as indicators of OA-like cartilage degradation. To test the effect 
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of atorvastatin on cartilage, we chose cartilage hypertrophic marker COL10 and 
cartilage degradative markers NITEGE and DIPEN.  
Our results demonstrate that the intensity and/or expression amount of COL10, 
NITEGE, and DIPEN in ApoE-/- mice and DIHC rats decreased in atorvastatin-treated 
groups compared to non-treated ones (Figure 4.35). This finding suggests that 
atorvastatin treatment in both animal models is able to alter the expression of OA-like 
markers. Our immunohistochemistry staining results are similar to the data obtained 
from histological Safranin O staining (Figure 4.34) where the condro-protective effect 
of atorvastatin was demonstrated. Moreover, total percentages of positive cells for OA-
like markers were significantly decreased in the atorvastatin-treated group compared 
to the non-treated animals (Figure 4.35). 
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Figure 4.35: Atorvastatin reduced intensity and expression of OA markers. 
Immunohistochemistry staining of COL10, NITEGE, and DIPEN after atorvastatin 
treatment in ApoE-/- mice and DIHC rats. Expressions of OA-like markers were 
decreased in atorvastatin-treated (Ator) ApoE-/- mice and DIHC rats compared to non-
treated (-Ator) groups (n=6). Total percentages of positive cells for all OA-like 
markers were significantly reduced after atorvastatin treatment in both ApoE-/- mice 
and DIHC rat model. Scale bars= 50μm. 
 
Atorvastatin inhibited cell death in ApoE-/- mice and DIHC rats 
We performed TUNEL staining assay as described in Section 3.2.24 to assess 
cell death as a result of apoptosis in ApoE-/- mice and DIHC rat models, developed as 
per Sections 3.3.1and 3.3.2, which received atorvastatin and compared them with the 
non-treated group. We used this method to further confirm that if a cholesterol level is 
reduced using a cholesterol lowering drug (atorvastatin), HCD-induced apoptosis 
(previously shown in Figure 4.28) will be decreased in ApoE-/- mice and DIHC rats as 
well.  
We previously demonstrated that ApoE-/- mice and DIHC rats fed a HCD 
exhibited more apoptotic cells compared to the CD group (Figure 4.31). Here we found 
that the number of TUNEL positive cells were decreased after atorvastatin treatment 
compared to the non-treated group (Figure 4.36). This may suggest that atorvastatin 
inhibited the cell death program, which was induced by HCD. Although atorvastatin 
has multiple effects on different pathways, this result signifies the anti-apoptotic effect 
of this drug in ApoE-/- mice and DIHC rats that received it.  
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Figure 4.36: Atorvastatin inhibited cell death in ApoE-/- mice and DIHC rats. 
TUNEL staining of apoptotic cells in HCD ApoE-/- mice and DIHC rats after 
atorvastatin treatmen t(n=6). The number of TUNEL positive cells were decreased in 
both ApoE-/- mice and DIHC rats after atorvastatin treatment (+ Ator) compared to 
the non-treated group (- Ator). Scale bars= 50μm. 
 
4.4 ADMINISTRATION OF ANTI-OXIDANT MITO-TEMPO/MITOQ 
COULD SLOW DOWN CHOLESTEROL-ASSOCIATED OA 
PROGRESSION IN OUR IN-VIVO AND IN-VITRO MODELS. 
Mito-TEMPO slowed cartilage damage in-vitro 
To test the effect of mito-TEMPO in our in vitro models, we performed ACCs 
pellet culture and bovine explant culture as outlined in Sections 3.2.4 and 3.2.5 
respectively. We then treated the ACCs pellets and bovine explants with a combination 
of 30μg/ml cholesterol and 10μM mito-TEMPO as described in Section 3.2.6. ACCs 
pellets and bovine explants treated with cholesterol only were used as a control. 
Histological Safranin O staining was performed on ACCs pellets and bovine explants 
as per Section 3.2.9.  
Our results show the protective role of mito-TEMPO in attenuating cartilage 
damage in-vitro. Quantifying sGAG content in the supernate of ACCs pellet culture 
revealed that the amount of sGAG was significantly decreased after mito-TEMPO 
treatment, suggesting less proteoglycan loss from ACCs pellets into the growing 
medium. Histological observation did not show a noticeable difference in bovine 
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explant culture after mito-TEMPO treatment; however, the amount of sGAG in the 
medium was lower in the mito-TEMPO treated group compared to the control (Figure 
4.37; P<0.05). 
                                   
Figure 4.37: Mito-TEMPO slowed cartilage damage in-vitro: Safranin O staining 
of cholesterol stimulated ACCs in 3D culture and bovine explants and corresponding 
sGAG amount in growing medium after mito-TEMPO treatment (n=3). P0-P2 
chondrocytes pellets were used for all of the experiments. Data are mean± SD. *P<0.05 
versus cholesterol-treated (control). 
 
Mito-TEMPO treatment changed the OA-like markers in ACCs pellets 
To analyse whether an antioxidant (mito-TEMPO) is able to improve 
chondrocytes homeostasis in vitro, we performed a 3D ACCs pellet culture as 
described in Section 3.2.4 and stimulated the pellets with a combination of 30μg/ml 
cholesterol/10μM mito-TEMPO as outlined in Section 3.2.6. To assess the expression 
of COL10 (cartilage hypertrophic marker), MMP13 (cartilage degradative marker) and 
aggrecan (ACAN; cartilage chondrogenic marker), we performed 
immunofluorescence staining as per Section 3.2.15.  
Similar results were obtained from immunofluorescence staining of ACCs 
pellets. We previously demonstrated that cholesterol stimulation increased COL10, 
and MMP13 expression in histological sections of ACCs pellets (Figure 4.7). Here we 
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found that the decreased expression of COL10 and MMP13 and increased expression 
of ACAN after mito-TEMPO treatment compared to the non-treated group (Figure 
4.38). 
                           
                         
 
Figure 4.38: Mito-TEMPO treatment changed the OA marker in ACCs pellets.  
Immunofluorescence staining of COL10, ACAN, and MMP13 after mito-TEMPO 
treatment in 3D cultured ACCs pellets. P0-P2 chondrocytes pellets were used for all 
of the experiments (n=3). Scale bars = 75μm 
Mito-TEMPO treatment changed the OA marker mRNA expression in ACCs 
pellets 
The above results from the immunofluorescence staining of ACCs pellets 
revealed an altered expression of COL10, ACAN, and MMP13 after mito-TEMPO 
treatment compared to non-treated groups. To further analyse the effect of mito-
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TEMPO on chondrocytes mRNA expression in vitro, 3D ACCs pellet culture was 
performed as outlined in Section 3.2.4 and ACCs pellets were treated with combination 
of 30μg/ml cholesterol and10μM mito-TEMPO as per Section 3.2.6. After completion 
of treatment, RNA was extracted from ACCs pellet and qRT-PCR was used to assess 
gene expression of MMP13, ACAN, RUNX2, and SOX9 at mRNA level as outlined 
in Section 3.2.16.   
At the RNA level, mito-TEMPO treatment down-regulated the expression of the 
catabolic marker (MMP13) and hypertrophic marker (RUNX2); however, they could 
not alter the expression of ACAN to a significant level (Figure 4.39; P<0.05). 
 
      
                                                                               
Figure 4.39: mito-TEMPO treatment changed the OA-like marker mRNA 
expression in ACCs pellets. The expression of MMP13, RUNX2, SOX9, and ACAN 
in 3D cultured ACCs after mito-TEMPO treatment (n=6). P0-P2 chondrocytes pellets 
were used for all of the experiments. Data are mean ± SD. Quantitative measurements 
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were determined using the (2−ΔΔCt); method and beta-actin expression were used as 
endogenous housekeeping genes. All samples were performed in triplicate. The data 
is normalised to control ACCs pellets (+vehicle) arbitrarily set to 1.*P<0.05 versus + 
Chol 
Mitochondrial function is recovered using mitochondrial-targeted antioxidant 
Mito-tempo 
Mitochondrial dysfunction was proposed as a potential mechanism playing a role 
in the OA-like phenotypical changes induced by excess cholesterol. We previously 
demonstrated that mitochondrial function is altered in ACCs after exposure to high 
levels of cholesterol (Figure 4.24). To test mito-TEMPO treatment effect on 
mitochondria, we performed the same diverse mitochondrial functional assessments. 
In all experiments, ACCs were treated with the combination of 30μg/ml 
cholesterol/10μM mito-TEMPO, and ACCs treated with 30μg/ml cholesterol was set 
as a control. We measured four parameters: the MTT for mitochondrial dehydrogenase 
activity as described in Section 3.2.18, RH-123 intensity for mitochondrial membrane 
potential as outlined in Section 3.2.20, DCFDA assay for ROS detection as explained 
in Section 3.2.21, and luciferase-based assay for ATP production as per Section 3.2.19, 
respectively.  
Our results indicate that antioxidant mito-TEMPO is able to restore 
mitochondrial function by preserving mitochondrial integrity by protecting 
mitochondria from inner membrane potential loss (RH-123 assay). Moreover, our 
findings indicate that mito-TEMPO is able to specifically regulate mitochondrial ATP 
production in the mitochondrial inner membrane and ROS generation (Figure 4.40; 
P<0.05). 
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Figure 4.40: Mito-TEMPO improved mitochondrial functional. MTT assay, ATP 
generation, Rhodamine 123 (RH-123) intensity, and ROS level were assessed in ACCs 
after mito-TEMPO treatment (n=6). Data are mean ± SD. All samples were performed 
in triplicate. *P<0.05 versus + Chol. 
 
Mito-TEMPO treatment altered the mitochondrial marker expression in ACCs 
pellets 
The above results show that antioxidant mito-TEMPO is able to attenuate 
mitochondrial function in vitro cultured ACCs. To further assess the effect of mito-
TEMPO on chondrocytes mRNA expression in vitro, a 3D ACCs pellet culture was 
performed as outlined in Section 3.2.4 and ACCs pellets were treated with combination 
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of 30μg/ml cholesterol/10μM mito-TEMPO as described in Section 3.2.6. After 
completion of the treatment, RNA was extracted from ACCs pellet and qRT-PCR was 
used to assess gene expression of BAX, CASP9, and CYCS at mRNA level as per 
Section 3.2.16.   
It was not entirely surprising that mito-TEMPO reduced the BAX expression at 
the mRNA level by inhibiting the translocation of BAX to mitochondria. Therefore, 
the mito-TEMPO positively tapered the cytochrome c release into the cytoplasm led 
to a decrease in expression of cytochrome c and CASP9 as apoptotic markers (Figure 
4.41; P<0.05). 
     
                                                                                         
Figure 4.41: Mito-TEMPO treatment altered mitochondrial marker expression 
in ACCs pellets. The expression of BAX, CASP9, and CYCS in 3D cultured ACCs 
after mito-TEMPO treatment (n=6). P0P2 chondrocytes pellets were used for all of the 
experiments. Data are mean ± SD. Quantitative measurements were determined using 
the (2−ΔΔCt); method and beta-actin expression were used as endogenous 
housekeeping genes. All samples were performed in triplicate. The data is normalised 
to control ACCs pellets (+vehicle) arbitrarily set to 1.*P<0.05 versus + Chol. 
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MitoQ/mito-TEMPO antioxidant did not change the plasma cholesterol level 
In the aim three of this study, we firstly demonstrated the protective effect of 
antioxidant against OA-like change in our in vitro models. To assess the potential role 
of oxidative stress in hypercholesterolemia-induced OA in vivo, we tested 
mitochondria-targeted antioxidants MitoQ and mito-TEMPO in our animal models. 
Although there are many natural antioxidants, including vitamin E, their effectiveness 
is limited as they do not accumulate in mitochondria, nor can they pass across lipid 
bilayers. Synthetic mitochondrial ROS (mtROS) scavengers such as mito-TEMPO and 
MitoQ have been developed to address this issue. These compounds easily pass 
through all biological membranes into cells and tissues affected by mtROS (M. P. 
Murphy & Smith, 2007). MitoQ is used to accumulate in mitochondria to protect from 
oxidative damage in vivo and mito-TEMPO protects cells from mitochondrial 
oxidative stress by playing a specific scavenger role against mitochondrial superoxide 
both in vivo and in vitro.  
The ApoE-/- mice and DIHC rat models developed as described in Section 3.31 
were subjected to MitoQ and mito-TEMPO treatment respectively as outlined in 
Section 3.3.1. Total serum cholesterol was measured as per Section 3.3.5 to investigate 
the effect of these antioxidants on plasma cholesterol levels. We did not find a 
significant difference in total plasma cholesterol levels in ApoE-/- mice and DIHC rats 
treated with MitoQ and mito-TEMPO respectively compared to the HCD (non-treated) 
group (Figure 4.42; P<0.05). Both MitoQ and mito-TEMPO had an antioxidant effect 
and no cholesterol-lowering effect in our animal models’ plasma samples. 
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Figure 4.42: MitoQ/mito-TEMPO antioxidant did not change the plasma 
cholesterol level. Total serum cholesterol level in ApoE-/- mice and DIHC rats that 
received MitoQ and mito-TEMPO respectively (n=6). There were no significant 
changes in the serum cholesterol levels of DIHC rats treated with mito-TEMPO in 
comparison with non-treated ones. Data are mean ± SD. All samples were performed 
in triplicate. *P<0.05 versus HCD. 
 
Mito-TEMPO/MitoQ antioxidants rescued cartilage integrity 
The knee joint of DMM ApoE-/- mice and MSX DIHC rats were histologically 
assessed to study the scavenging effect of mito-TEMPO and MitoQ on OA 
development in the HCD group. Animals were developed as described in Sections 
3.3.1.and 3.3.2. After three weeks of drug administration, we euthanized the animals 
and processed their knee joint samples for histological assessment. We performed 
Safranin O staining on sections obtained from the knee joints of the ApoE-/- mice and 
DIHC rats as per Section 3.2.9. Our findings demonstrated that MitoQ restored OA 
development in cartilage of ApoE-/- mice compared to animals that did not receive 
MitoQ. The corresponding Mankin score of the ApoE-/- mice that received MitoQ was 
significantly lower compared to the non-treated animals (-Mito) (Figure 4.43, P<0.05). 
Moreover, we found less proteoglycan loss, less vertical fissure, and better cartilage 
structure in DIHC rats treated with mito-TEMPO compared to the non-treated (-Mito) 
group. Mankin scoring of the cartilage in DIHC rats treated with mito-TEMPO was 
correlated with histological results, where cartilage integrity was saved after mito-
TEMPO treatment compared to the non-treated group. Accordingly, the Mankin score 
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was significantly reduced after mito-TEMPO treatment in DIHC rats (Figure 4.43; 
P<0.05).  
                                              
Figure 4.43: Mito-TEMPO/MitoQ antioxidants rescued cartilage integrity. 
Safranin O staining and Mankin score of HCD ApoE-/- mice and DIHC rats received 
MitoQ and mito-TEMPO respectively for three weeks (n=6). Histologically 
assessment of the knee joints of ApoE-/- mice and DIHC rats received antioxidants (+ 
Mito) revealed attenuated cartilage damage compared to non-treated (- Mito) ones. 
The corresponding Mankin scores were markedly decreased in both animal models 
treated with either MitoQ or mito-TEMPO compared to non-treated controls. Scale 
bars = 100μm. Data are mean ± SD. *P<0.05. 
 
Mito-TEMPO and MitoQ antioxidants did not change subchondral bone volumes  
To test the effect of antioxidants treatment on subchondral bone in ApoE-/- mice 
and DIHC rats, a Micro-Ct scanner was used. The tibia plateau of ApoE-/- mice and 
DIHC rat model developed as described in Sections 3.3.1 and 3.3.2 were scanned in a 
Micro-CT scanner as outlined in Section 3.2.25 to evaluate subchondral bone changes. 
We used a proximal part of the medial tibia plateau to assess the ratio of bone volume 
over tissue volume (BV/TV). According to the Micro-CT analysis, the 3D structure of 
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the medial tibia plateau in ApoE-/- mice and DIHC rats was not changed after receiving 
MitoQ and mito-TEMPO respectively. Micro-CT assessment exhibited that mito-
TEMPO and MitoQ had a small, but not significant, additive effect on the BV/TV in 
tibia plateau of the ApoE-/- mice and rats that received treatment (+Mito) compared to 
the non-treated (-Mito) ones (Figure 4.44; P<0.05).  
 
             
Figure 4.44: Micro-CT tibia plateau scanning of animals that received 
antioxidants. Micro-CT three-dimensional reconstructions of ApoE-/- mice and rats 
that received MitoQ and mito-TEMPO respectively, and bone volume/tissue volume 
ratio (BV/TV, %) measurement in the tibia plateau. Bone fraction and 3D structure of 
medial tibia plateau of ApoE-/- mice and DIHC rats that received antioxidants (+Mito) 
were not altered in comparison to non-treated groups (-Mito). Scale bar =100μm. Data 
are mean ± SD. All samples were performed in triplicate. *P<0.05 
 
MitoQ and mito-TEMPO attenuated expression of OA markers 
To assess the effect of antioxidants on the expression of OA-like molecular 
markers, we performed immunohistochemistry staining as described in Section 3.2.14 
on sections obtained form ApoE-/- mice and DIHC rats’ models developed as per 
Sections 3.3.1 and 3.3.2. We used the same OA-like marker as that used in our previous 
experiments as indicators of OA-like cartilage degradation. To test the effect of 
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MitoQ/mito-TEMPO on cartilage, we chose the cartilage hypertrophic marker COL10 
and cartilage degeneration markers NITEGE and DIPEN.  
Our results show that the expression of COL10, NITEGE, and DIPEN in ApoE-
/- mice treated with MitoQ was decreased compared to the non-treated group (Figure 
4.45). This result signifies the protective role of antioxidant MitoQ against cartilage 
degradation. Furthermore, we found a reduced expression of NITEGE, DIPEN, and 
COL10 in mito-TEMP treated DIHC rats in comparison with the non-treated group 
(Figure 4.46). Our immunohistochemistry staining findings are in line with our 
histological observation (Figure 4.45), whereas a protective effect of antioxidants 
treatment against OA development was revealed. In addition, the total percentage of 
positive cells for OA-like markers was significantly diminished in the antioxidants-
treated group compared to non-treated animals (Figure 4.45). 
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Figure 4.45: MitoQ and mito-TEMPO attenuated expression of OA markers. 
Immunohistochemistry staining of COL10, NITEGE, and DIPEN after MitoQ and 
mito-TEMPO treatment in ApoE-/- mice and DIHC rats respectively. Expressions of 
OA-like markers were decreased in both ApoE-/- mice and DIHC rats that received 
antioxidants treatment compared to the non-treated groups. Percentages of total 
positive cells for OA-like markers were significantly reduced after antioxidant 
treatment in both ApoE-/-mice and DIHC rat model. Scale bars= 50μm.   
 
MitoQ/ mito-TEMPO antioxidants repressed mitochondrial apoptosis 
We performed TUNEL staining assay as outlined in Section 3.2.24 to assess 
apoptotic cells in the ApoE-/- mice and DIHC rat models, developed as per Sections 
3.3.1 and 3.3.2 that received antioxidants and compare them with the non-treated 
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group. We did this experiment to demonstrate that if chondrocytes’ mitochondria were 
protected using MitoQ or mito-TEMPO, HCD-induced apoptosis (previously shown 
in Figures 4.28) would decrease in ApoE-/- mice and DIHC rats as well.  
We previously demonstrated that ApoE-/- mice and DIHC rats fed a HCD 
exhibited more apoptotic cells compared to the CD group (Figure 4.31). We also found 
that the number of TUNEL positive cells decreased after atorvastatin treatment 
compared to the non-treated group (Figure 4.36). Here, we tested whether the anti-
oxidant mito-TEMPO/MitoQ was able to decrease the apoptosis program by 
protecting mitochondria from HCD damage.  
ApoE-/- mice and rats treated with MitoQ and mito-TEMPO respectively were 
evaluated for apoptosis. There were less TUNEL-positive cells in MitoQ and mito-
TEMPO treated groups compared to the control (Figure 4.46). This observation may 
suggest that using a cholesterol-lowering drug inhibits the cell death program, which 
was induced by HCD. 
                    
Figure 4.46: MitoQ/ mito-TEMPO antioxidants repressed mitochondrial 
apoptosis. TUNEL staining of apoptotic cells in HCD ApoE-/- mice and rats after 
MitoQ and mito-TEMPO treatment respectively. Scale bars= 50μm. 
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Chapter 5: Discussion 
5.1 GENERAL DISCUSSION 
Although still of uncertain pathology, there are many clinical factors that 
contribute to the risk and progression of OA, including metabolic syndromes. 
Metabolic syndromes are classified as obesity, dyslipidemia, high blood pressure, and 
diabetes (C. DAY, 2007). Metabolic OA has now been characterized as a subtype of 
OA, and the links between this phenotype and metabolic syndrome have been 
indicated in numerous studies. Related to metabolic syndrome is hypercholesterolemia 
that can result as an abnormal dietary cholesterol intake and/or inappropriate 
regulation of plasma cholesterol levels.  
The role of cholesterol in the development of coronary artery disease is well 
documented, with numerous studies demonstrating its deleterious effects in the 
development of atherosclerosis (G. K. Hansson, 2005; P. Libby, Ridker, & Hansson, 
2011). Its role in the etiology of OA is less understood, although epidemiological 
studies suggest a strong association between elevated serum cholesterol levels and OA 
(de Seny et al., 2015; Erb, Pace, Douglas, Banks, & Kitas, 2004; Q. Zhuo, W. Yang, 
J. Chen, & Y. Wang, 2012).  In thelast century, the correlation between lipid 
abnormalities and OA was identified with the presence of increased levels of serum 
cholesterol in OA patients (DEBORAH J Hart et al., 1995; T. Stürmer et al., 1998). A 
study by Hart and colleagues showed that moderately raised serum cholesterol found 
in both knee and hand OA patients was independent of BMI (DEBORAH J Hart et al., 
1995).   
Literature data suggests that chondrocytes are able to produce cholesterol even 
if the mechanisms regulating this pathway remain unclear. High levels of cholesterol 
are naturally found in the cell membrane of chondrocytes (Ghadially, Mehta, & 
Kirkaldy-Willis, 1970) and proteins necessary for cholesterol biosynthesis, such as 3-
hydroxy-3-methylglutaryl-coenzyme A synthase 1 (HMGCS), acetyl-coenzyme A 
acetyltransferase 1 (ACAT1), or low density lipoprotein receptor (LDLR) are all 
expressed in human chondrocytes (Arkill & Winlove, 2006).  
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Recent evidence suggesting that cholesterol biosynthesis deregulation is  
presentin cartilage has given new strength to the studies focused on the cholesterol 
pathway in the OA. Studies have also shown aberrant regulation of cholesterol 
homeostasis in OA cartilage. Abnormal cholesterol accumulation occurs when 
cholesterol influx into the cell (through the action of apolipoproteins) exceeds 
cholesterol efflux. In OA chondrocytes, the gene expression of the two LXR subtypes 
alpha (NR1H3) and beta (NR1H2), as well as of the cholesterol transporter, APOA1 
and ABCA1 are down-regulated compared to normal chondrocytes (24). We 
demonstrated that this differential expression pattern of cholesterol efflux genes, 
which are in line with recent findings (Gentili et al., 2005; A. Tsezou et al., 2010; 
Zerega et al., 2004), may signify a causal relationship between cholesterol homeostasis 
and the development and/or progression of OA. In another study, abnormal 
accumulation of cholesterol and fatty acids has been reported in articular cartilage, in 
particular, in the superficial area, during OA development. In mice, one study has 
shown that prolonged exposure to a high cholesterol diet can induce OA-like cartilage 
degenerative changes. Despite the fact that the above studies have demonstrated 
important and complex interactions between cholesterol and OA, the mechanisms 
remain unclear. More confirmatory in vivo evidence is required to establish the role of 
this risk factor in the development of OA and potential treatment options.  
In our preliminary in vitro study, we demonstrated the abnormal lipid 
distribution in OA cartilage compared to the control, which might be a characteristic 
of OA tissues obtained from OA individuals. This hypothesis was further examined by 
a filipin staining where we found more intracellular cholesterol in OA ACCs compared 
to normal ACCs. Cholesterol is a major component of cell membrane structure. 
Dysregulation in cholesterol regulatory gene’s expression, which is confirmed by a 
qRT-PCR experiment, may elucidate intracellular accumulation of cholesterol in OA 
samples compared to controls. As we demonstrated, cholesterol influx genes (SREBF2 
and NPC1L1) were expressed more in OA tissue and ACCs pellets compared to the 
control, whereas cholesterol efflux genes (NR1H3 and ABCA1) were down-regulated 
in OA samples. Abnormal cholesterol regulatory genes expression led to intracellular 
accumulation of cholesterol. Our results are in line with previous evidence that 
highlighted the cholesterol biosynthesis deregulation role in regards to OA 
development cartilage (A. Tsezou et al., 2010). Moreover, we found most significant 
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abnormal cholesterol gene expression at the cartilage tissue level, suggesting that 
cholesterol abnormal uptake happens more frequently in the late stage rather than early 
stage, since we get most of cholesterol dysregulation in G4 cartilage obtained from 
late stage OA patinets; however, further investigation is required to determine the 
cellular mechanism behind these results. We proposed that abnormal cholesterol 
uptake due to genetic disorder and/or high cholesterol intake causes cellular 
dysfunction, which leads to cartilage damage. When Cholesterol abnormal uptake at 
cellular level accompany with OA pathological condition triggers vicious circle that 
contributes more to dysregulated cholesterol at the cellular levels. All of this may be 
an explanation for results we found at cartilage tissue level.  
To better understand the potential association between hypercholesterolemia and 
OA, we designed in vivo and in vitro models. Two animal models, ApoE-/- mice and 
DIHC rats, were used to mimic human hypercholesterolemia and our results showed 
changes in the cartilage and subchondral bone in both models. Our confirmatory 
results showed that serum total cholesterol levels in animals fed a HCD significantly 
increased the levels considered to be hypercholesterolemia. Moreover, the data from 
both animal models’ body  mass measurement did not show any significant differences 
between the CD and HCD groups. This helped us to study the effect of high cholesterol 
levels independent of body mass; however, we have to aknowledge that potential 
changes in activity levels, muscular function and gait patterns alter external loading of 
the joint, and this contributes to loading of articular surfaces. Cartilage 
histopathological changes have been well-evidenced and scored during different stages 
of OA development. Briefly, OA cartilage changes entail cartilage degradation, loss 
of matrix, and surface fibrillation (Pritzker et al., 2006). Subchondral bone changes in 
human OA have been found to have an increase in bone mineral density, bone volume 
(sclerosis), and subchondral bone remodelling (Miller, Novatt, Hamerman, & Carlson, 
2004). To evaluate the contribution of hypercholesterolemia to subchondral changes, 
we used fluorochrome bone turnover markers (Calcein and Alizarin red). We found 
increased bone remodelling and turnover in the subchondral bone of animals fed a 
HCD compared to the CD group. Increasing evidence has shown that subchondral 
bone turnover increases in patients with OA (Ratcliffe & Seibel, 1990). Our Micro-CT 
analysis presented a decreased subchondral bone volume in animals fed a HCD 
compared to CD. Subchondral bone volume changes during development of OA is 
 Chapter 5: Discussion 149 
highly dependent on the time point post-surgery that has been chosen to analyse the 
subchondral bone. Early subchondral bone changes have been reported in animal 
models of both surgically induced and spontaneous OA (K. Brandt et al., 1997; Mason 
et al., 2001). Dedrick and coworkers also demonstrated subchondral bone loss in early 
stage OA, and subchondral bone sclerosis at the late stage of OA in a dog model of the 
disease (D. Dedrick, Goulet, Huston, Goldstein, & Bole, 1991; D. K. Dedrick et al., 
1993). In addition, Hayami et al. also demonstrated the same trend of subchondral 
bone changes in their surgically induced rat model, where they found subchondral 
bone loss at two weeks post-surgery, but not at 10 weeks post-surgery (Hayami et al., 
2004). 
We also tested phenotypical changes, as well as molecular changes using a pour 
in vitro 3D ACCs pellets culture model. It has been known that expansion of primary 
ACCs using monolayer passaging results in a loss of the chondrogenic phenotype 
(Benya, Padilla, & Nimni, 1978; Z. Lin, Willers, Xu, & Zheng, 2006; von der Mark, 
Gauss, von der Mark, & Müller, 1977). To avoid this differentiation phenomenon in 
cartilage degradation applications and ACCs studies, primary ACCs in relatively early 
passages induce redifferentiation through selected medium supplements (e.g., ascorbic 
acid, TGFβ isoforms, insulin, transferrin, selenite, and others) (Chua, Aminuddin, 
Fuzina, & Ruszymah, 2005; de Haart, Marijnissen, van Osch, & Verhaar, 1999). This 
method is generally combined with 3D culture techniques that mimic the cartilage 
environment (Z. Lin et al., 2006). Moreover, the overall gene expression data showed 
that redifferentiation of ACCs in 2D and 3D culture systems leads to diverse 
chondrocyte phenotypes from which the 3D systems support the best chondrogenic 
differentiation, while the 2D monolayer system induces hypertrophic/mineralization 
markers (Caron et al., 2012). To evaluate the effect of excess cholesterol induction in 
our 3D ACCs pellets culture, we used the chondrocytes hypertrophic marker (COL10 
and RUNX2), chondrocytes degradative marker (MMPs and ADAMTS-4,5), and 
chondrocytes chondrogenic (ACAN and SOX9) markers. Chondrocytes normally 
synthesize the chondrogenic-related genes. During OA development, it is expected that 
cartilage reduces the synthesis of extracellular matrix genes. However, several studies 
have demonstrated increased synthesis of chondrogenic components, in particular 
ACAN in OA (Hedbom & Häuselmann, 2002; Lippiello, Hall, & Mankin, 1977). 
Chondrocytes have raised anabolic activity to repair the damaged matrix during OA 
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development (Van der Kraan & van den Berg, 2000). Therefore, testing enzymatic 
degradation of matrix components might be a better hallmark to evaluate the metabolic 
imbalance in cartilage and 3D pellet culture, such as matrix degradative enzymes are 
MMPs and aggrecanase (ADAMs). Overall, we demonstrated the altered expression 
of ACCs anabolic and catabolic markers during cholesterol induction in our in vitro 
model.  
Apart from in vitro phenotypical changes in response to high cholesterol 
induction, we also found molecular changes in our in vivo studies, similar to those in 
OA. DIPEN and NITEGE markers were used as matrix degradative markers to 
evaluate cartilage molecular metabolism. These two neoepitopes detect N or C 
terminus of aggrecan degradation products. DIPEN distinguish MMP- driven aggrecan 
loss and NITEGE distinguish aggrecanase (ADAMTS-4, 5)-driven aggrecan loss in 
the late-stage disease. It has been well-demonstrated that aggrecan is degraded, either 
with MMPs or aggercanase in OA patients, and the expression of both is significantly 
enhanced during a course of OA. Previous studies have reported that ‘chondrocytes 
from OA cartilage have an altered phenotype, characterized by a decrease in cartilage 
matrix expression and increase of the terminal differentiated phenotypic changes’ 
(Howell, 2002; O Pullig, Weseloh, Ronneberger, Käkönen, & Swoboda, 2000). Our 
findings showed an increased expression of COL10, DIPEN, and NITEGE in response 
to HCD in both models, suggesting an anabolic role for hypercholesterolemia in 
cartilage haemostasis.  
Moreover, we found a significant increase in the synovial membrane activation 
induced by a HCD in both ApoE-/- mice and DIHC rat models. Based on histological 
analyses, we found that greater than 40% of animals fed a HCD exhibit synovial 
inflammation, with chronic inflammation appearing as diffuse infiltrates of 
macrophages scattered throughout the synovia of the affected joint and thickening of 
synovial membrane. From previous studies we know that synovial inflammation is 
important for OA pathology. Macrophages are a significant source of ECM degrading 
proteases, including MMPs, as well as of pro- and anti-inflammatory cytokines that 
regulate ECM remodelling, inflammatory cell recruitment and activation, and 
apoptosis. It has been reported that these factors, when released by inflammatory cells 
in the synovium, can precipitate a degenerative phenotype change of the cartilage 
(Andujar, Serrano, & Gomez-Zurita, 2012), a finding similar to those found in the 
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present study and that implicates high-cholesterol in macrophage mediated 
inflammation of the synovia. Interestingly, LDL receptor deficient mice (LDLr-/-) have 
an accumulation of oxidized LDL in macrophages lining the synovium, which leads 
to activation of TGF-β and osteophyte formation in experimental OA (Hendrich, Pons, 
Ribera, & Balke, 2010). These studies, together with our own, support the hypothesis 
that cholesterol induced OA shares many similarities with atherosclerosis, especially 
the initial stages of macrophage in-filtration of the arteries. They also support the 
notion that hypercholesterolemia induces OA-like symptoms of the whole-joint, which 
include cartilage and subchondral bone changes, osteophyte formation and synovial 
inflammation. Our findings may also point to a potentially pro-inflammatory effect of 
hypercholesterolemia on joint health.  
 The knee joint synovial circulation is physically connected to the systemic 
circulation via the synovial capillaries and lymphatic system (Levick & McDonald, 
1995). The most obvious difference between the synovial and systemic circulations is 
that the former operates at low pressure and the latter at high pressure. It is still an 
open question regarding whether or not metabolic factors, such as high cholesterol, 
affect the synovial circulation in a similar way to that of the systemic vasculature. The 
changes seen in the cartilage have been attributed to both direct and indirect effects of 
high cholesterol. A significant level of cholesterol has been found in the synovial fluid 
of OA patients and correlates with serum cholesterol levels (F. Oliviero et al., 2012). 
Under such circumstances, chondrocytes are exposed to elevated cholesterol levels in 
the synovial fluid, which then may diffuse into the cartilage (Ananth, Prete, & 
Kashyap, 1993; F. Oliviero et al., 2012; F. Oliviero et al., 2009). This could alter the 
fluidity of the cell membrane and activate the membrane lipid, signalling pathways 
causing damage to chondrocytes. Alternatively, it is known that high cholesterol levels 
in the ApoE-/- mice and rat models can trigger the inflammatory cytokine expression 
such as TNF-α, IL-1β and IL-6 (Rajamaki et al., 2010). Several studies have previously 
reported that some of these factors released by the synovium inflammatory cells can 
lead to alterations in the degenerative phenotype of the cartilage using co-culture 
studies (Chowdhury, Akanji, Salter, Bader, & Lee, 2008; S. R. Goldring & Goldring, 
2004).    
Increased body weight did not appear to have an effect on the development of 
OA, as no correlation was found between body mass and cartilage changes in either 
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animal model. This is, therefore, a strong indication that the effects of excess 
cholesterol have a greater role in OA development, particularly in conjunction with 
the mechanical instability caused by surgically induced OA (DMM or MSX) in these 
models. The changes observed in this study can, therefore, be directly and indirectly 
attributed to the effects of high cholesterol, independent of variables such as body 
mass. Althought, subchondral bone loss has been suggested to be, in part, related to 
disuse or limb and joint unloading, by muscular atrophy (Abusara et al., 2016; Egloff 
et al., 2014) and hind limb suspension (Anderson et al., 2016; Christiansen et al., 2012) 
which suggest there are multiple biomechanical and biochemical factors at work in the 
OA pathways. To better answer the question whether high cholesterol affect 
subchodral bone loss using same mechanisms, further investigation needed. 
Corroborating our findings is a recent study that showed dietary cholesterol played a 
role in the development of OA in an APOE*3Leiden mouse model. In that study, the 
drug ezetimibe was used to lower plasma cholesterol by inhibiting intestinal 
cholesterol absorption. Treatment with ezetimibe did not reduce the severity of OA in 
animals fed a cholesterol-rich diet, which suggests that factors other than cholesterol 
exposure contributed to the development of OA (L. M. Gierman et al., 2013). Another 
study has shown that overal HDL-C plasma levels may be less critical compared to 
impaired HDL functionality as a measure of predisposition to OA (Laakmann, Auel, 
& Kochzius, 2012).  
In the present study, the results of the in vitro experiments mirrored the in vivo 
results, in as much as chondrocytes treated with physiological concentrations of free 
cholesterol had impaired cartilaginous gene expression and displayed degenerative 
changes. The first sign of obvious histological characteristics of OA is the onset of 
fibrillation at the surface of articular cartilage as matrix molecules, including that type 
II collagen and aggrecan are damaged (A. Robin Poole et al., 1996). This is associated 
with increased cleavage of the collagen by collagenases and aggrecan loss (Mwale, 
Tchetina, Wu, & Poole, 2002). ‘After the initial cleavage of type II collagen by 
collagenases it is denatured and lost. Chondrocytes subsequently undergo further 
phenotypic change becoming hypertrophic and expressing and secreting COL10’ (A. 
R. Poole, Kobayashi, M., Yasuda, T., Laverty, S., Mwale, F., Kojima, T., ... & 
Tchetina, E, 2002). We demonstrated decreased aggrecan and increased MMP-13 
expressions in cholesterol stimulated chondrocytes; however, aggrecan expression at 
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the molecular level did not demonstrate a lessening trend after cholesterol treatment, 
which might be due to the compensatory mechanism of cells to maintain cartilage 
matrix homeostasis. Furthermore, increased COL10 expression in cholesterol-treated 
chondrocytes supported chondrocytes’ hypertrophic phenotype as a late marker of OA. 
The final phase of OA seems to reflect a failure of the reparative process, resulting in 
degradation of the matrix, cell death, and total loss of cartilage integrity (Blanco, 
Guitian, Vázquez-Martul, de Toro, & Galdo, 1998). These findings suggest that 
cholesterol directly affects the function of the chondrocytes, possibly through changes 
to the fluidity and function of the cell membrane, resulting in abnormal cell behaviour 
and cholesterol accumulation (N. Wang et al., 2000). 
We also demonstrated, for the first time, an increased incidence of bone marrow 
lesions in the subchondral bone area of cholesterol fed animals, an observation that 
corresponds to a recent epidemiology study that found a positive correlation between 
the level of serum cholesterol and triglycerides and an increased incidence of bone 
marrow lesions, a common symptom in OA patients (M. L. Davies-Tuck et al., 2009). 
In addition to cartilage changes, we also found significant changes to the subchondral 
bone, as well as osteophyte formation—both symptomatic of OA development—in the 
ApoE-/- and DIHC animals fed a high cholesterol diet. 
The detrimental effects of cholesterol on chondrocytes and resulting OA changes 
can be attributed to a number of mechanisms. Mitochondria are vital organelles that 
produce energy for cells, particularly in the cartilage. Mitochondria are involved, not 
only in energy production, but also in other cellular activity including apoptosis. 
Mitochondrial dysfunction is known to be induced by hypercholesterolemia, 
hyperglycemia, hypertriglyceridemia, as well as by the process of aging (Lee & Wei, 
2012; Puddu et al., 2005). A number of studies have shown an association between 
increased cholesterol oxidation products and mitochondrion-derived oxidative stress, 
which typically leads to increased production of mitochondrial mt-ROS (Lordan et al., 
2009). Mitochondrial oxidative pathways produce ROS to synthesise ATP to maintain 
normal cartilage homeostasis when subject to physiological mechanical strains, with 
the signal cascade stimulated by mechanical distortion of the mitochondria (Brouillette 
et al., 2014; Montagne et al., 2014; Wolff et al., 2013).  Excess ROS is typically 
produced by mitochondria and, under optimal conditions, is neutralized by the 
mitochondrial cellular defence mechanisms. Excessive ROS can overwhelm the 
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mitochondrial oxidative stress defences, inducing irreparable harm in susceptible cells, 
thereby causing permanent damage to the associated tissues. Increased production of 
ROS, in particular, superoxide and radicals derived from superoxide, has been 
associated with cartilage dysfunction in human disease (Ostalowska et al., 2006) and 
animal models (Johnson et al., 2004), and evidence shows a link between oxidative 
stress and cartilage degeneration in humans (Afonso et al., 2007; Regan et al., 2005). 
On the other hand, chondrocyte matrix synthesis and mineralization are modulated by 
the balance between ATP generation and consumption; therefore, it is essential to 
regulate mitochondrial function as a source of energy production to maintain cartilage 
homeostasis. Recent ex vivo studies have found mitochondrial dysfunction in human 
OA chondrocytes, and analyses of mitochondrial electron transport chain activity in 
these cells shows decreased activity of Complexes I, II and III compared to normal 
chondrocytes. In Maneiro et al.’s study, mitochondrial mass was increased in OA, as 
revealed by a significant increase in enzymatic activity (Maneiro et al., 2001). 
Consequently, a rise in mitochondrial mass might be a compensatory mechanism of 
OA chondrocytes against electron transfer deficiency via complexes II and III leading 
to low ATP production per mitochondrion (Hsin-Chen, Pen-Hui, Ching-You, Chin-
Wen, & Yau-Huei, 2000). In addition, OA cells demonstrated a loss of the 
mitochondrial membrane potential (Δψm) as shown by means of the fluorescent probe 
JC-1. It has been revealed that OA chondrocytes have a lower red/green fluorescence 
ratio than normal chondrocytes as demonstrated by flow cytometry, indicating the 
mitochondria depolarization (Blanco, López-Armada, & Maneiro, 2004). Previous 
studies also reported that loss of Δψm is related to the outer mitochondrial membrane 
disruption, mitochondrial swelling, and the discharge of pro-apoptotic molecules, 
including apoptosis-inducing factor, cytochrome c, and pro-caspases from the 
intermembrane space (Crompton, 1999). This evidence highly supports chondrocyte 
mitochondrial impairment as a mediator of the initiation and/or development of OA. 
However, it remains unknown whether excess cholesterol levels can affect 
chondrocyte mitochondrial function due to the impaired mitochondria potential and 
ROS production. Numerous studies have shown that a major source of nutrients for 
cartilage is synovial fluid, and because synovial fluid is an ultrafiltrate of plasma, 
chondrocytes receive their nutrients via a double diffusion system. Accordingly, it is 
highly possible that a high level of plasma cholesterol directly influences chondrocytes 
function through synovial fluid high levels of cholesterol in plasma. 
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In the present study, we found that cholesterol induced OA-like changes were 
triggered by means of mitochondrial pathways. Strong evidence for this hypothesis 
was the observation that cells subjected to a cholesterol challenge suffered a loss of 
mitochondrial membrane integrity that activated the intrinsic apoptotic pathway 
resulting in the release of a number of cell-death promoting molecules, including 
cytochrome c. The other major clue of a mitochondrial involvement was the 
observation that cholesterol treated cells produced excess ROS commensurate with 
cartilage degeneration. Mitochondrial dysfunction affects other pathways implicated 
in cartilage degradation, including ‘oxidative stress, defective chondrocyte 
biosynthesis, increased cytokine-induced chondrocyte inflammation and matrix 
catabolism, cartilage matrix calcification, and increased chondrocyte apoptosis’ (L. 
Wang et al., 2013).   
To support this finding, we reported that cholesterol-treated cells trigger the 
intrinsic apoptosis pathway by causing the loss of mitochondrial membrane integrity, 
leading to the release of multiple death-promoting molecules such as cytochrome c. 
Moreover, mitochondria is a major source of ROS in the cells and we found that 
cholesterol treated cells produce excess ROS that can lead to cartilage 
degradation. Mitochondrial dysfunction can impact on some pathways that have been 
associated with cartilage degradation, including ‘oxidative stress, increased cytokine-
induced chondrocyte inflammation and matrix catabolism, defective chondrocyte 
cartilage matrix calcification, biosynthesis and growth responses, and increased 
chondrocyte apoptosis’ (Blanco, Rego, & Ruiz-Romero, 2011). This is in line with our 
findings, suggesting that cholesterol stimulation of cells can alter mitochondrial 
morphology and structure led to mitochondrial functional impairment activating 
mitochondrial apoptosis pathway. Here we tested oxidative stress-induced apoptosis 
as growing evidence supporting the strong link between MetS and oxidative stress 
condition (Furukawa et al., 2004; Matsuda & Shimomura, 2013; Roberts et al., 2006). 
We demonstrated for the first time that cholesterol challenge influences cartilage 
haemostasis resulting in chondrocytes apoptosis. We stressed that oxidative stress 
pathways such as P-ERK and P-JNK are involved in the chondrocytes apoptosis, 
which play a role in down-stream events of oxidative stress-induced apoptosis under 
excess cholesterol environment. 
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Atorvastatin is an HMG-CoA reductase inhibitor that has been prescribed as a 
cholesterol lowering drug for the past two decades. We tested the efficacy of 
atorvastatin to attenuate cholesterol induced OA symptoms in both in vivo and in vitro 
experiments. The in vivo results showed a statistically significant protective effect 
from atorvastatin conferred on articular cartilage and subchondral bone, against the 
progression of OA-like symptoms. Similar effects were also observed in vitro, in the 
form of a significant reduction of catabolic and hypertrophic marker expressions. 
Apart from their cholesterol lowering properties, statins also exert pleiotropic effects 
that include immunomodulation, anti-inflammation, anti-angiogenesis, and anti-
apoptosis (Bhandari et al., 2015; Khurana, Gupta, Bhalla, Nandwani, & Gupta, 2015; 
Nezic et al., 2009; Tremoulet, 2015; Zhao et al., 2015). Statins can also affect several 
target proteins that are related to mitochondrial ROS production (Lim & Barter, 2014), 
proteins whose expression was increased in ApoE-/- mice and DIHC rats fed a high 
cholesterol diet. The in vitro experiments revealed that atorvastatin treatment had anti-
oxidative effects, decreased expression of matrix metalloproteinases and interleukins, 
and increased the expression of aggrecan and type II collagen in chondrocytes. In 
synovial cells, atorvastatin reduced the production of matrix metalloproteinases, 
interleukins, chemokines, and induced apoptosis of synovial fibroblasts. It is possible 
that statins may affect the progression of osteoarthritis by inhibiting osteoclastogenesis 
and vascular pathology, which in turn stimulates bone formation and counteracts the 
underlying mechanisms of OA. Therefore, at this stage we cannot draw definitive 
conclusions as to which of atorvastatin’s effects is the most important in terms of 
reducing cartilage degeneration; be that the reduction of plasma cholesterol in the 
ApoE-/- mice and DIHC rats or the drug’s potent anti-inflammatory effects.   
The in vitro results pointed to mitochondrial dysfunction as a likely culprit for 
the adverse effects of high cholesterol on chondrocytes. This prompted us to evaluate 
a mitochondrial specific anti-oxidant that targets the most upstream mitochondrial 
event to prevent OA development induced by high cholesterol levels. Mito-TEMPO 
was chosen over more common antioxidants such as ascorbic acid or tocopherols due 
to its demonstrated specificity against mitochondrial ROS and superoxide production 
(Dikalova et al., 2010). Mito-TEMPO is a physicochemical compound as one of SOD 
mimics. It has an ability to pass through lipid bilayers easily and accumulate 
selectively in mitochondria (Dakilova et al., 2010). Superoxide and alkyl radical 
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scavenging properties A mito-TEMPO as a mitochondria-targeted antioxidant have 
been confirmed both Bin vitro and in vivo studies (Liang et al. , 2010, Dakilova et al., 
2010, Liu, M., Liu, H., & Dudley, S. C., 2010). It has been reported that mito-TEMPO 
preserves physiological ROS signalling in non-malignant skin fibroblasts and 
selectively targets tumour cells with abnormal mitochondrial activities (Nazarewicz et 
al., 2013). Mito-TEMPO decreases mitochondrial superoxide levels by mimicking the 
action of super oxide dismutase. Therefore, I hypothesised that mito-TEMPO prevents 
the formation of O2 derived ROS, including cytosolic H2O2 and self-propagating lipid 
peroxides and allows the cells to clear out excess ROS. All of this toghether would 
prevent cartilage tissue from ROS damage. 
 In particular, we report that mito-TEMPO prevents high cholesterol-induced 
OA changes in both animal models and in vitro cell culture studies. Mito-TEMPO 
specifically targeted inner membrane potential of mitochondria and prevented 
chondrocytes from overwhelming production of ROS, which influenced triggers 
oxidative stress pathways. These findings offer a rationale to test mitochondria-
targeted anti-oxidants as a genuine treatment option against hypercholesterolemia 
induced OA.  
 
5.2 FUTURE PERSPECTIVES AND CLINICAL IMPLICATIONS  
A new concept of OA is emerging, indicating that OA is not a unique disease, 
but is a heterogeneous syndrome with different clinical phenotypes, eventually leading 
to common clinical manifestations. Although all phenotypes of OA demonstrate the 
same clinical symptoms, the mechanisms involved in such a manifestation are not the 
same.  
OA is a heterogeneous condition affecting whole joint heath and whole 
animal/human behaviour, e.g. physical activity and movement, which will also affect 
biomechanical pathways for disease. Moreover, pathological changes of OA happen 
at cartilage, bone, synovium and menisci and muscles covered joint capsule. 
Therefore, it is important to study the effect of cholesterol on different tissue involved 
in OA pathogenesis and also tight relationship between altered biomechanics, 
biochemistry and tissue structure and morphology needs to explored and understood. 
One future direction of this study is to investigate whether the destructive effect of the 
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cholesterols starts from the subchondral bone or cartilage and better understand which 
tissue will be secondarily affected. Using animal models of hypercholesterolemia will 
be an effective tool to OA pathogenesis at different time points to clarify the etiology 
of cholesterol-induced OA. 
Another interesting future perspective that should be tested is whether 
cholesterol plays a role in the angiogenesis process. As we demonstrated that an excess 
amount of cholesterol induced alterations in the dynamical interactions of the 
biomechanical, biochemical with mitochondria structural changes result in a system 
that is seen as mitochondria dysfunction, hypercholesterolemia may also play a role in 
angiogenesis. Both in vivo and in vitro testing of effect of high cholesterol level on 
angiogenesis markers would be interesting to determine other possible pathways from 
which excess cholesterol begins to affect cartilage and synovial inflammation. 
Studying the potential role of hypercholesterolemia in angiogenesis is another angle 
that might be approached to address the pathogenesis of cholesterol-induced OA.  
Moreover, further in vitro and in vivo experimental models are required to study 
the role of synovial macrophages in promoting inflammatory and destructive 
responses in OA of hypercholesterolemia associated metabolic syndrome phenotypes 
and to better understand the potential synergic mechanism underlying this process. 
This will assist clinicians to modify strategies for managing OA patients. Successful 
completion of these studies will thus provide a platform from which to develop novel 
treatments based on careful manipulation of the immune system that can be applied to 
OA patients. 
 In addition, targeting mitochondrial dysfunction as a mechanism involving in 
cholesterol-induced OA requires further in-vivo and in-vitro models. Using 
commercially available mitochondrial trackers for both in vivo and in vitro models 
would be a complementary method to observe mitochondrial structure and function 
during the course of cholesterol-induced OA.  
This PhD study has demonstrated a strong association between OA and 
hypercholesterolemia independent of obesity or any other known risk factors for OA 
development. This conception has great importance for the potential development of 
‘disease-modifying anti-OA drugs (DMOADs. A future real world implication of this 
project would be testing the clinical trial of antioxidant mito-TEMPO to provide a new 
therapeutical drug targeting OA development.  
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5.3 CONCLUDING REMARKS 
In this study we demonstrated in two animal models that elevated plasma 
cholesterol levels could trigger oxidative stress in the mitochondria and chondrocytes 
apoptosis that led to OA development. We further showed that the cholesterol lowering 
drug atorvastatin and the mitochondria specific antioxidant Mito-tempo/Q could have 
protective effects that attenuate OA symptoms caused by high cholesterol. 
Current knowledge on the association between hypercholesterolemia and OA 
mostly rely on epidemiological studies. These studies investigated the link between 
these two disorders in OA individuals as a study group, however; their outcomes were 
controversial. There is only one experimental study in this field, which evidenced a 
direct link between hypercholesterolemia and OA. Although the author claimed a 
direct association between OA and hypercholesterolemia, his conclusion was drawn 
based on basic histological changes of cartilage only. Moreover, the molecular 
mechanism behind this association was not answered. The current understanding of 
OA is that alterations are not only limited to cartilage, but the underlying subchondral 
bone tissues and synovium also undergo pathological changes, described mostly by 
subchondral sclerosis and elevated subchondral bone remodelling and synovial 
inflammation (Lajeunesse, Hilal, Pelletier, & Martel-Pelletier, 1999). Therefore, there 
is an increasing evidences that recognize OA as a whole-of-joint whole-of-person 
pathological condition (Andriacchi et al., 2004). An ideal investigation for effect of 
high levels of cholesterol on OA-like changes and disease treatment should target the 
structural alteration to all of these tissues. Hence, it is essential that the specific factors 
responsible for these structural alteration, to be identified and targeted in order to 
accomplish such outcomes. In this project we have investigated role of 
hypercholesterolemia in OA initiation and/or progression. 
In order to investigate our aims, we characterized cholesterol distribution and 
regulation in OA samples comparing to normal. Differential cholesterol regulation 
pathways between OA and normal samples, which were concluded from our first aim, 
led us to test direct effect of high levels of cholesterol on ACCs phenotype and 
function.  Upon completion of the second aim of this project, we have demonstrated 
strong destructive effect of excess cholesterol on chondrocytes phenotype. For the first 
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time, we have indicated that chondrocytes phenotypical changes in response to high 
levels of cholesterol may be due to mitochondrial dysfunction. In addition, we also 
showed that mitochondrial morphology and function changes trigger oxidative stress 
pathway, which is one of the key molecular drivers in OA development. As a part of 
aim two of this study, we investigated molecular mechanism underlying excess 
cholesterol and ACCs changes which has been further tested in our in vivo models 
Next, we have used two animal models to further manipulate our in vitro results 
in the in vivo condition. ApoE-/- mice and dietary induced hypercholesterolemia rats 
were used in order to test the impact of cholesterol regulatory gene deficiency and high 
cholesterol food intake on joint health. These two risk factors are the most important 
contributing elements in human hypercholesterolemia. In this part of this project we 
have shown a direct association between hypercholesterolemia and OA-like changes 
in the whole-joint tissues including cartilage, subchondral bone and synovium. 
Moreover, we found mitochondrial-related changes in our animals models fed HCD 
compared to CD group supporting our in vitro results. 
 In the last part of our study, we have used specific antioxidant mito-TEMPO in 
both in vivo and in vitro models. These antioxidants specifically target mitochondrial 
inner-membrane potential and function. Our in vitro findings suggest that use of 
antioxidant in combination with cholesterol can restore mitochondrial function and 
ACCs phenotype consequently. For the first time, we have reported that OA-like 
changes in response to the condition mimicked hypercholesterolemia were attenuated 
by the use of antioxidant in our animal models. 
It is important to understand how metabolic risk factors such as 
hypercholesterolemia contribute biologically to the development of OA because most 
of the risk factors can be modified with simple life style changes without the need of 
surgical interventions or expensive drug and medical treatments. This study has 
advanced our understanding of how high cholesterol levels influence the joint biology. 
In summary, our results indicate that hypercholesterolemia is a critical mediator of 
increased mitochondrial oxidative stress which leads to the progression of OA. 
Inhibition of mitochondrial oxidative stress and dysfunction by the use of 
mitochondria-targeted antioxidants offer therapeutic potential for the prevention and 
treatments tailored specifically for this risk group. 
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